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ABSTRACT 
Methylglyoxal (MG) is a reactive metabolite presents in all biological systems. 
The accumulation of MG in diabetic patients and animals has been long recognized. 
Recently, studies have shown that MG levels are elevated in hypertensive rats. However, 
the pathological effects of MG in diabetes and related insulin resistance syndrome such 
as obesity are currently unknown. In the present study, the role of MG in the 
pathogenesis of insulin resistance was investigated. 
First, it was observed that MG induced structural and functional changes of 
insulin. Incubation of human insulin with MG in vitro yielded MG-insulin adducts, as 
evidenced by additional peaks observed upon mass spectrometric (MS) analysis. Tandem 
MS analysis of insulin B-chain adducts confirmed attachment of MG at an arginine 
residue. [3H]-2-deoxyglucose uptake ([3H]-2-DOG) by 3T3-L1 adipocytes was 
significantly and concentration-dependently decreased after treatment with MG-insulin 
adducts, in comparison with the effect of native insulin at the same concentration. A 
significant decrease of glucose uptake induced by MG-insulin adducts was also observed 
in L8 skeletal muscle cells.  Unlike native insulin, MG-insulin adducts did not inhibit 
insulin release from pancreatic β-cells. The degradation of MG-insulin by cultured liver 
cells was also decreased. In conclusion, MG modifies insulin by attaching to internal 
arginine residue in the β-chain of insulin.  The formation of this MG-insulin adduct 
decreases insulin-mediated glucose uptake, impairs autocrine control of insulin secretion, 
and decreases insulin clearance. These structural and functional abnormalities of the 
insulin molecule may contribute to the pathogenesis of insulin resistance. 
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Second, the effects of MG on the insulin signaling pathway were investigated. 
After 9 weeks of fructose treatment, an insulin resistant state was developed in Sprague-
Dawley (SD) rats, demonstrated as increased triglyceride and insulin levels, elevated 
blood pressure, and decreased insulin-stimulated glucose uptake by adipose tissue. A 
close correlation between insulin resistance and the elevated MG accumulation in adipose 
and skeletal muscle tissues was observed. The insulin resistant state and the elevated MG 
level were reversed by the MG scavenger, N-acetyl cysteine (NAC) and metformin. In 
cultured adipose cells, MG treatment impaired insulin signaling as measured by 
decreased tyrosine phosphorylation of insulin-receptor substrate-1 (IRS-1) and the 
decreased kinase activity of phosphatidylinositol 3-kinase (PI3K). The ability of NAC to 
block MG-impairment of PI3K activity and IRS-1 phosphorylation further confirmed the 
role of MG in the development of insulin resistance. In cultured skeletal muscle cells, 
MG treatment significantly reduced the expression of IRS-1 and PI3K at the mRNA level. 
Similar to adipose cells, MG also decreased tyrosine phosphorylation of IRS-1 and PI3K 
activity. We also examined the mechanism of metformin to inhibit AGEs. Using mass 
spectrometry, stable metformin-MG adducts were identified.  
In addition, we investigated the causative effect of MG in the pathogenesis of 
obesity, another form of insulin resistance. This study revealed a previously unrecognized 
effect of MG in stimulating adipogenesis by up-regulating Akt signaling.  Further study 
suggested that MG accumulation stimulates the phosphorylation of Akt and its effectors 
p21 and p27. The activated Akt pathway then increased the activity of Cdk2 and 
accelerates the cell cycle progression and proliferation of pre-adipocytes. The effects of 
MG were efficiently reversed by both alagebrium, and Akt inhibitor SH-6.  
 - iv-
Overall, the current study investigated the effect of MG during the pathogenesis 
of insulin resistance syndrome. MG, as the most potent precursor of AGEs, impairs the 
activity of insulin signaling pathway by glycating the insulin molecule and other insulin 
signaling proteins. Moreover, this study observed a previously unrecognized causative 
effect of MG in the proliferation of adipocytes by up-regulating the Akt signaling 
pathway. The results from this study offer new mechanisms to explain the development 
of insulin resistance and to prevent the related diseases.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1. Insulin resistance 
Insulin resistance is a state in which the biological functions of insulin are 
impaired. An increased amount of insulin is required for the cells of the body to produce 
a given biological response under insulin resistant state. Although the resistance to 
insulin can happen in different tissues, the three most important tissues that usually linked 
to the development of metabolic insulin resistance are skeletal muscle, liver and adipose 
tissue. Under insulin resistance state, the physiological metabolism of the body is largely 
altered. For example, insulin resistance increased hydrolysis of triglycerides in stored in 
adipocytes and resulted in the elevated accumulation of free fatty acids in the blood 
plasma. As the skeletal muscle cells are responsible for uptaking majority of the 
circulating glucose, insulin resistance in skeletal muscle tissue reduces glucose uptake 
from circulating system. In liver, insulin resistance leads to a reduced glycogen synthesis 
and an enhanced glucose production. Therefore, insulin resistance is involved in different 
forms of diseases including obesity, dyslipidemia, hypertension and athrosclerosis. 
Increased levels of plasma insulin and glucose resulted by insulin resistance are reported 
to be the origin of various metabolic syndromes and related complications. In particular, 
the impaired insulin function will ultimately elevate blood glucose level and contribute to 
the pathogenesis of type 2 diabetes mellitus. Furthermore, increased insulin levels result 
in the retention of sodium and fluid, which leads to hypertension and congestive heart 
failure. A study (Gallistl et al., 2000) showed that overweight children with high blood 
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levels of insulin are likely to have high levels of homocysteine, a substance which 
appears to raise the risk of cardiovascular diseases, stroke, and birth defects. Since insulin 
induces cellular proliferation, its effect on the pathogenesis of cancer is also suspected 
(Boyd, 2003). 
 
1.1.1. Insulin 
Insulin is a hormone with a molecular weight of approximately 6000 Daltons 
produced and secreted exclusively by pancreatic β-cells. It is essential in regulating the 
metabolism of carbohydrates and fat in the body. The primary amino acid sequence and 
the unique covalent structure of insulin were identified over 50 years ago (Sanger and 
Tuppy, 1951). The pathway behind the biosynthesis of insulin in pancreatic β cells, 
specifically as a proinsulin precursor, was also determined in the same era (Steiner et al., 
1969). Although insulin is one of the most studied molecules in biochemistry and 
physiology field, there are many details of the mechanisms behind its secretion and 
signaling still remain unidentified. 
 
1.1.1.1. Structure of insulin 
Circulating and biologically active insulin is monomeric which contains two 
polypeptide chains, chain A and chain B. In most species, these two chains have 21 
amino acids and 30 amino acids, respectively (Figure 1-1A).  They are covalently 
tethered together by two disulfide bridges between A chian and B chain (residues A7 to 
B7, and A20 to B19) and the additional disulfide bridge within A chain (residues A6 to 
A11).  The positions of these disulfide bonds are highly conserved in all mammalian 
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forms of insulin. Insulin has a tendency to dimerize in solution and further associates into 
hexamers in the presence of Zinc ion (Smith, 1971). The hexamer form is the form in 
which insulin stored in the beta cells and secreted into the blood stream. 
Insulin has a compact three-dimensional structure. Although the amino acid 
sequence of insulin differs among different species, this basic conformation is present in 
all members of the insulin peptide family (Figure 1-1B). This is due to the conserved 
positions of the three disulfide bonds and the conserved amino acid residues of both ends 
of the A chain and the C-terminal sequence of the B chain. The hydrophobic residues that 
form the core of insulin contribute to its stability.  The molecular structure is further 
stabilized by the three disulfide bridges (two between A chian and B chain and one 
within A chain). The insulin monomer has two extensive nonpolar surfaces around its 
core.  The first one buried in insulin dimer and contributes to the formation of an 
antiparallel beta sheet structure.  The other one is more extensive and is buried when 
insulin hexamer is formed.  Insulin uses these hydrophobic surfaces for the receptor 
binding and self-assembly into dimmers and hexamers.  
 
1.1.1.2. Biosynthesis of insulin 
Insulin is synthesized in the β cells of the pancreatic islets. It is origianaly 
produced as a single chain precursor called preproinsulin. After the insulin mRNA is 
translated into preproinsulin in the ribosomes of the rough endoplasmic reticulum, its 
signal peptide is cleaved and forms proinsulin. The proinsulin is then transported to the 
Golgi apparatus and wrapped into secretory granules located close to the cell membrane.  
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A 
Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn
Phe-Val-Asn-Gln-his-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu
Thr-Lys-Pro-Thr-Tyr-Phe-Phe-Gly
Arg
A 1     2      3      4      5       6       7       8      9    10    11     12    13     14    15    16     17     18    19     20     21
B 1       2      3       4     5      6        7      8      9    10     11    12     13   14     15   16      17    18    19    20     21
22
30     29    28    27    26    25     24      23  
B 
 
 
Figure 1-1. Sequence and structure of human insulin. A) The A chain of human 
insulin is shown in blue and the B chain is shown in orange. The disulfide bridges are 
shown as black bonds connecting the cysteine residues. B) shows quaternary structure of 
insulin. The two chains are assembled via post-translational modification that includes 
disulfide bridge formation (shown in yellow) and removal of the C-peptide. This figure  
is obtained from www.betacell.org.
 - 5-
Proinsulin has three domains including an amino-terminal B chain, a carboxy-terminal A 
chain and a connecting C-peptide between A chain and B chain. Some specific 
endopeptidases excised the C-peptide in the endoplasmic reticulum, thereby producing 
the mature form of insulin. Both of the C-peptide and the mature insulin are packaged 
into secretory granules and accumulate in the cytoplasm. When the pancreatic β cells are 
stimulated by increased blood glucose level or other factors, insulin is then secreted by 
exocytosis and diffuses into islet capillary blood. At the same time, equal molar of C-
peptide is secreted into circulation with insulin. Around 50% of the insulin and C-peptide 
are then delivered into the portal venous system which leads them directly to the liver 
while the remainder is distributed throughout the body (Polonsky, 1995). 
 
1.1.1.3. The regulation of insulin secretion 
Insulin secretion is stimulated by various agents including glucose, metabolites of 
fatty acid such as acetone and acetoacetic acid, and amino acids (arginine, lysine). 
However, it is especially sensitive to the increased blood glucose level. Glucose elicits a 
biphasic release of insulin which consists of an immediate insulin release and a sustained 
insulin secretion. The immediate release of insulin is due to the release of pre-synthesized 
insulin stored in secretory granules. This is followed by a more prolonged release of 
newly synthesized insulin.  
The pancreatic islet cells are connected by tight cell-cell junctions, which play an 
important role in synchronizing insulin secretion by controling the transport of ions, 
metabolites, messenger molecules from one cell to another. When glucose enters the β 
cells via glucose transporter GLUT2, it is activated and phosphorylated by glucokinase 
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and leads to ATP production. The enhanced intracellular ATP synthesis therefore closes 
ATP-dependant potassium channels and shuts down the potassium exit. Consequently, 
the voltage-dependant calcium channels are depolarized opened. The increased 
intracellular calcium concentration activates  phospholipase C, which catalyzes the 
membrane phospholipid phosphatidyl inositol 4,5-bisphosphate into inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). The binding of IP3 to its receptor on ER 
membrane launches the discharge of Ca2+ from the ER and thus further raises intracellular 
Ca2+ concentration. Subsequently, the previously synthesized insulin from the secretory 
vesicles is secreted.  
When the glucose level returns to the normal physiologic value, insulin release 
from the β cells slows down or being terminated. If blood glucose level decreases further 
to lower than normal value, glucagon is released from pancreatic Langerhans' α cells and 
forces glycogenolysis in the liver, thus enhances the circulating glucose level. By 
regulating blood glucose level, hyperglycemic hormones prevent the occurrence of life-
threatening hypoglycemia. In addition to food intake, the β cells are also influenced by 
the autonomic nervous system. For example, norepinephrine is released in response of 
stress thus inhibites insulin secretion and leads to increased blood glucose levels.   
 
1.1.1.4. Clearance and degradation of insulin 
In view of the significant effect of insulin in lowering blood glucose level, it is 
critical for the fine regulation of the biological function of insulin. One of the regulated 
processes that linked to insulin action is to degrade and clear the circulating insulin. 
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Impairment of insulin clearance results in different diseases including Type 2 diabetes 
(Duckworth et al., 1998). 
The uptake of insulin is mainly through a receptor mediated specific process at 
physiological concentrations. At higher concentrations, non-receptor mediated insulin 
uptake plays a more important role. Same as in the initiation of insulin signaling, the first 
step in insulin degradation is to bind to the insulin receptor. This receptor mediated 
insulin uptake and degradation undergo in all of the insulin-sensitive tissues such as liver, 
adipose and skeletal muscle (Duckworth et al., 1998).  However, liver and kidney are the 
primary site of insulin clearance (Sato et al., 1991). The molecular mechanism behind 
insulin clearance and degradation has been extensively studied. The most popular model 
for insulin degradation includes three steps: receptor binding, receptor-mediated 
internalization of insulin and insulin degradation. The receptor-bound insulin spends 
different time in different tissues. The endogenously secreted insulin spend much longer 
time binding to hepatic insulin receptor than to the insulin receptor in skeletal mucle 
tissue and adipose tissue (Hovorka et al., 1993). Binding to insulin receptor does not 
necessarily lead to the degradation of insulin. Namely, not all receptor-bound insulin is 
internalized into endosomes. In fact, a significant portion of insulin return back to the 
circulation with full or partial biological function. Some of this partially degraded insulin 
retains receptor binding and biological activity. As they are also immunoreactive to anti-
insulin antibody, this partially degraded insulin still contributes to measurable insulin 
levels. The uptake of insulin is altered by nutrient intake and the insulin level in the 
circulation. Shortly after internalization, endosomes acidify and result in dissociation of 
insulin from IR. This is followed by degradation of insulin by insulin degradation enzyme 
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(IDE) through multipal pathways. insulin that not cleared by liver and kidney is 
eventually removed by other insulin-sensitive cells, such as skeletal muscle cells, 
adipocytes (Ardevol et al., 1996; Jochen et al., 1989), fibroblasts (Baldwin et al., 1981), 
monocytes (Powers et al., 1980), lymphocytes (Buffington et al., 1986) and 
gastrointestinal cells (Bai et al., 1995). The circulating insulin was degraded very fast by 
insulinase in liver and kidney. As a result, insulin has an extremely short half-life of 
about 6 minutes in systemic circulation. This short duration of action allows rapid 
changes in the circulating levels of insulin.  
 
1.1.1.5. Biological functions of insulin 
As seen in Figure 1-2, the major biological function of insulin is to regulate the 
metabolism of glucose, protein and lipid. In addition, it modulates DNA synthesis and 
transcription, alters the expression of numerous mRNAs and stimulates growth.  
 
1.1.1.5.1. Regulation of protein synthesis 
Insulin stimulates protein synthesis by promoting cellular uptake of amino acid 
and inhibiting protein degradation in different type of cells and tissues (Saltiel and Kahn, 
2001). At molecular level, insulin promotes translational initiation and elongation of 
specific proteins by mTOR signalling pathway. The activation of mammalian target of 
rapamycin (mTOR) through Akt and the inactivation of TSC1–TSC2 promote each stage 
of protein synthesis including ribosome biogenesis, cap-dependent translational initiation 
and translational elongation (Proud, 2006). The mTOR is a kinase that shares homology. 
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Figure 1-2. Schematic illustration of major biological effects of insulin. Binding of 
insulin to its receptor activates its intrinsic tyrosine kinase activity and causes 
autophosphorylation of insulin receptor. The activation of insulin receptor phosphorylates  
IRS proteins and other docking proteins such as CAP and Crk on tyrosine residues. The 
phosphorylated IRS proteins therefore initiates signaling cascades and leads to the 
activation of multiple downstream effectors which ultimately transmit the insulin signal 
to a various intracellular pathways that regulates protein synthesis, glycogen synthesis, 
and lipogenesis. In addition, by inhibiting FoxO and cdk inhibory proteins including p21, 
p27, insulin also inhibits apoptosis and stimulates cell proliferation.  
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with similar catalytic domain of lipid kinases from the PI3K family. The activated mTOR 
causes phosphorylation and activation of p70S6K which in turn increases 
phosphorylation of eEF2 kinase and thus inititiate translation elongation. Because insulin 
induces p70S6K activity and increases phosphorylation on eEF2 kinase, the eEF2 
becomes much more sensitive in response to insulin action (Asnaghi et al., 2004). 
Furthermore, the inactivation of GSK3, which is known for phosphorylating and  
inactivating glycogen synthase, increases the dephosphorylation of eIF2B and promote 
protein synthesis and storage of amino acids (Lizcano et al., 2002).  
 
1.1.1.5.2. Regulation of lipid synthesis 
Synthesis of fatty acids takes place in the cytoplasm of hepatocytes. The effect of 
insulin in liver is to promote fatty acids uptake and stimulates lipid synthesis, and at the 
same time inhibite lipolysis. Previous studies indicate that the insulin pathway mediating 
different metabolic effects (Kitamura et al., 1999; Kitamura et al., 1998) demonstrate 
differential degree of sensitivity to insulin. For example, a very low concentration of 
insulin is enough to induce the anti-lipolytic effect while a much higher insulin dose is 
required for the stimulation of glucose transport. As a result, the antilipolytic effect of 
insulin can still be active even when the glucose transport is impaired.  It provides a 
molecular mechanism for insulin to maintain and expand the body adipose stores. The 
transcription factor ADD-1 (adipocyte determination and differentiation factor-1) and 
SREBP-1c (sterol regulatory element–binding protein-1c) play critical roles in regulating 
adipocyte gene expression (Foretz et al., 1999; Kim et al., 1998; Shimomura et al., 1999). 
The physiological role of insulin through SREBP-1c is to induce expression of lipogenic 
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genes and repressing the genes that involved in fatty acid oxidation. Meanwhile, insulin 
inhibits lipid catabolism through diminishing the cellular cAMP concentrationsf by 
activating cAMP specific phosphodiesterase in adipocytes (Kitamura et al., 1999). 
 
1.1.1.5.3. Regulation of cell growth and cell survival 
Insulin is involved in the control of cell growth and cell survival by regulating 
some signal transduction proteins such as Growth factor receptor-bound protein 2 (Grb2) 
(Figure 1-2), an adaptor protein that contains SH3 domains that involved extensively in 
signal transduction and cell communication. Activated by phosphorylated IRS, Grb2 
associates with the guanine nucleotide exchange factor SOS and stimulates the MAPK 
signaling pathway which leads to mitogenic responses (Ogawa et al., 1998). The 
activation of MAPK could also be triggered by Shc, another substrate for the IR. Once 
being phosphorylated, Shc associates with Grb2 and directly activate the MAPK pathway 
independently of IRS.  In addition, insulin also reduces apoptosis through Akt pathway. 
In response to insulin action, the activated Akt phosphorylates and inhibits the activity of 
transcription factor FoxO3a, and in turn reduces apoptosis. 
 
1.1.1.5.4. Negative regulation and termination of insulin signaling 
Termination of insulin signaling is basically achieved by internalizing the insulin-
IR complex into endosomes and the degrading insulin by IDE (Bevan, 2001). Negative 
regulation of insulin signaling is necessary to maintain the normal physiological 
metabolism of the body. Meanwhile, it is also a major cause of insulin resistance. Insulin 
activates two major signaling pathways including the PI3K/Akt pathway and Ras-MAPK 
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pathways. These two pathways regulate metabolic processes and cell growth, respectively. 
Inhibitors of both pathways have been reported (Huang et al., 2009). The phosphatase 
and tensin homologue (PTEN, a 3’ phosphatase) and  the Src homology 2 family 
containing inositol 5’-phosphatase (SHIP, a 5’ phosphatase) attenuates the PIP3 signaling 
by degrading PIP3 to PIP2 (Lazar and Saltiel, 2006), and lead to the termination of 
PI3K/Akt pathway. Similarly, the negative regulation of Ras-MAPK is also through 
changing the expression and phosphorylation of target proteins.   
 
1.1.2. Causes of insulin resistance 
Pathogenesis of insulin resistance involves both genetic background and 
environmental influences. It could be a result of hereditary defects including the 
mutations of IR, glucose transporter and other signaling proteins. But most of insulin 
resistance is cause by certain acquired factors such as inadequate physical activity level, 
over-nutrition induced hyperglycemia (glucose toxicity), increased free fatty acids and 
the aging process (Lutsey et al., 2008). Cellular development of insulin resistance 
involves pre-receptor defects, receptor defects and post-receptor defects. Compare to the 
decreased bioavailability of insulin, defective insulin receptor and impaired insulin 
signaling are more frequently observed in individuals with insulin resistance. As obesity 
usually is associated with decreased IR number and failure in activating postreceptor 
insulin signaling cascade (such as reduced postreceptor tyrosine phosphorylation), 
obesity is regarded as the most common cause of insulin resistance. 
 
1.1.2.1. Pre-receptor reasons of insulin resistance 
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Pre-receptor defects is usually refered to reduced bioavailability of insulin in 
circulation. Some forms of insulin resistance can be resulted by the high titer and/or 
affinity of insulin antibodies. These insulin antibodies competitively bind to insulin and 
reduce the maximum action of insulin. Therefore, this type of insulin resistance is called 
immunological insulin resistance (Lupsa et al., 2009). IgG antibodies in response to 
exogenous insulin are often found in patients with insulin therapy  (Hirano et al., 2008). 
Mutations in human insulin cause an autosomal-dominant insulin resistance syndrome. 
The mutated insulin may either reduce the binding capacity to its receptor or impair the 
subcellular trafficking and processing of the proinsulin in pancreatic β-cells. Patients with 
mutated insulin usually respond normally to exogenous insulin but shows increased 
fasting plasma insulin level due to delayed receptor-mediated clearance of the mutated 
insulin (Steiner et al., 1990). In addition to the mutation of insulin, there are also 
possibilities that certain reactive chemicals in the circulation could modify the structure 
of insulin and alter its biological function. 
 
1.1.2.2. Defects of insulin receptor resulting insulin resistance 
Alterations in the expression, binding, phosphorylation and kinase activity of 
insulin receptor account for major types of insulin resistance. 
The insulin receptor is a heterotetrameric glycoprotein that belongs to receptor 
tyrosine kinase super family. It consists of two α-subunits and two β-subunits which 
linked together by two disulphide bridges. The extracellular α-subunits contain insulin 
binding sites whereas the β-subunit is composed of an extracellular domain, a 
transmembrane domain, and an intracellular domain. The intracellular domain of β-
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subunit possesses the intrinsic tyrosine kinase activity of IR. The entire insulin receptor is 
expressed in two isoforms, isoform A and isoform B. The isoform B contains a 12-
amino-acid peptide at the COOH-terminus of the α-subunit while the isoform A lacks this 
insertion. The isoform B shows a two-fold higher affinity for insulin as compared to the 
A isoform (Kosaki et al., 1995). The different ligand binding affinity of these two 
isoforms results in different sensitivity to insulin and the subsequent biological function 
in both anabolism and metabolism (Kosaki and Webster, 1993). Increased expression of 
the B isoform in skeletal muscle has been positively correlated with both hyperglycaemia 
and hyperinsulinaemia. Thus, the different distribution abundance of these two isoforms 
in insulin target tissues may  contribute to the pathogenesis of insulin resistant state 
(Mosthaf et al., 1991). Furthermore, it might explain the pathogenesis of tissue specific 
insulin resistance.  
Mutations of IR may alter its expression, ligand binding and tyrosine kinase 
activity in insulin sensitive tissues (Taylor et al., 1990). A number of different genetic 
mutations of IR gene have been identified in patients with extreme insulin resistance 
syndrome. These mutations decrease the number of insulin receptors on cell surface by 
reducing the insulin-receptor mRNA levels or impairing the recruitment of receptors to 
cell membrane.  Another type of IR mutation increases the insulin-IR affinity and impairs 
the dissociation of insulin from its receptor in the endosomal acidic pH. This defect 
inhibits the recycling of IR back to the plasma membrane and accelerates receptor 
degradation, which also lead to a decreased number of insulin receptors on the cell 
surface (Accili et al., 1989). 
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In addition to auto-phosphorylation on tyrosine residues, the activity of IR is also 
regulated by the serine/threonine phosphorylation of its β subunit. The serine/threonine 
thephosphorylation reduces the tyrosine kinase activity of IR. Under insulin resistant state, 
the chronic elevation of insulin might stimulate the phosphorylation level on certain 
serine residues of IR. As a result, the tyrosine kinase activity of IR decreases and thus 
exacerbates the insulin resistance state. Indeed, impaired phosphorylation of the IR in 
response to insulin has been observed in insulin sensitive tissues (skeletal muscle tissue, 
adipose tissue and liver) of morbidly obese individuals with/without Type 2 diabetes 
(Caro et al., 1987; Goodyear et al., 1995; Nolan et al., 1994). 
 
1.1.2.3. Defects of post-receptor insulin signaling in insulin resistance 
Previous studies of the insulin resistant subjects suggested that the reduced 
insulin-mediated glucose transport in insulin sensitive tissues is mainly resulted by 
dysfunction of insulin signalling cascade such as the reduced expression and tyrosine 
phosphorylation of IRS proteins and PI3K/Akt (Brozinick et al., 2003; Goodyear et al., 
1995; Kim et al., 1999). In the skeletal muscle tissues of obese and diabetic individuals, 
defects in insulin activation of PKC-ζ have also been observed. The defects in PKC-ζ 
activation were also observed in cultured myocytes and adipocytes from obese subjects 
(Sajan et al., 2004). Previous studies demonstrated contradictive results of the expression 
and activation of Akt in insulin resistance state. Although insulin-stimulated Akt 
phosphorylation was shown to be reduced in adipocytes and skeletal muscles of glucose 
intolerant type 2 diabetics patients compared with control subjects (Brozinick et al., 2003; 
Krook et al., 1998), other studies failed to detect alterations in insulin-induced Akt 
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activation in skeletal muscle of obese subjects with or without Type 2 diabetes (Kim et al., 
1999). Impairment of insulin signaling may also results from the up-regulation of the 
insulin signaling inhibitors. The inhibitive effect of the intracellular enzyme protein-
tyrosine phosphatases (PTPase) 1B and the transmembrane PTPase leukocyte antigen-
related protein have been recognized by recent studies. It is observed that obese non-
diabetic subjects exhibited increased expression and activity of PTPases in adipose tissue 
and skeletal muscle (Ahmad et al., 1997a; Ahmad et al., 1997b). In addition, IR tyrosine 
kinase inhibitor glycoprotein PC-1 was also found to be correlated with BMI value. The 
increased glycoprotein PC-1 expression dramatically reduced insulin sensitivity in 
adipose tissue (Frittitta et al., 1997). These PTPases have been identified as new targets 
to enhance insulin action in insulin-resistant diseases. 
There is growing evidence associates chronic, low-grade inflammation with the 
insulin resistance state. Increased level of proinflammatory cytokines contribute to the 
pathogenesis of clinical features of insulin resistance syndrome including 
hyperinsulinemia, hyperlipidemia, decreased HDL cholesterol concentration and 
increased body mass index (BMI)/waist circumference (Pickup, 2004). For example, 
increased expression of inflammatory cytokines such as tumor necrosis factor-α (TNF-α) 
and interleukin-6 (IL-6) were detected in adipose tissue in obese subjects (Kern et al., 
2001).  TNF-α induces site-specific serine phosphorylation and decreases tyrosine 
phosphorylation of IRS-1. The alteration on IRS-1 phosphorylation dissociates the 
protein from IR and thus induces IRS protein degradation. Likewise, several other serine 
kinases have also been characterized for their activities in phosphorylation of IRS-1 at 
serine residues, such as Akt, mTOR, inhibitor κB kinase (IKK-β), c-Jun NH2-terminal 
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kinase (JNK), and extracellular signal-regulated kinase (ERK) (Draznin, 2006). Moreover, 
accumulation of intracellular metabolites of fatty acids including diacylglycerol and fatty 
acyl-CoAs were reported to induce site-specific serine phosphorylation of IRS-1 by 
activating PKCθ (Li et al., 2004). Nevertheless, it is uncertain whether the association of 
these inflammatory markers and acute reactants with insulin resistance is independent of 
measures of obesity and insulin resistance as they are already included in a risk prediction 
mode. 
 
1.1.2.4. Impaired GLUT expression and function 
The insulin stimulated uptake and metabolism of glucose in insulin target cells are 
ultimately regulated by glucose transport, which is mediated by specific plasma 
membrane glucose transporters. GLUT-4 is a protein with 12-transmembrane domains 
which mediates the majority of insulin-stimulated gluose transport in peripheral tissues.  
Therefore, defect in the GLUT4 translocation machinery contribute to impaired insulin-
stimulated glucose uptake in cardiac muscle, skeletal muscle, and adipose tissues (Garvey 
et al., 1998; Zierath et al., 1996).  
Population studies did not find specific GLUT4 gene mutation that account for 
Type 2 diabetes in different human ethnic groups although the pre-translational 
suppression of GLUT4 gene expression was observed to diminish the content of GLUT4 
protein (Gould and Bell, 1990). The morbidly obese people showed a reduced insulin-
stimulated glucose transport in skeletal mucle, which at least partially due to the 
decreased GLUT4 expression (Dohm et al., 1991). However, GLUT4 protein expression 
in skeletal muscle is not altered in non-obese type 2 diabetic patients (Handberg et al., 
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1990). Therefore, the insulin resistance at skeletal-muscle level is most likely resulted by 
defects in the insulin-signalling pathways that regulate GLUT4 translocation. Moreover, 
defects in the recruitment and transportation of GLUT4 to the plasma membrane may 
also be a major reason  (Garvey et al., 1998). Indeed, more recent studies showed that 
decrease in serine phosphorylation of GLUT-4 contributes to insulin resistance state 
(Chiappe De Cingolani and Caldiz, 2004). 
 
1.1.3. Insulin resistance and obesity 
Although the strong correlation between obesity and Type 2 diabetes has been 
pointed out for decades and extensive studies have been carried out in this field, there are 
still many unidentified details to clarify the causative effect of obesity in inducing 
systemic insulin resistance. Furthermore, it is also assumed insulin resistance and 
hyperinsulinemia, other than being results of obesity, may also contribute to the 
development of obesity. This possibility needs to be clarified in future investigations. 
 
1.1.3.1. Definition for obesity 
The terms ‘overweight’ and ‘obesity’ are referred to abnormally increased 
accumulation of fat. As the bodyweight is always corresponded to the height of adult 
people, the overweight and obesity ranges are usually determined by body mass index 
(BMI) which measures of body fat based on height and weight. BMI is calculated based 
on formula: BMI = (Weight in Kilograms / (Height in Meters) x (Height in Meters)). A 
BMI value between 25 and 29.9 indicates overweight of an adult person whereas a BMI 
value equal or greater than 30 indicates the development of obesity. However, although 
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BMI associates with the amount of body fat, it does not directly reflect the body fat 
accumulation and is not a proper indicator to show the increased distribution of 
abdominal fat. Therefore, other measurements including skinfold thickness, waist 
circumference and waist-to-hip circumference ratio have also been performed together 
with BMI caulculation to estimate body fat and body fat distribution. In addition, more 
efficient techniques including ultrasound, magnetic resonance imaging and computed 
tomography have been developed for a more accurate determination of body fat 
distribution. 
 
1.1.3.2. Epidemiology of obesity 
As a major risk factor of many major health problems incuding carviovascular 
diseases, obesity has become a major concern especially in most developed countries. 
Most recent data shows an increased prevalence of obesity in different populations. The 
incidence of obesity varies by age, sex and race-ethnic group. According to the American 
Obesity Association (AOA), the number of obese population in the United States 
increased from 31.1% to 33.3% during the period of 2003 to 2005 among adult men. 
Among adult women, the incidence of obesity increased from 33.2% to 35.3%. In the 
same period, more than 16% of children and adolescents between 2 and 19 years old were 
found obese. The increasing rate of obesity in children and adolescents not only 
associates with health problems, but also become an important social problem. The 
increased incidence of obesity greatly increases the risk of many diseases and health 
complications, including cardiovascular disease, Type 2 diabetes. There are a significant 
number of genes identified in rare monogenic form obesity.  In contrast, it is difficult to 
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identify the genes related to polygenic form obesity without observable simple Mendelian 
mode. Previous studies demonstrated that obesity increased the incidence of nonalcoholic 
fatty liver disease, cancers in various tissues, hypertension, and various metabolic 
syndromes including elevated total cholesterol, LDL cholesterol and triglycerides levels, 
liver steatosis and gallbladder disease. Furthermore, obesity is also an important causal 
factor of sleep apnea and respiratory problems, and even gynecological problems (such as 
abnormal menses, infertility). 
 
1.1.3.3. Etiology of obesity 
 Obesity usually develops chronically due to long-term energy imbalance resulted 
by excessive caloric consumption. It is a result of interaction between genetic background 
and environmental factors. Common obesity is more likely due to environment factors 
such as inadequate general activity level and calorie expenditure rate which results in an 
impaired oxidation of fat and excessive fat storage with non-reactive lipolysis in 
adipocytes. There are a few genes, namely melanocortin 4 receptor and brain-derived 
neurotrophic factor, have been shown involved in both monogenic obesity and common 
obesity cases (Qi and Cho, 2008; Xu et al., 2003). Leptin, encoded by LEP gene, plays a 
critical role in the regulation of energy balance through acting on both food intake and 
energy expenditure. The increased fat mass is determined by adipocyte hypertrophy and 
hyperplasia, which refered to as increased size and number of adipocytes, respectively. A 
significant larger population of adipocytes is only observed in early-onset obesity but not 
in normal adult onset obesity. The enlargement of adipocytes through increased fat 
deposit is thought to be responsible for the adult form obesity (Spalding et al., 2008).  
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There are two types of adipocytes found in mammalians known as white fat cells 
and brown fat cells. White fat cells are monovacuolar cells which have a flattened 
nucleus that situates at the periphery. They contain a large lipid droplet but only a thin 
layer of cytoplasm. A typical white fat cell is around 0.1mm in diameter with a variation 
in size from 0.05 mm to 0.2 mm. The fat stored in white fat cells is primarily triglycerides 
and cholesteryl esters in a semi-liquid state. In addition to store energy, mature white fat 
cells secrete fatty acids and cytokines like resistin, adiponectin and leptin (Fajas, 2003; 
Fonseca-Alaniz et al., 2007). These adipogenic factors work as paracrine factors and 
stimulate the proliferation of preadipocytes, thus increase the absolute number of fat cells 
(Hausman et al., 2001). More importantly, they show multiple functions in regulating 
immune and inflammation response. Unlike white fat cells, brown fat cells (plurivacuolar 
cells) are polygonal in shape. These cells have considerable cytoplasm with a round, 
eccentrically located nucleus. Instead of a large lipid droplet, the small lipid droplets 
scattered throughout the brown fat cell. The biological function of brown fat cells is to 
generate heat by uncoupling the respiratory chain of oxidative phosphorylation within 
mitochondria. The brown adipose tissue presents widespreadly in human infants but 
located only around the neck and large blood vessels of the thorax. The induction of 
active brown adipose tissue in adult people by therapeutic intervention may be applied 
for the treatment of obesity. 
The cellular development of adipose tissue involves both cellular hypertrophy and 
hyperplasia.  Hypertrophy increases the size of existing adipocytes due to surplus 
triglyceride accumulation resulted by a positive energy balance. Hyperplasia is also 
called adipogenesis. It includes both proliferation and differentiation of pre-adipocytes 
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which is resulted by the recruitment of new adipocytes from precursor cells into mature 
adipocytes. The increase in total fat cell number originating from adipocyte precursor 
cells is called proliferation. Traditionaly, adipose precursor cells, preadipocytes, are 
thought capable of replication while mature adipocytes are not. However, human 
preadipocyte studies indicate that partially differentiated cells remain capable of 
replication. Moreover, there were several reports of the replication of mature adipocytes 
in vitro (Hausman et al., 2001). Differentiation referred to the transition from 
undifferentiated fibroblast-like pre-adipocytes into mature round lipid-filled fat cells and 
is characterized by change in morphology from fibroblastic to unilocular appearance of 
the mature fat cell. Differentiation also is characterized by the expression of transcription 
factors in a regulatory cascade which result in the expression of adipose-associated genes 
and an increased lipogenic capacity of the cell. 
The processes regulating proliferation have been extensively studied. The major 
factors that regulate adipocyte proliferation include hormonal factor, paracrine factor and 
neural factor. Thyroid hormones and glucocorticoids, for example, enhanced adipocyted 
development in rat models (Bray et al., 1992; Freedman et al., 1986; Hausman et al., 
2001; Levacher et al., 1984). Under in vitro condition, glucocorticoid or its synthesized 
analogue dexamethasone, combined with insulin, stimulate recruitment and/or 
differentiation of pre-adipocyte by inducing the sequential expression of 
CCAAT/enhance binding protein transcription factors (C/EBPs) including the early 
expression of C/EBPβ, C/EBPδ and the late expression of C/EBPα. The activation of 
adipogenic transcription factors and different cell cycle proteins drive the adipogenesis of 
pre-adipocytes (Yeh et al., 1995). Thyroxine (T4) were also found involving in the 
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development of adipose tissue by inducing fetal pre-adipocyte development and 
regulating the expression of insulin-like growth factor-I (IGF-I) and IGF binding proteins 
(Hausman et al., 2001). In addition to these hormones, recent investigation reported a role 
of sympathetic nervous system in adipocyte proliferation and lipolysis (Youngstrom and 
Bartness, 1998). The selective induction of pre-adipocyte proliferation is believed due to 
the stimulation of α2-adrenoceptors (Valet et al., 1998). Although the mechanism 
remains to be elucidated, the development of pre-adipocyte could also be regulated by 
adipocyte derived paracrine factors, such as leptin, resistin, IGF and IGF binding proteins, 
TGF-β, TNF-α and angiotensin II (Lau et al., 1996; Mohamed-Ali et al., 1998). 
The cellular and molecular mechanisms of adipocyte differentiation have been 
studied using pre-adipocyte culture systems. The best characterized in vitro model of 
adipogenesis is the 3T3-L1 cell line, a substrain of the Swiss 3T3 fibroblast cell line 
(Green and Kehinde, 1975). The committed pre-adipocytes enter growth arrest couple 
times during adipogenesis so that they can maintain the capacity for growth but withdraw 
from the cell cycle before adipose conversion. The growth arrest is mainly brought about 
by the cooperative expression of two transcriptional factors, C/EBPα and PPARγ (Altiok 
et al., 1997). After growth arrest at confluence, pre-adipocytes receive mitogenic and 
adipogenic signals to continue through subsequent differentiation steps. By chronological 
changes in the expression of adipogenic markers at both mRNA and protein levels, the 
preadipocytes gradually differentiated into mature adipocytes with adipocyte phenotype. 
Expression of lipoprotein lipase mRNA has been cited as an early sign of adipocyte 
differentiation (Ailhaud, 1996; MacDougald and Lane, 1995). Similarly, SREBP-1c, a 
bHLH-leucine zipper protein that involved in cholesterol metabolism is also activated in 
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the early stage of differentiation (Kim and Spiegelman, 1996). In contrast, the early 
expression of C/EBP and PPAR is responsible for terminal differentiation by 
transactivation of adipocyte specific genes. During the terminal phase of differentiation, 
the cultured adipocytes markedly increase lipogenesis and acquire sensitivity to insulin. 
This is followed by increased activity and expression of the enzymes that associate with 
lipid metabolism such as ATP citrate lyase, acetyl-CoA carboxylase (ACC), glycerol-3-
phosphate acyltransferase (GPAT) and fatty acid synthase (FAS) (Weiner et al., 1991). In 
addition to these triglyceride metabolism enzymes, mature adipocytes secrete certain 
adipose tissue-specific markers such as adipocyte specific fatty acid binding protein, aP2. 
The synchronized activation of aP2, GLUT4, and leptin follows the early PPARγ and 
C/EBP gene expression and leads to terminal differentiation of adipocytes. In contrast to 
these adipogenic factors, the adipocyte differentiation is negatively regulated by the 
expression and activity of several endogenous negative regulators including Pref-1 and 
Wnt-10b. These genes are highly expressed in undifferentiated 3T3-L1 cells and down-
regulated upon addition of adipogenesis induction (Mei et al., 2002; Ross et al., 2000). 
 
1.1.3.4. Mechanism linking obesity and insulin resistance 
Obesity is the most critical factor that contributes to the pathogenesis of metabolic 
diseases.   The white adipose tissue releases variety of factors including non-esterified 
fatty acids (NEFA), glycerol, leptin, adiponectin, and proinflammatory cytokines. Under 
obese condition, the production of these products is increased. Increased NEFA release 
promptly induces the development of insulin resistance in humans within hours (Roden et 
al., 1996). On the other hand, insulin-mediated glucose uptake and glucose tolerance 
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improve with an acute decrease of NEFA (Santomauro et al., 1999). It was reported that 
the intracellular accumulation of NEFA could inhibite the activity of pyruvate 
dehydrogenase, phosphofructokinase and hexokinase II by competing with glucose for 
substrate oxidation (Randle et al., 1963). Furthermore, the elevated NEFA delivery or 
decreased intracellular fatty acid and its metabolites (diacyglycerol, fatty acyl-coenzyme 
and ceramides) cause serine/threonine phosphorylation on IRS-1/IRS-2. Subsequently, 
the downstream insulin signaling was diminished by a reduced PI3K activity. Another 
adipocyte-derived factor, retinol-binding protein-4, also induces insulin resistance 
through reducing PI3K signaling. It reduces PI3K activity in skeletal muscle tissue and 
increases gluconeogenesis in liver through a retinol-dependent pathway (Yang et al., 
2005). In addition, products from macrophages and other cells that populate adipose 
tissue may also contribute to the development of insulin resistance. TNF-α and IL-6 act 
through receptor-mediated processes to stimulate both the c-Jun amino-terminal kinase 
(JNK) and the IKK-β/nuclear factor-κB(NF-κB) pathways, resulting in upregulation of 
potential mediators of inflammation that can lead to insulin resistance (Wellen and 
Hotamisligil, 2005). Moreover, the suppression of cytokine signaling proteins and 
inducible nitric oxide synthase (iNOS) mediate cytokine-induced insulin resistance by 
inducing the secretion of proinflammatory proteins, particularly monocyte 
chemoattractant protein-1 from adipocytes, endothelial cells and monocytes (Mooney et 
al., 2001; Picard et al., 2001). The impaired insulin signaling in the hypothalamus 
increases food consumption, increases lipolysis in adipocytes, decreseas the inhibition on 
glucose production in liver and reduces the glucose uptake in skeletal muscle tissue. As a 
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result, leading to an increased plasma levels of NEFA and other adipocyte-derived factors, 
and deteriorates insulin resistance state (Kahn et al., 2006). 
1.2. Advanced glycation end products  
Maillard reaction is a non-enzymatic modification of proteins by reducing sugars. 
It results in the formation of advanced glycation end products (AGEs) under in vivo 
conditions. There has been a growing body of evidence shows that formation and 
accumulation of AGEs and AGE precursors contribute to the development of insulin 
resistance in major insulin sensitive tissues such as liver, skeletal muscle and adipopose 
tissue. 
 
1.2.1. Formation of AGEs 
 Maillard reaction was first described in 1912, which it is also called as glycation, 
browning reaction or “nonenzymatic glycosylation”. It is a nonenzymatic chemical 
reaction involving three major steps. The first step of Maillard reaction is the 
condensation reaction between the carbonyl group of reducing sugars and the N-terminus 
or free-amino groups of proteins via a nucleophilic addition, which resulting in the rapid 
formation of a Schiff base (Figure 1-3). As the Schiff base products are extremely active, 
they form more stable Amadori products through intra-molecular re-arrangement and 
acid-base catalysis. During the lifetime of most cellular and plasma proteins, the levels of 
intermediate Amadori-products varied depend on the glucose concentrations and keep in 
equilibrium with glucose. Part of these Amadori-products undergo further oxidative 
reactions and irreversibly form AGEs. There is a growing population of chemically 
characterized AGE adducts found in human and experimental animals, such as pyrraline, 
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pentosidine, Nε-(carboxymethyl)lysine (CML) (Ikeda et al., 1996), carboxyethyllysine 
(CEL) (Ahmed et al., 1997) and argpyrimidine (Oya et al., 1999) (Figure 1-4). 
Formation of AGEs usually occurs slowly, which is the reason why the long-lived 
proteins of the extracellular matrix, collagen and elastin are especially susceptible to 
AGE accumulation. AGEs sometimes form covalent cross-links with other proteins, 
lipids, and DNA or RNA. By changing their natural structure, AGEs disrupt the normal 
activity of enzymes, hormones and alter immune function. For example, the AGE cross-
links between endothelial proteins and oxidized LDL cholesterol give rise to the 
formation of atherosclerotic plaque in vasculature system. A variety of pathological 
conditions such as hyperglycemia induce the accumulation of AGEs to an above than 
normal level. These AGEs may constitute a chronic environmental risk factor for tissue 
injury (Goldberg et al., 2004). In addition, increased AGE formation is also observed in 
the state of insulin resistance, hyperlipidemia and pathological conditions with increased 
oxidative stress, decreased anti-oxidant activity and reduced renal clearance of AGE-
precursors. However, whether these factors are the causative factors to induce AGE 
formation is still unclear. 
The formation of AGEs is usually endogenous but can also be derived from 
exogenous sources, especially from food intake (Koschinsky et al., 1997). As AGEs are 
produced by Maillard products, foods cooked at high temperature generates more AGEs 
than natural sources. It is very likely that these AGEs products could be absorbed and 
incorporated in body components efficiently. Indeed, different investigations showed that 
dietary AGEs contribute significantly to the total circulating and tissue AGEs. Same as 
their endogenous counterpart, these exogenous AGEs induce variety of pathological  
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Figure 1-3. Simplified scheme of the Maillard reaction and the formation of some 
advanced glycation endproducts from glucose, protein and lipid. 
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Figure 1-4. Chemical structure of major AGEs.  
CEL: Nε-(Carboxyethyl)lysine 
CML: Nε-(Carboxymethyl)lysine 
DOLD: 3-deoxyglucosone lysine dimer 
MOLD: methylglyoxal lysine dimmer 
GOLD: glyoxal lysine dimmer
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effects including potential risk of inflammation and vascular complications in insulin 
resistance. The significant effect of dietary AGEs in the development of insulin resistance 
has been evidenced by different animal experiments  (Sandu et al., 2005). 
The expression of proinflammation markers is increased with the dietary AGE 
consumption. In addition, the close correlation between endothelial dysfunction and 
exogenous AGEs was also shown in diabetic patients and animals (Stirban et al., 2006). 
These results suggest a causative role of dietary AGEs in inducing inflammation, insulin 
resistance and vascular dysfunction. However, because these dietary based studies 
usually use different type and amount of food to feed animals, the conclusions from these 
studies could be contradictive. Further investigations are required to differentiate between 
endogenous and exogenously derived AGEs and then relate them to specific pathological 
damage.  
 
1.2.2. Receptor for AGEs 
Cell surface receptors that binding AGEs include the scavenger receptor and the 
receptor for advanced glycation end products (RAGE).  Scavenger receptor recognizes 
proteins that highly modified by glycation adducts, by which results in the clearance of 
these glycated proteins. RAGE are cell surface molecules that belongs to the IgG 
immunoglobulin superfamily (Neeper et al., 1992; Schmidt et al., 1994; Schmidt et al., 
1993). It is composed of three immunoglobulin-like regions including one “V” type 
domain, two “C” type domains, a short transmembrane domain, and a cytoplasmic tail 
(Neeper et al., 1992; Schmidt et al., 1994; Schmidt et al., 1993). Unlike scavenger 
receptor, binding of AGEs to RAGE does not accelerate the clearance and degradation of 
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AGEs. Instead, engagement of RAGE results in activation of different intracellular 
signaling pathways. Because RAGE has multiple ligands, it binds not only AGEs but also 
different proteins such as proinflammatory cytokines, Ca2+-binding S100 proteins and 
nuclear high mobility group protein box-1 (Dumitriu et al., 2005; Geroldi et al., 2006). 
This ability to bind different ligands implies novel roles for RAGE in a broad range of 
chronic diseases. By interacting with RAGE, AGEs trigger the activation of secondary 
messenger pathways such as protein kinase C and NF-κB. When activated, NF-κB                               
is translocated to the nucleus where it increases transcription of a number of proteins, 
including intercellular adhesion molecule-1, E-selectin, endothelin-1, vascular endothelial 
growth factor (VEGF), and proinflammatory cytokines (Goldin et al., 2006; Schiekofer et 
al., 2003). Moreover, the expression of RAGE on T lymphocytes, monocytes and 
macrophages suggests its essential effect on immune responses under in vivo condition 
(Hofmann et al., 1999). 
 
1.2.3. Pathological effects of AGEs 
The accumulation of AGEs may alter the structural properties of tissue proteins 
and reduce their susceptibility to catabolism (Ahmed, 2005; Ceriello and Motz, 2004). In 
addition, RAGE–ligand interaction may directly induce the generation of reactive oxygen 
species via NADPH oxidases and/or other identified mechanisms (Lander et al., 1997; 
Wautier et al., 2001). 
Since the 1980’s, the pathophysiological significance of AGEs has attracted 
attention in medical science. AGEs accumulation has been linked to diabetes, especially 
various diabetes complications. Although diabetic complications is caused by multipal 
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factors, the accelerated formation of advanced glycation endproducts in diabetes as a 
result of chronic hyperglycemia has been considered to be a major cause. With the 
proceeding of diabetes and hyperglycemia, an accelerated intermolecular collagen cross-
linking was formed with increased AGEs accumulation. As a result, the arterial and 
myocardial compliance is reduced and vascular shows stiffness. AGEs accumulate in 
different organs that damaged in diabetes, including kidney, retina, and vascular system 
(Ahmed, 2005; Baynes, 2001; Monnier et al., 1981; Singh et al., 2001; Smit and Lutgers, 
2004). For example, the presence of argpyrimidine has been identified in arterial walls of 
the kidneys and lenses from diabetic patients (Bourajjaj et al., 2003). It has also been 
localized to atherosclerotic lesions and contribute to atherosclerosis by enhancing 
endothelial dysfunction, elevating vascular low-density lipoprotein (LDL) levels, 
promoting plaque destabilization, inducing neointimal proliferation, and inhibiting 
vascular repair in response to injury (Baynes and Thorpe, 2000; Stitt et al., 1997; 
Vlassara, 1996). Moreover, a large body of evidence has indicated the importance of 
AGEs in diseases such as inflammation (Basta et al., 2002), neurodegenerative disorders 
(Munch et al., 2002; Sasaki et al., 1998; Yan et al., 2001), hypertension (Wang et al., 
2007b; Wang et al., 2004; Wang et al., 2008) and even cancer (Abe and Yamagishi, 
2008). In hypertensive rat aortic tissues, immunohistochemical study showed an age-
dependent increase in CEL and CML staining localized at the endothelial layer (Wang et 
al., 2005). The intensity of CEL and CML staining in aortic tissues was significantly 
higher in SHR than in age-matched WKY rats. Positive CEL and CML staining was even 
detected in aortic tissues from very young age (5-week old) SHR. As different type off 
AGEs have been found on lymphocytes, it is possible that AGEs are involved in 
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modulating interactions between cells and alters immune response including antigen 
presentation and T cell responses. (Poggioli et al., 2002). Futher studies suggested that 
AGEs accumulation reduced the ability of dendritic cells to stimulate primary T cell 
responses in spite of the accelerated cell development (Price et al., 2004). As a result, the 
AGE-enriched environment may enventually re-direct immune responses under in vivo 
conditions.  
 
1.2.4. Clearance of AGEs 
 The modification of proteins by Maillard reaction involves complicated and 
sequential reactions. At the early-stage of Maillard reaction, some liable and reversible 
intermediates including fructosyl-lysine and fructosamines are formed.  With further 
molecular rearrangement and oxidation reaction, these adducts turn into stable end-stage 
AGEs. The degradation of AGEs by proteolysis release glycated adducts with different 
molecular weights. The small free glycated adducts whose molecular weight is less than 
500 Da are mainly excreted in urine in human objects (Gugliucci et al., 2007; Thornalley, 
2005). However, the extracellularly-derived AGE proteins are usually very large in 
molecular weight. They have to be degraded into glycated-peptides or glycated free 
adducts before passing through the basal membrane of the renal corpuscle. Peripheral 
macrophage and liver sinusoidal endothelial cells and Kuppfer's cells  have also been 
implicated involved in AGEs clearance. However, the physiological role of hepatic cells 
in AGEs degradation and clearance remains unclear. 
 
1.2.5. Precursors of AGEs 
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In addition to glucose, a number of glycolytic intermediates such as glyoxal, 
methylglyoxal (MG) and deoxyglucosone, are known to form AGEs and called AGE 
precursors. Among these glycolytic intermediates, MG has recently received considerable 
attention as it is believed to be the most potent glycating agent (Shinohara et al., 1998; 
Westwood and Thornalley, 1995). 
 
1.2.5.1. Physical characterization of MG 
MG (CH3-CO-CH=O or C3H4O2) is also known as pyruvaldehyde, pyruvic 
aldehyde, 2-oxopropanal, 2-ketoproprion-aldehyde or acetyl-formaldehyde. It is called 
dicarbonyl compound because of having two carbonyl groups. 
Endogenous MG exists in two forms, free and bound. More than 99% of MG is 
estimated to be involved in reversible or irreversible interaction with proteins (Chaplen et 
al., 1998). This part of MG cannot freely move into or out of cells. In alkaline 
envinronment, MG undergoes an intramolecular Cannizzaro rearrangement with the 
formation of lactate. In aqueous solution it is polymerized and hydrated. At pH 7.0, MG 
exists in three forms including monohydrate, dihydrate and unhydrated forms (Creighton 
et al., 1988). The percentile distribution of these species is 56%, 44% and trace amount, 
respectively. 
 
1.2.5.2. Chemical reactions of MG 
With both aldehydic and ketonic groups, MG becomes an extremely active 
molecule and reacts with compounds with either thiols and amine groups. Compared to 
the ketonic group, the aldehydic group is more susceptible to be attacked by other 
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functional groups (Leoncini, 1979). These reactions provide the chemical basis of the 
MG-induced modification on amino acids, proteins and nucleic acids, and thus explain 
the mode of action of this α-oxoaldehyde in biological systems (Kalapos, 1999). 
When MG reacts with pyrimidines or purines, it produces interstrand crosslinks, 
especially in AT-rich regions in duplex DNA (Rahman et al., 1990). The MG-DNA 
adducts were detected in DNA extracts of peripheral human lymphocytes incubated with 
MG (Vaca et al., 1994). The reaction between MG and nucleic acids lead to both 
mutagenic and clastogenic effect. A variety of mutations including sister chromatid 
exchanges, single strand breaks and DNA-protein crosslinks were observed in plasmid or 
cells after preincubation with 0.1-200 μM MG and transfection into a mouse lymphoid 
cell line (Papoulis et al., 1995; Tucker et al., 1989). These MG-induced modifications 
occur even under physiological conditions (Figure 1-5). It reacts with arginine residues in 
proteins to form the non-fluorescent products 5-hydro-5-methylimidazolone and 
tetrahydropyrimidine, as well as the major fluorescent product argpyrimidine (Bourajjaj 
et al., 2003; Oya et al., 1999). Although MG reacts primarily with arginine under 
physiological concentration (<5 µM), MG–lysine adducts are also very common. 
CML,CEL and MOLD have been shown accumulate with the aging of animals and 
human (Ahmed et al., 1997; Baynes, 2001). As a typical Millard reaction, the reaction 
between MG and proteins includes both reversible phase and non-reversible phases.  In 
the first phase, MG irreversibly binds to side-chain guanidine of arginine and ε-amine 
residue of lysine. Irreversible reactions result in the formation of different imidazole 
derivatives, arginyl-pirimidine, CML, and imidazolium crosslinks. In addition to arginine  
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Figure 1-5.  Formation of main MG adducts with cystine, arginine and lysine residue 
CEL: Nε-(Carboxyethyl)lysine 
CML: Nε-(Carboxymethyl)lysine 
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and lysine, MG reacts with cysteine residues and forms hemithioacetal. The reaction 
between MG and cysteine is irreversible (Kalapos, 2008).  
 
1.2.5.3. Metabolism of MG 
In mammals, MG is synthesized by bacteria of the gut or by the host itself. It can 
also be taken up from food. Both nonenzymatic and enzymatic reactions are responsible 
for endogenous MG formation. For the enzymatic reaction, MG is synthesized by three 
pathways: the glycolysis bypass, acetone metabolism and protein catabolism (Figure 1-6), 
which, involve methylgloxal synthase, cytochrome P450, and amino oxidases, 
respectively (Chang and Wu, 2006; Kalapos, 1994). Methylgloxal synthase was first 
found in prokaryotic cells and then in mammalian cells (Ray and Ray, 1981). Its activity 
is inhibited by inorganic phosphate and it was suggested that this enzyme regulates 
glycolysis depending on the availability of intracellular Pi (Cooper, 1984). MG is also 
formed from acetone by cytochrome P450 IIE1 isoenzymes. With consumption of 
NADPH + H+,  this enzyme catalyses the sequential formation of hydroxyacetone and 
MG (Koop and Casazza, 1985). Another source of MG production is from protein 
metabolism. Aminoacetone, a protein metabolite, can be catalyzed by amine oxidases to 
form MG (Lyles and Chalmers, 1992). Among the amine oxidase family, semicarbazide-
sensitive amine oxidase (SSAO) is the most studied enzyme. SSAO is present either as 
membrane-associated or soluble form in vascular tissues and adipocytes (Lyles, 1996). 
The activity of serum SSAO is found increased in patients with diabetic complications, 
vascular disorders, and heart diseases (Yu et al., 2004; Yu et al., 2003). 
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Hemithioacetal
 
 
 
Figure 1-6. Formation and degradation of methylglyoxal. G3P, glyceraldehyde-3-
phosphate; DHAP, dihydroxyacetone phosphate; TPI, triosephosphate isomerase; MG, 
methylglyoxal; SSAO, semicarbadize-sensitive amine oxidase; AMO, acetol 
monooxygenase; and GSH, reduced glutathione (Chang and Wu, 2006). 
 - 40 - 
 
Under physiological conditions, the non-enzymatic fragmentation and elimination 
of triose-phosphate intermediates (glyceraldehyde 3-phosphate, dihydroxy-
acetonephosphate) during glycolysis (Phillips and Thornalley, 1993; Richard, 1991) is 
disputable. However, under pathological conditions, it is well-accepted that the 
deprotonation of substrate to an enediolate phosphate followed by the cleavage of 
phosphate group from the carbon skeleton results in the formation of MG (Richard, 1993). 
As triose-phosphates convert to MG non-enzymatically, the formation of MG occurs in 
all cells and organisms. Based on previous studies (Phillips and Thornalley, 1993), the  
rate of MG formation under normoglycaemic conditions is 120 µM per day (Phillips and 
Thornalley, 1993). As the relative contribution of enzymatic and nonenzymatic pathways 
to total MG formation is not clear, whether nonenzymatic or enzymatic pathway is more 
important in MG formation awaits to be determined. Efficient gene knock-out or knock 
down animal/cell models might be helpful in clarifying the involvement of different 
pathway in MG production. 
The detoxification of MG is mainly through the glyoxalase pathway and the α-
ketoaldehyde dehydrogenase(s) pathway (Figure 1-6). The glyoxalase system is 
comprised of glyoxalase I and II using reduced glutathione (GSH) as the cofactor. MG 
reacts with GSH and spontaneously forms hemimercaptal which is converted into S-D-
lactoyl-glutathione by glyoxalase I. S-D-lactoyl-glutathione is then metabolized into D-
lactate by glyoxalase II (Racker, 1951). In mammalian system, D-lactate is further 
degraded to pyruvate by mitochondrial 2-hydroxyacid dehydrogenase (Thornalley, 1993). 
In the α-ketoaldehyde dehydrogenase pathway, MG is directly converted to pyruvate by 
NADPH-dependent α-ketoaldehyde dehydrogenase. Minor routes for MG degradation 
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have also been reported. For example, formaldehyde dehydrogenase, methylglyoxal 
reductase and pyruvate dehydrogenase complex can catalyze the conversion of this α-
oxoaldehyde to spyruvylglutathione, L-lactaldehyde and acetyl CoA, respectively 
(Kalapos, 1994). 
 
1.2.5.4. Pathological effect of MG 
The pathological effect of MG can occur through four major mechanisms. The 
initial cytotoxicity effect is induced by high concentration of MG that damages cell 
functions. Second, the oxidative stress due to free radical production from MG 
metabolism results in a further decrease of cell viability. Third, MG reacts with proteins 
(including enzymes) to form AGEs and alters the physiological function of these proteins 
(enzymes). Furthermore, the reaction between MG and DNA or RNA provides 
carcinogenicity potencial of MG.  
Plasma MG concentration in healthy rats is approximately 5 µM (Nagaraj et al., 
2002). A previous study from our lab detected plasma MG levels at 33.6 µM in 20-week-
old spontaneously hypertensive rats (SHR) and 14.2 µM in age-matched Wistar–Kyoto 
(WKY) rats (Wang et al., 2004). An even higher MG concentration of 310 µmol/L was 
reported in cultured Chinese hamster ovary cells (Chaplen et al., 1998). This discrepency 
of MG concentration reported from different labs might due to the differences with 
various measurement assays and experimental settings.  
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1.2.5.4.1. MG-induced AGE formation 
MG is believed to be the most important source of AGEs (Bourajjaj et al., 2003; 
Shinohara et al., 1998). Studies indicate that the formation of MG-derived AGEs is 
increased with elevated MG levels under hyperglycemia and hypertensive conditions.  
MG treatment significantly increased the formation of AGEs in cultured mesenteric 
artery smooth muscle cells from SD rats. This MG-induced AGEs formation was 
significantly inhibited by pretreatment with MG scavenger N-Acetyl Cysteine (NAC)  
(Wu, 2005). These observations indicate a critical role of MG in the formation of AGEs. 
Recent studies found that MG not only reacts with long half life proteins, but also reacts 
with various circulating proteins, such as HSP27 (Sakamoto et al., 2002), p38MAPK (Liu 
et al., 2003), EGF receptor (Portero-Otin et al., 2002) and transcriptional corepressor 
(Yao et al., 2006). Modification of these cellular proteins leads to alteration of their 
physiological function and triggers diverse cellular responses such as cell activation, 
inflammatory response, growth arrest, and apoptosis. Modification of antithrombin III 
and Cl inhibitor puts forward changes in regulation of coagulation and inflammation 
(Aleksandrovskii, 1992). The MG-induced glycation on mSin3A, a transcription 
suppressor, causes increased expression of angiopoietin-2 and plays a role in the 
pathology of diabetic vascular diseases (Yao et al., 2007). More importantly, since 
arginine, lysine, and cysteine residues are usually involved in active sites of enzymes, 
irreversible reaction of MG with these residues would potentially alter the normal 
activities of these enzymes. It is found that the increased MG-induced AGEs formation 
dramatically inhibited the activities of antioxidant enzymes including glutathione 
reductase and glutathione peroxidase (Morgan et al., 2002; Wang et al., 2005).  The 
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excessive glycation of extracellular superoxide dismutase induced by MG impaired its 
activity  in diabetic patients (Ciechanowski et al., 2005; Kang, 2003). Moreover, the MG-
induced modification of different mitochondrial membrane proteins and antioxidant 
enzymes results in increased oxidative stress (Rosca et al., 2005; Wang et al., 2009) and 
contributes to multiple forms of insulin resistance. 
 
1.2.5.4.2. MG induced oxidative stress 
 
Oxidative stress is a state with increased production and/or decreased 
degeneration of reactive oxygen species (ROS). In addition to the cytotoxic effect of ROS, 
its role in intracellular signaling has also been recognized (Feng et al., 1995; Forman and 
Torres, 2002). Autooxidation and photolysis of MG result in the production of free 
radicals such as hydroxyl radicals and hydrogen peroxide. In cultured rat hepatocytes, a 
dose-dependent effect of MG on hydrogen peroxide formation was detected. The MG-
induced formation of free radicals was also observed in human platelets (Leoncini and 
Poggi, 1996). Under in vitro conditions, , MG administration to the incubation medium 
resulted in a concentration dependent increase of oxidation-sensitive fluorescence of 5-
(and 6)-carboxy-2’,7’-dichlorodihydrofluoresceindiacetate (DCFH-DA) in different cell-
types (Chang et al., 2005; Kikuchi et al., 1999; Leoncini and Poggi, 1996). As 
intracellular GSH plays an important role in the protection of cells against oxidative 
damage, a continuous and significant decrease of GSH level was observed in the presence 
of increasing concentrations of MG (Kalapos et al., 1992). Conversely, the oxidative 
stress-dependent process contributes to the generation of MG-derived AGEs. MG-
induced glycation on mitochondrial membrane proteins and antioxidant enzymes result in 
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further increased oxidative stress. Indeed, the hyperglycaemia-induced ROS production 
by the mitochondrial electron-transport chain has been demonstrated to be responsible to 
hyperglycaemia-induced vascular damage (Nishikawa et al., 2000) in cultured endothelial 
cells. Moreover, free radical production and the subsequent GSH depletion lead to 
decrease of cell viability. The changes of plasma MG levels which parallel ROS 
production has also been observed in hypertension and Alzheimer disease (Wu and 
Juurlink, 2002; Yu, 2001). 
 
1.2.5.4.3. Effect of MG on cell proliferation 
Cell proliferation involves both cell growth and cell division which leads to the 
increase in total cell number. Binding of growth factors to their receptor stimulates a 
cascade of intracellular signaling pathways include protein phosphorylation and 
transcription initiation (binding of transcription factors to DNA), which ultimately 
activates nuclear regulatory proteins that trigger cell division. Modulations of any of 
these cell cycle related proteins, can either stimulate or inhibit cell proliferation process. 
The cell cycle consists of four distinct phases: G1 phase, synthesis phase (S phase), 
G2 phase  and mitosis phase (M phase). Activation and progression of any of these cell 
cycle phases is subsequent to the proper completion of the previous one. Under some 
special physiological condition, some cells stopped dividing temporarily and reversibly 
enter G0 phase which is a state of quiescence. Different cell cycle checkpoints are 
responsible for the regulation and monitoring of the cell cycle progress (Elledge, 1996). 
Normally, a cell does not proceed to the next cell cycle phase only when all the 
checkpoint requirements have been met. Temporary withdraw from cell cycle progress 
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allows the repair of DNA damage and thus prevent the damaged or incomplete DNA to 
pass on to daughter cells. The G1/S checkpoint and the G2/M checkpoint are the two 
main checkpoints. G1/S transition controls the rate-limiting step of cell cycle and 
therefore is also known as restriction point. The Cyclin-dependent kinases (Cdks) family 
plays a central role in initiating the cell cycle proceedings. Cdks are small 
serine/threonine protein kinases that catalyze the covalent attachment of phosphate 
groups derived from ATP to protein substrates of the cell cycle machinery. They are 
activated by binding to regulatory proteins called cyclins. Different types of cyclins are 
produced at different cell cycle phases, resulting in the periodic formation of distinct 
cyclin-Cdk complexes that trigger different cell cycle events. A wide range of 
mechanisms contribute to the regulation of cyclin levels and Cdk activity, resulting in a 
complicated Cdk regulatory network that forms the core of the cell cycle control system. 
Such regulation involves the controlled expression and destruction of cyclins and other 
proteins that associate with Cdks/Cdk/cyclin complexes, thus activate or inhibit the 
phosphorylation of Cdks. Cdk-1 and Cdk-4 act in G2/M and G1 phase, respectively. In 
contrast, Cdk2 acts subsequent to Cdk4/6 to promote G1/S and S phase progression. 
Cdks regulate cell cycle progression by associating with variety of small 
inhibitory proteins, especially p21, p27 and p57. These inhibitory proteins in mammals 
are also known as the "Cdk inhibitory proteins (Cip)” or “kinase inhibitor protein (Kip)”  
family (Sherr and Roberts, 1999), which halt the cell cycle in G1 phase by binding to and 
inactivating cyclin-Cdk complexes. The cyclin-Cdk complex of early G1 is Cdk2, Cdk4, 
or Cdk6 bound cyclin D isoform. In response to DNA damage, intracellular p53 
accumulation increases and induces the p21-mediated inhibition of cyclin D/Cdk. 
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Another protein that plays essential role in cell cycle regulation is Mdm2. By inactivating 
p53, Mdm2 leads to the feedback inhibition of p21 and arrest the cells in G1 phase 
(Giono and Manfredi, 2007a; Giono and Manfredi, 2007b). In addition, the cyclin D/cdk 
complex can also be inhibited by the activation of TGF-β receptors and cyclic AMP 
through p15 or p27, respectively (Iavarone and Massague, 1997; Koff et al., 1991). When 
the cyclin D/Cdk complex is inhibited, the phosphorylation of retinoblastoma protein (Rb) 
reduced and therefore Rb can tightly bind to the transcription factor E2F, inhibiting its 
activity. Conversely, activation of the cyclin D/Cdk complex phosphorylates Rb and 
triggers the cells to transit the G1/S phase and initiates DNA replication by dissociating 
from E2F. The Cyclin/Cdk complex that controls G1/S checkpoint is Cyclin E/Cdk2 
which accumulates during late G1 phase and triggers the passage into S phase.  
Extensive evidences have linked MG accumulation with cell proliferation. In 
MG-treated mammalian cells, DNA synthesis, RNA synthesis and protein production 
were detected depressed. As a result, intraperitoneally or intravenously administered MG 
inhibits the growth of tumor cells in vivo. This inhibitive effect could be attributed to the 
competition in hydrogen bonding between nucleic acid bases to form pairs or bind to MG. 
Moreover, MG was found to inhibit histone acetylation in cell-free extract of rat uterus 
(Procaccini et al., 1971). This suggests an additional mechanism to the action of MG on 
DNA replication. 
Increased generation of many apoptotic markers such as caspase-3 activation, 
DNA ladder formation and cytochrome C release were observed in cells treated with 
extra exogenous MG (Chan et al., 2007; Du et al., 2001b). Multiple mechanisms by 
which MG induce apoptosis were therefore proposed. First, p38 MAPK activation was 
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suggested to be an important signaling intermediate of MG-induced apoptosis in kidney 
epithelial cells and Schwann cells (Fukunaga et al., 2004; Liu et al., 2003). Second, ROS 
generated by MG-induced modification of mitochondrial glutathione reductase also 
triggers apoptosis (Amicarelli et al., 2003; Du et al., 2001b). Third, the JNK pathway was 
suggested to mediate MG-induced apoptosis (Chan et al., 2007). In addition to apoptosis, 
the effect of MG on cell proliferation and growth may also result from its modulation of 
growth factor signaling (Cantero et al., 2007). Inceased accumulation of of MG altered 
the PDGF-induced PDGFRβ-phosphorylation, ERK1/2-activation, and nuclear 
translocation, and the subsequent proliferation of mesenchymal cells (smooth muscle 
cells and skin fibroblasts). The formation of AGE adducts on PDGFRβ was reversed by 
arginine and aminoguanidine, the carbonyl scavengers. A recent study also showed that 
MG affects cell viability via desensitization the signaling of gp130/STAT3, a key 
regulator of cytokine-induced gene expressions, and thereby promotes cytotoxicity in 
neuroglial cells (Lee et al., 2009). 
 
1.2.5.4.4. Effect of MG/AGE on insulin signaling 
  The formation of AGEs/MG is increased in various pathological conditions 
including diabetic nephropathy (Beisswenger et al., 2005; Mostafa et al., 2007), diabetic 
retinopathy (Fosmark et al., 2006; Miller et al., 2006),  hypertension (Wang et al., 2004), 
Alzheimer’s disease (Kuhla et al., 2005), and atherosclerosis (Price and Knight, 2007). 
Most of these diseases also show dysfunction in insulin signaling. Being the most 
potential intermediate of AGE formation, the effect of MG is considered by modifying 
the key insulin signaling proteins. MG-induced modifications of these proteins alter the 
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function of pancreatic β cells, endothelial cells, mesangial cells and smooth muscle cells 
and therefore impair insulin signalling transduction pathway. 
 The majority of the MG-modified proteins in plasma exist as Amadori-glycated 
proteins rather than in the more labile Schiff base form or AGEs. These Amadori-adducts 
are not inert and their direct role in the pathogenesis of diabetic vascular complications 
has been implicated. In diabetic patients with hyperglycemia-induced microvascular 
complications, researchers not only found a correlation between the Amadori-glycated 
albumin and endothelial dysfunction, but also estabolished an independent association 
between the accumulation of early glycated proteins and diabetic nephropathy or 
retinopathy. It was reported that glycated albumin activated different signalling pathways 
and affected specific cellular receptors in variety of cell types. In human monocytic cells, 
glycated albumin induced the release of TNF-α, a factor involved in insulin resistance 
(Naitoh et al., 2001).  More importantly, another study demonstrated that human glycated 
albumin selectively inhibited the PI3K/Akt pathway of the insulin signalling cascade and 
directly cause insulin resistance in skeletal muscle cells (Miele et al., 2003).  The effect 
on PI3K/Akt inhibition was dependent on a PKC-mediated serine/threonine 
phosphorylation of IRS-1/2 proteins, but independent of ROS production. Thus, by 
deregulating intracellular insulin signalling, human glycated albumin may exacerbate the 
insulin-resistant state.  
Conventionally, AGE formation is considered between a carbonyl compound and 
a long half-life protein, such as albumin. In contrast to long half-life proteins, insulin has 
an extremely short half-life, which is about 5–10 min in circulating system.  Therefore, it 
is not expected that insulin itself can be modified in the circulating system under in vivo 
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conditions. Recently, the rapid AGE formation of short-lived proteins under in vivo 
conditions has attracted attention (Giardino et al., 1994; Giardino et al., 1996). Studies 
from different labs reported that MG may react with and impair the function of cellular 
proteins including HSP27 (Sakamoto et al., 2002), p38MAPK (Liu et al., 2003) and EGF 
receptor (Portero-Otin et al., 2003), insulin receptor (Riboulet-Chavey et al., 2006), and 
transcriptional corepressor mSin3A (Yao et al., 2006). Impaired cellular signaling may 
lead to inflammatory responses, growth arrest, and apoptosis (Cantero et al., 2007; Park 
et al., 1998; Riboulet-Chavey et al., 2006). Moreover, some previous studies indicated 
that a substantial proportion of insulin and proinsulin is glycated in the pancreatic ß-cells 
during the stages of insulin synthesis and storage.  Using GlycoGel B boronate affinity 
chromatography, N-terminal glycated insulin has been detected in the pancreas of various 
animal models of Type 2 diabetes and in isolated islets (Abdel-Wahab et al., 1997c; 
Abdel-Wahab et al., 1996). Concentrations of glycated insulin was increased  in the 
circulation of diabetic obese ob/ob mice (Abdel-Wahab et al., 1997c) and in  cultured ß-
cells (Abdel-Wahab et al., 1997a; Abdel-Wahab et al., 1997b). The modification of 
insulin has been demonstrated in vitro under hyperglycemic conditions in the presence of 
sodium cyanoborohydride whose effect is similar to glucose. An insertion of a single 
glucose molecule at the amino-terminus of the insulin B-chain was detected. The effects 
of monoglycated insulin on plasma glucose homeostasis and in vitro cellular glucose 
transport and metabolism was investigated in isolated abdominal muscle of mice. The 
same research group reported that the monoglycated insulin was approximately 20% less 
effective than native insulin in stimulating glucose uptake and both indices of metabolism 
(Boyd et al., 2000). Later, they detected glycated insulin in human diabetic plasma. Using 
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the euglycemic-hyperinsulinemic clamp technique, they found  that the biological activity 
of human glycated insulin was also decreased (Hunter et al., 2003). An increase in 
glycated  insulin was also identified later by radioimmunoassay in human Type 2 
diabetes (Lindsay et al., 2003) .  
The effect of MG in inducing insulin resistance has been conventionally attributed 
to the oxidative stress subsequent to MG accumulation. However, the MG-induced 
modification on insulin signaling proteins could be very specific. For example, a recent 
study demonstrated that a short exposure of L6 muscle cells to MG inhibited insulin-
stimulated phosphorylation of  Akt and Erk1/2 but did not affect tyrosine phosphorylation 
of IR  (Riboulet-Chavey et al., 2006).  Importantly, the deleterious effect of MG is 
independent of ROS. Instead, it appears to be the direct outcome of an imparied tyrosine 
phosphorylation on IRS-1 which is subsequent to the its binding to MG. These results 
strongly imply that the impaired biological function of MG-modified insulin may directly 
contribute to glucose intolerance seen in diabetes. The neutralization or inhibition of 
glycated-albumin and insulin may be a potential novel target for therapy against the 
development of diabetes and its complications. As the glyction reaction between reducing 
sugar and the N-terminal of proteins is well recognized, the glycation of insulin or 
proinsulin at N-terminal is not surprising. However, as maillard reaction can also occur 
on the amino acid residues with free amino group(s), the existence of glycated insulin on 
the Lys residue and/or Arg residue has not yet been detected.  
Maillard products produced by food processing may incorporated into different 
tissues and organs of the body after intestinal absorption. Therefore, AGEs in food are 
potential risk factors for inflammation and vascular complications and insulin resistance. 
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Although only a minor part of dietary AGEs can be absorbed and deposited in tussues, it 
is one of the major sources of circulating AGEs and mediates significant pathological 
effects. In a group of diabetic subjects, dietary AGE was associated with increased levels 
of serum AGEs in parallel with impaired flow mediated dilation and increased serum 
markers of inflammation as well as markers of endothelial dysfunction (Stirban et al., 
2006).  The dietary AGEs/AGE precursors also modulate insulin signaling. Experiments 
performed in animal models have indicated a significant role for dietary AGEs in 
inducing insulin resistance (Hofmann et al., 2002; Sandu et al., 2005).  
Although the role of MG/AGEs accumulation has been studied and some of the 
mechanisms are revealed, the biological consequences of glycation need to be further 
investigated, especially the effect of MG/AGE accumulation in the pathogenesis of 
insulin resistance and the pathway leading to insulin resistance.  
 
1.2.6. Agents that inhibit/scavenge AGE formation 
In view of wide occurrence of AGE formation and their deleterious consequences, 
numerous agents have been developed as potent scavengers of these reactive α-
dicarbonyl products (Table 1-1). A variety of scavengers are identified as AGE inhibitors, 
such as aminoguanidine (Pimagedine®, AG), metformin (dimethylbiguanide), and some 
synthetic thiazolidine derivatives (Rahbar et al., 2000a; Ruggiero-Lopez et al., 1999; 
Thornalley et al., 2000). Another strategy to reduce AGE deposition might be achieved 
by using cross-link breakers including phenacyl thiazolium bromide (PTB) and its stable 
derivative alagebrium (Vasan et al., 1996; Wolffenbuttel et al., 1998). In addition, 
different antioxidants, by providing extra GSH, may induce the detoxification of MG and 
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AGEs and prevent the AGE-induced damage. Among all these AGEs inhibitors, only 
very few of them (i.e. metformin, pioglitazone and pentoxyfylline) are being applied in 
clinical practice or underclinical trials (i.e. alagebrium). The rest of them are generally 
used in vitro or in vivo research to study the role of AGEs or MG in the pathogenesis of 
different disease conditions.  
 
1.2.6.1. Inhibitors of AGE formation 
 To date the most promising AGE inhibitor under investigation is AG. It is a 
hydrazing reagent with guanidine structure. Guanidine compounds can react with and 
trap α-dicarbonyl compounds and prevent their further reactions with the free amine 
groups of protein. The effect of AG in preventing hyperglycemia-induced protein cross-
linking in arterial wall was first reported in diabetic animals in 1986 (Brownlee et al., 
1986). Since then, a growing body of evidence has shown the causative role of AGEs in 
variety of diseases and pathological states. Treatment with AG inhibited the accumulation 
of AGEs in capillary arterioles and thereby prevented abnormal endothelial cell 
proliferation and diabetic complications (Hammes et al., 1991; Soulis-Liparota et al., 
1991). An in vitro study showed that AG can act as an antioxidant and quench hydroxyl 
radicals and cleave cross-links (Giardino et al., 1998). However, the biochemical side 
effects of AG might raise chronic toxicity problems in long-term treatment (Ou, 1993). 
Other amadarines, such as arnosine and pyridoxamine, also have antiglycation properties. 
Pyridoxamine has been shown to be more effective than AG. Unlike AG, it does not 
interact directly with the carbonyl moiety of the Amadori intermediate, but it interferes 
  
 
Table 1-1. Inhibitors and breakers of advanced glycation endproducts  
Agent Chemical Type Mechanism of action 
Aminoguanidine 
(Pimegedine®, AG) 
 
Metformin 
(dimethylbiguanide) 
Guanidine structure - Traps reactive di-carbonyls impeding conversion to AGE 
- Prevents cross-link formation 
- Inhibits free radical formation, lipid peroxidation and oxidant induced  
apoptosis 
- Large quantities can generate H202 and so inhibit Catalase. 
- Depletion of essential carbonyls in the body can also occur e. g. Vitamin 
B6 
Vitamin C and E  
Nicarnitine 
Antioxidants - Inhibit oxidative conversion involved in di-carbonyl and AGE formation 
N-acetyl cysteine 
(NAC)  
an altered form cysteine - work as antioxidant, help to synthesize glutathione 
A717 Monoclonal antibody - Acts on Amadori adducts containing albumin with evidence of retarding 
development of diabetic nephropathy 
Pyridoxamine 
(Pyridorin, PM) 
Vitamin B complexs - Inhibitor of the conversion of Amadori intermediates to AGE 
 
OPB-9195 Synthetic Thiazolidine  
Derivative 
- Trap carbonyl intermediates of advanced glycation 
- Suppress TGFβ and VEGF expression 
2,3-diamino 
phenazine (2,3 DAP) 
 - In vitro work using rat diabetic models showed AGE accumulation and  
mesenteric vascular hypertrophy 
Losartan Angiotensin II receptor  
inhibitor 
- Reduce serum AGE in rat remnant kidney model. Mechanism unknown,  
but was independent of blood pressure changes 
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Pyruvate a-keto acid - Prevent glycation of protein competitively by forming a Schiff base 
between free keto groups and free amino groups in proteins. 
- Inhibits oxidative conversion of the initial glycation product to an AGE. 
Phenacyl thiazolium 
bromide (PTB) 
Alagebrium  
(ALT-711) 
Thiazolium Compound - Cross-link breakers that could cleave di-ketone bridges between two 
adjacent carbonyl groups which could form intermolecular cross-links 
Adapted from (Singh et al., 2001)
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with post-Amadori oxidative reactions by binding catalytic redox metal ions (Voziyan et 
al., 2003). Inhibition of the post-Amadori reactions could also decrease the production of 
ROS, which are known to be formed during this process (Voziyan and Hudson, 2005). 
Pyridoxamine is also able to bind intermediates of lipid peroxidation and prevent 
alteration of lysine residues and formation of CML, CEL and other derivatives during the 
oxidation of LDL in vitro. 
 Being an oral antihyperglycemic agent for the management of type 2 diabetes, 
metformin may also have an effect in inhibiting glycation reactions (Bailey and Turner, 
1996). Like AG, metformin has a guanidine structure. Its inhibitory effect on protein 
glycation has been reported by several research groups (Rahbar et al., 2000a; Rahbar et 
al., 2000b; Ruggiero-Lopez et al., 1999). Glycation-induced functional and structural 
alterations of the diabetic myocardium were prevented by metformin. This is another 
possible mechanism to explain the beneficial effects of metformin on diabetic vascular 
complications (Beisswenger and Ruggiero-Lopez, 2003). 
 Some synthetic compounds with thiazolidine structure, such as OPB-9195, have 
recently been found to be effective inhibitors of AGE formation. OPB-9195 is known to 
trap carbonyl intermediates of advanced glycation and showed inhibitive effects on 
diabetic neuropathy and nephropathy (Tsuchida et al., 1999). Administration of OPB-
9195 was found to restrain the cellular production of growth factors such as TGF-β and 
VEGF  (Tsuchida et al., 1999). In addition, it improved motor nerve conduction velocity 
and suppressed the oxidative stress-induced DNA damage in diabetic rats (Wada et al., 
2001).  
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 Plenty of in vitro and in vivo studies have verified the effectiveness of other 
agents to inhibit AGE accumulation. Antioxidant such as Vitamin E, C and nicarnitine 
inhibit oxidant activity and unspecifically increase the clearance of AGE. The 
monoclonal antibody A717 acts on Amadori adducts containing albumin and prevent the 
development of diabetic nephropathy. Interestingly, an angiotension II receptor 
antagonist, Losartan, was also observed to reduce serum AGE in rat kidney model. 
Although the mechanism is unknown, this effect was shown to be independent of blood 
pressure changes (Sebekova et al., 1999).   
 
1.2.6.2. AGE breakers 
The abnormal accumulation of glycation-induced crosslinks between proteins 
increases the stiffness of tissues or organs, especially vascular wall. Immpaired biological 
function of related tissues thus leads to decreased elasticity of connective tissue and 
matrix components which is one of the major characteristics of the normal aging process 
of mammals. Moreorver, it is the major reason that causes thet vascular complications of 
diabetes. Although AG and related compound have been applied in medical practice, they 
demonstrate severe side effect. In addition, they cannot reverse the existing AGEs 
deposited in the tissues to improve the pathogenesis of aging that associated with diabetes 
and hypertension. In 1996, the first AGE-crosslink breaker, PTB was reported (Vasan et 
al., 1996). In the same study, its effect on vascular hypertrophy in streptozotocin-induced 
diabetic rats was investigated. Intra-peritoneal administration of PTB resulted in 
reduction of AGE accumulation on blood vessels and attenuated the diabetes induced 
mesenteric vascular hypertrophy. As PTB is unstable in physiological buffers, its analog 
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alagebrium (4,5-dimethyl-3-phenacylthiozolim chloride) with higher stability was 
developed and exclusively used in different in vitro and in vivo studies (Vasan et al., 
2003; Wolffenbuttel et al., 1998). 
Alagebrium is a stable 4, 5-dimethylthiazolium derivative of the prototype 
compound PTB. It directly targets the abnormal protein crosslinks leading to the stiffness 
of the cardiovascular system. Treatment of alagebrium resulted in reduced abnormal 
protein crosslinking bonds and leads to diminished inflammatory and sclerotic signaling 
which contribute to the deposition of additional amounts of matrix proteins that 
physically stiffen tissues. In animal study, 1–3 week treatment of alagebrium in 
streptozotocin-induced diabetic rats efficiently supressed the hyperglycemia-induced 
stiffness in vascularture system including aortic artery and carotid artery. The systemic 
arterial compliance aortic impedance, carotid compliance and carotid distensibility were 
siginificantly improved with alagebrium treatment (Wolffenbuttel et al., 1998). As 
alagebrium does not disrupt the natural carbohydrate modification to proteins, natural 
intra-molecular crosslinking and peptide bonds and therefore normal protein structure and 
function are maintained while abnormal crosslinking is removed. This AGE-targeting 
specifity provides more potential for the application of alagebrium in the treatment of 
patients with hypertension/diabetes related complications and aging. 
1.3. Hypothesis and objectives 
  Although the linkage between AGEs accumulation and diabetes has been 
extensively observed, the role of MG in the development of insulin resistance has not 
been well studied. In the present study, it is hypothesized that MG is a critical factor that 
leads to the pathogenesis of insulin resistance syndrome. To test this hypothesis, we first 
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tested whether MG can react with the insulin molecule and change its biological function. 
After that, whether and how MG impairs insulin signalling pathway was examined in 
normal glycemic rats. As obesity is one of the major causative factors of insulin 
resistance, we then explored the effect of MG in the pathogenesis of obesity. 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1. Cell preparations 
3T3-L1 cells (mouse fibroblast cell line), L8 cells (rat skeletal muscle cell line), 
and H4-II-E cells (rat hepatocyte cell line) were purchased from American Type Culture 
Collection.  
 
2.1.1. Culture of 3T3-L1 cells 
            3T3-L1 pre-adipocytes was grown to confluence in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen, ON, Canada) containing 10% bovine calf serum 
(Invitrogen, ON, Canada). At two days postconfluence, cell differentiation was induced 
by adding insulin (2.5 µg/ml, Sigma, St Louis, MI, USA), dexamethasone (0.25 µM, 
Sigma-Aldrich, MO, USA), and isobutylethylxanthine (IBMX, 0.5 mM, Sigma-Aldrich, 
MO, USA) to media for 3 d according to the protocol described previously (Brady et al., 
1999). The cells then were grown in postdifferentiation media (DMEM containing 10% 
fetal calf serum and 2.5 µg/ml insulin). After completion of the differentiation protocol, 
>95% of the cells exhibited an adipocyte phenotype. The post-differentiation medium 
containing different concentrations of MG and/or different MG inhibitor/scavenger 
including NAC or metformin (concentrations as indicated) was changed every day until 
cells were differentiated. Insulin solution (100 nM) was added into the medium 20 min 
before harvesting the cells. Cells were then washed with phosphate buffer saline (PBS) 
for three times and ready for different experiments. 
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2.1.2. Culture of L8 cells and H4-II-E cells 
 L8-cells were cultured in a 4:1 mixture of DMEM and Medium 199 (Invitrogen, 
ON, Canada), complemented with 10% horse serum and antibiotics.  
 H4-II-E cells were cultured in DMEM medium with 10% of fetal calf serum and 
grow till confluence. 
 
2.1.3. Culture of INS-1E cells 
 Cloned INS-1E cells were derived and selected from the parental rat insulinoma 
(Iezzi et al., 1999). The cell line was a gift from Dr. Claes Wollheim (University Medical 
Center, Geneva, Switzerland). INS-1E cells were cultured in RPMI 1640 (Invitrogen, ON, 
Canada) containing: 11.1 mM glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 
mM HEPES, 5% fetal calf serum (Invitrogen, ON, Canada), 50 µM ß-mercaptoethanol 
(Sigma-Aldrich, MO, USA), and 110 U/ml penicillin (Invitrogen, ON, Canada). The 
cultured cells were passaged weekly by gentle trypsinization and seeded at a density of 
1.2 x 104 cells/cm2, i.e., 1 x 106 cells in a 10 cm Falcon dish with 8 µl complete medium. 
For most experiments, INS-1E cells were seeded in Falcon 12-well plates at 2 x 105 cells/ 
well. 
 
2.2. Animal treatment 
 All the animals were purchased from Charles River laboratories, Inc. (MA, 
USA), housed in temperature-regulated animal facility and maintained at 22-23°C.   The 
experimental animals were exposed to a 12 h light/dark cycle with free access to water 
and different diet recipes.  Rats were treated in accordance with guidelines of the 
 - 61 -
Canadian Council on Animal Care and the experimental protocols were approved by the 
Animal Care Committee of the University of Saskatchewan.  
 
2.2.1. Treatment of Sprague-Dawley rats  
Twenty nine, 7-week-old male Sprague Dawley (SD) rats were randomly divided 
into control group (n = 7), fructose-fed group (n = 10), fructose–NAC co-treated group 
(n = 8), and NAC treated group (n = 4) with a feeding period of 9 weeks. Standard rat 
chow (Prolab® RMH 3000, PMI® Nutrition Intl. USA) and water were given to the 
control group. Fructose-enriched diet consists of 60% fructose, 22% crude proteins, 5% 
crude fat, 5% crude fiber, 6% ash, and 2% added minerals. Body weight, blood glucose 
level, and systolic blood pressure were measured weekly. Blood glucose was determined 
using the OneTouch® blood glucose monitoring system (LifeScan, Inc, USA). For NAC 
or fructose–NAC treated groups, NAC was administered with water at a dose of 
10 mg/kg/day.  At the end of week 9, different tissues were isolated and frozen under 
-80°C after anaesthetization of rats by intraperitoneal injection of sodium pentobarbital 
(50 mg/kg body weight).  
For metformin treated experiment, rats were randomly divided into control group 
(n=7), fructose-fed group (n=10), fructose-metformin co-treated group (n=8) and 
metformin treated group (n=4) with a feeding period of 9 weeks.  The fructose-enriched 
diet, which consists of 60% fructose (replacing the 60% starch) with the remaining 
components in the diet the same as in standard lab rat chow (Galipeau et al., 2001; 
Harada et al., 2004; Song et al., 2004), has been widely used in insulin resistance studies 
(Galipeau et al., 2001; Harada et al., 2004; Song et al., 2004). For the fructose-metformin 
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co-treated group, in addition to fructose-enriched diet, metformin was administered in 
water at 500 mg/day/kg body weight. Body weight, plasma glucose levels, and systolic 
blood pressure were measured weekly. Systolic blood pressure was measured by a 
standard tail cuff noninvasive BP measurement system (Model 29-SSP, Harvard 
Apparatus, Canada) (Wu et al., 2004).  
 
2.2.2. Treatment of Zucker rats  
Eight 8-week-old male Zucker fatty rats and eight age-matched lean Zucker rats 
were fed with standard rat chow (Prolab® RMH 3000, PMI® Nutrition Intl. USA) and 
water. Body weight, blood glucose level were measured weekly using a Quantichrom 
glucose assay kit (Bioassay Systems, CA, USA). Blood samples (0.5 ml) were obtained 
from tail vein at the age of 10, 12 and 14 weeks for serum MG measurement. 
Intraperitoneal glucose tolerance test (IPGTT) was carried out after overnight fasting at 
the age of 16 weeks. At the end of week 16, different tissues were isolated and frozen at -
80 °C after anaesthetization of rats by intraperitoneal injection of sodium pentobarbital 
(50 mg/kg body weight), 
 
2.3. Patients 
Blood samples were obtained from 20 untreated patients with mild to moderate 
hypertension from the clinical research units at the Sacré-Coeur Hospital and at the 
Hôtel-Dieu Hospital in Montreal.  Based on the BMI value (=body weight in kg/ square 
of the height in meter), the patients were divided into obese (BMI≥30) and non-obese 
(BMI<30) groups. Both groups were comprised of males and females ranging in age from 
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46 to 68 years. All subjects provided informed written consent approved by the ethics 
committees of both hospitals. Venous blood was drawn into pre-chilled tubes (BD, NJ, 
USA) containing EDTA (K3). The samples were vortexed and centrifuged immediately at 
4 °C for 20 min at 3000 rpm and the plasma samples were stored at -80 °C. 
 
2.4. MG measurement 
Quantitation of MG was done by the widely accepted o-phenylenediamine (o-
PD)-based assay as described by Chaplen et al. (Chaplen et al., 1996), with some 
modifications. Briefly, the supernatant of tissue homogenate or serum was incubated with 
100 mmol/L o-PD (derivatizing agent) for 3 h at room temperature. The quinoxaline 
derivative of MG (2-methylquinoxaline) and the quinoxaline internal standard (5-
methylquinoxaline) were measured using a HITACHI D-7000 high-performance liquid 
chromatography (HPLC) system (HITACHI Ltd., Ontario, Canada). The column was a 
Nova-Pak® C18 column (3.9 x15 mm, and 4 um particle diameter; Waters, MA, USA). 
The mobile phase was composed of 80% (vol) of 10 mmol/L NaH2PO4 (pH 4.5) and 20% 
(vol) of HPLC grade acetonitrile. Duplicate injections of each sample were made. 
Samples were calibrated by comparison with a 2-MQ standard. 
 
2.5. Protein extraction  
The cultured cells were washed with ice-cold Krebs buffer (118 mM NaCl, 4.7 
mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 4.2 mM NaHCO3, 2 mM CaCl2, 10 mM 
glucose, 200 µM sulphinpyrazone and 10 mM Hepes, pH 7.4) for 2 times. The cells were 
then scraped and collected into a centrifuge tube. After centrifugation at 1000 rpm for 10 
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minutes, the supernatant was discarded and the pellet was resuspended in 0.2 ml of 
Krebs/ RIPA buffer containing 1% protease inhibitor (Sigma-Aldrich, MO, USA). After 
the powdered frozen rat tissue or cells in Kreb’s buffer were sonicated using a ultrasonic 
homogenizer, transferred the supernatant into another eppendorf tube to determine the 
protein concentration.  
 
2.6. Determination of protein concentration  
The protein concentration of samples was determined by BCA (bicinchoninate) 
assay (Smith et al., 1985). Briefly, 50 volumes of Reagent A (1g BCA, 2g sodium 
carbonate, 0.16g sodium tartrate, 0.4g NaOH, 0.95g sodium bicarbonate) and 1 volume of 
Reagent B (4% CuSO4.5H2O)  were mixed to make the working solution. The dilution 
series of BSA and sample protein were then prepared. Sealed samples and incubated at 
37oC for 30 minutes. The spectrophotometric absorbance of the samples was determined 
using a plate reader (Thermo Labsystems, Finland) at 562 nm. The protein concentration 
of the unknown samples was then estimated by the machine according to the slope of the 
standard curve. 
 
2.7. Tricine SDS-PAGE 
           Samples were separated on Tricine SDS-PAGE gels containing 16.5% (w/v) 
acrylamide, as described by Schägger and von Jagow (Schagger and von Jagow, 1987). 
Samples were boiled for 10 min in solubilization buffer [62.5 mM Tris-HCl, pH 6.8; 2% 
(w/v) SDS; 10% (v/v) glycerol; and 0.025% (w/v) bromphenol blue]. After 
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electrophoresis, the gels were stained with Coomassie brilliant blue G (Sigma, ON, 
Canada) and photographed. 
 
2.8. Western blotting 
The supernatants containing crude cellular proteins were boiled, run on a 10-12% 
SDS-PAGE gel, and then transferred to a PVDF membrane (polyvinylidene difluoride, 
PALL Corporation, ON, Canada).  The membrane was blocked with 5% skim milk 
solution in PBS containing 0.05% Tween-20 (PBS-T) at room temperature for 1 h and 
incubated with primary antibody (1:500 for p21, p27, phosphor-p21 (p-p21) and 
phosphor-p27 (p-p27) antibodies, Santa Cruz, MO, USA; 1:1000 for Akt and phosphor-
Akt (p-Akt) and β–actin antibodies, Cell Signaling Technology, MA, USA). After 
washing for 3 times with the PBST for 30 min, the membrane was incubated with the 
HRP-conjugated secondary antibody (1:10000) for 1 h at room temperature. The 
immunoreactions were visualized by ECL and exposed to X-ray film (Kodak Scientific 
Imaging film, X-omat Blue XB-1). β-actin was used as a housekeeping protein to 
normalize the data for variations in loading. 
 
2.9. Protein immunoprecipitation 
Protein A/G–sepharose beads (Sigma-Aldrich, MO, USA) were used for 
immunoprecipitation.   Approximately 200 μl of beads were washed with 1.6 ml of PBST 
3-4 times in a screw-capped Eppendorf tube.  The beads were re-suspended in 1.6 ml of 
PBST containing 5 μl anti-PI3K p85 antibody (Upstate Biotechnology, NY, USA) and 50 
mg BSA.  The tubes were set horizontally on a gentle rocking platform to keep the beads 
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in motion and rocking was continued overnight at 4oC.  The following day, the pre-
absorbed beads were centrifuged at 2,000 g for 2 min. After removing the supernatant, 1 
ml of crude protein extract was added to the Eppendorf tube. The mixture was then 
carefully transferred to a clean 1.5 ml Eppendorf tube, and 300 μg of crude protein 
extract were added.  The Eppendorf tubes were placed horizontally on a gently rocking 
platform overnight on ice.  The following day, the beads were centrifuged at 2000 xg for 
2 min.  The supernatant was removed, and pre-chilled PBS-T was added to wash the 
beads.  The washing was repeated at least 8 times.  To elute the protein from the beads, 
100 µl of protein loading buffer with fresh 10 mM Dithiothreitol (DTT) was added and 
heated to 95oC for 5 min.  After boiling, iodoacetimide was added to Eppendorf tubes to a 
concentration of 25 mM from a fresh 0.5 M stock to inhibit disulfide bonds from 
reforming.  After gentle vortexing, the tubes were centrifuged at 16,000 g for 1 min.  The 
supernatant was carefully collected without disturbing the beads and loaded onto a 
protein gel as detailed above. 
 
2.10. PI3K activity assay 
PI3K activity in the immunoprecipitates was analyzed with a PI3K enzyme-linked 
immunosorbent assay (ELISA) (from Echelon Biosciences, UT, USA) according to the 
manufacturer's instructions. Briefly, immunoprecipitated enzyme and PI(4,5)P2 substrate 
were incubated for 1 h at room temperature in the reaction buffer. Kinase reaction was 
stopped by pelleting the beads by centrifugation and transferring the reaction mixture to 
the incubation plate and incubated overnight at 4°C with a PI(3,4,5)P3 detector protein, 
then added to the PI(3,4,5)P3-coated microplate for 1 h for competitive binding. A 
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peroxidase-linked secondary detection reagent and colorimetric detection (absorbance 
was measured at 450 nm) is used to detect PI(3,4,5)P3 detector protein binding to the 
plate. The colorimetric signal is inversely proportional to the amount of PI(3,4,5)P3 which 
produced by PI3K. The expression levels of the PI3K components p85 for each time point 
were detected by western blot analysis of pelleted beads.  
 
2.11. Cell proliferation assay 
The proliferation of 3T3-L1 cells was measured by the Celltiter 96® non-
radioactive cell proliferation assay kit (Promega, WI, USA). Briefly, cells were seeded 
onto 96-well plates (5000 cells per well) and cultured in DMEM medium (HyClone, 
Ontario, Canada). When they reached ~50% confluency, the medium was removed and 
the cells were washed with serum-free medium and incubated in serum-free medium for 
48 h. The cells were then treated with/without MG, SH-6 (10 µM) or alagebrium (50 µM) 
for 48 h in serum-containing DMEM medium supplemented. After that, the cells were 
incubated with MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
solution (final concentration 0.5 mg/ml and stock solution 5 mg/ml MTT in PBS) for at 
37°C for 4 h and then with solubilization solution at room temperature for 1 h. The 
spectrophotometric absorbance of the samples was determined by a plate reader (Thermo 
Labsystems, Finland) at 570 nm. 
 
2.12. Cell cycle assay 
Cell cycle analysis was performed by propidium iodide (PI) staining. Briefly, 
3T3-L1 cells were firstly seeded into 10 cm dishes. When they reached ~50% of 
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confluence, the cells were incubated in serum-free medium for 48 h and then treated with 
MG, SH-6 (10 µM) or alagebrium (100 µM) for 12, 16 or 20 h. Subsequently, the cells 
were harvested and re-suspended in PBS at 1 × 106/ml and fixed with 70% cool ethanol 
for 1 h. After the cells were washed and centrifuged, the pelleted cells were re-suspended 
in 1 ml PBS and added with 50 ml of RNase A stock solution (10 g/ml). Followed a 3 h 
incubation at 4°C, the cells were then pelleted and added with 1 ml of PI staining solution 
(3.8 mM sodium citrate, 50 mg/ml PI in PBS) and analyzed by flow cytometry on an 
Beckman Coulter Epics XL flow cytometer (Beckman Coulter Canada Inc, ON, Canada). 
Analysis was performed after 10 000 counting events.  
 
2.13. Cdk2 activity assay 
Cdk2 activity was determined by measuring ATP consumption with a PKLight 
Assay Kit (LT07-500, Cambrex Bio Science, ME, USA). Briefly, after incubation of 200 
μg of proteins with 2 μg of anti-Cdk2 antibody (Santa Cruz) in cell lysis buffer for 4 h at 
4°C, protein A/G plus agarose beads (20 μl) were added and the mixture was incubated 
overnight at 4°C with shaking. Beads were washed 3 times and suspended in 40 μl of 
Cdk2 kinase assay buffer containing 20 μM ATP and 0.1 μg/μl histone H1. The above 
mixture was reacted at 30°C for 30 min in 96-well plate before kinase stop solution and 
ATP detection reagent were added according to the manufacture’s protocol. 
Bioluminescent signal in each well was detected using a microplate spectrofluorometer 
(NovoStar, BMG LABTECH Inc., NC, USA). Cdk2 activity was expressed as ATP 
consumption from 3 experiments. 
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2.14. MG-insulin adduct preparations 
            For mass spectrometric analysis, the adducts formed between MG and insulin 
(MG-insulin) were prepared by incubating human insulin (0.01–1 µg/µl) with MG (10 
µM–1 mM) for 2 to 72 h in vitro in phosphate buffer (pH 7.4) at 37°C under sterile 
conditions (Lo et al., 1994). For other studies, MG-insulin adducts were prepared by 
incubating human insulin (0.01–1 µg/µl) with MG (1–100 µM) for 3 d in vitro in 
phosphate buffer (pH 7.4) at 37°C under sterile condition (Lo et al., 1994). To separate 
free MG molecules from the MG-insulin, the reaction mixture was centrifuged on a 
Microcon® YM-3 centrifugal filter tube [nominal MW cut-off 3000 dalton (Da), 
Millipore Corporation, MA, USA] at 12000 rpm for 30 min. After the first centrifugation, 
an equal vol of ddH2O was added and the reaction mixture was centrifuged again. This 
process was repeated three times at room temperature. The retained molecules on the 
membrane were then recovered in ddH2O, and the MG concentration was measured using 
HPLC. Quantitation of MG was done by o-PD based assay as described previously 
(Chaplen et al., 1998; Lo et al., 1994; Wang et al., 2004).  
 
2.15. Mass Spectrometry 
            Samples containing human insulin, and insulin incubated with MG, were reduced 
with 10 mM DTT (pH 8.0) at 55°C for 1 h and alkylated with 55 mM iodoacetamide (pH 
8.0) in dark to separate the A- and B-chains of (modified) insulin. This technique ensured 
that the site(s) of modification could be determined by using mass spectrometry (MS). 
Insulin samples and MG-insulin incubates were first analyzed by matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) MS, before and after 
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reduction/alkylation. Samples and incubates were purified by solid-phase extraction using 
packed disposable pipette tips (ZipTipC18, Millipore, Billerica, MA, USA), according to 
the manufacturer’s instructions. Extracted samples (0.75 µl) were then combined with an 
equal vol of dihydroxybenzoic acid (DHB) matrix solution (20 mg/mL in 75% 
acetonitrile containing 0.1% TFA) and applied to a 96-well MALDI target plate. Mass 
spectra were acquired on a Voyager-DE STR instrument (Applied Biosystems, MA, 
USA), operating in the positive ion and linear modes, with delayed ion extraction. 
Typical operating conditions were: accelerating voltage 25,000 V, grid voltage 95.5%, 
guide wire voltage 0.05%, extraction delay time 400 ns, and laser power 1790. Spectra 
were generated by combining the scans from 200 laser shots. Mass-to-charge (m/z) ratios 
for the observed protonated peptide ion peaks were determined using bovine insulin (m/z 
5734.65) for close eternal calibration. 
 Reduced and alkylated MG-insulin incubates were further analyzed by liquid 
chromatography-mass spectrometry (LC-MS) and tandem mass spectrometry (MS/MS) to 
locate the site(s) of MG attachment. Samples were diluted 50-fold in 0.1% aqueous TFA. 
A 5 µl aliquot was then analyzed by LC-MS using a capLC ternary HPLC system 
interfaced to a Q-Tof Ultima Global hybrid tandem mass spectrometer fitted with a Z-
spray nanoelectrospray (nanoES) ion source (Waters). Typical operating conditions were: 
nanoES capillary 3.50 kV, lens 1 100 V, cone 100 V, source temperature 80°C, 
desolvation temperature 150°C, cone gas flow 143 L/h, collision energy 10 eV (MS), and 
32 eV (MS/MS). Solvents A and C comprised 0.2% formic acid in water, while solvent B 
consisted of 0.2% formic acid in acetonitrile. Reduced-insulin and MG-insulin peptides 
were captured on a C18 trapping column (Symmetry 300, 0.35x5 mM Opti-pak; Waters 
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Milford, MA, USA) and washed for 3 min using solvent C at a flow rate of 30 µl/min. 
The flow path was then switched using a 10-port rotary valve, and the peptides eluted 
onto a C18 analytical column (PepMap, 75 µm x 15 cm, 3 µm particle size; LC Packings). 
Separations were performed using a linear gradient of 0:100 to 60:40% B:A over 43 min. 
The composition was then changed to 80:20% B:A and held for 10 min to flush the 
column before re-equilibrating for 7 min at 0:100% B:A. Mass calibration of the Q-Tof 
instrument was performed using a product ion spectrum of Glu-fibrinopeptide B acquired 
over the m/z range 50 to 1900. Predicted m/z ratios for possible A- and B-chain MG-
insulin were based on the known molecular masses of human insulin and MG and the 
formation of multiple adducts with and without concomitant loss of water (vide infra). 
Multiply protonated (4+) ions corresponding to the insulin B-chain and various MG-
insulin adducts were detected by LC-MS (m/z 400 to 1900). These were selected for LC-
MS/MS analysis (m/z 100 to 1900), and the resulting product ion spectra deconvoluted 
using the instrument software (MaxEnt 3) to identify N-terminal (b-type), C-terminal (y-
type), immonium, and internal fragment ions. 
To study the reaction between metformin and MG, a solution containing 25 µM 
MG and 25 µM metformin in 0.2 M sodium phosphate buffer (pH 7.4) was prepared and 
incubated at 37 ºC for 24 h. The resulting incubate was diluted 1000-fold in 50:50 v/v 
water/acetonitrile containing 0.1% formic acid and analyzed by flow injection 
electrospray ionization mass spectrometry (FI-ESI-MS), using a HP1100 binary solvent 
pump and autosampler (Hewlett-Packard, Palo Alto, USA) coupled to a Quattro LC 
quadrupole tandem mass spectrometer via a Z-sprayTM interface (Micromass, Manchester, 
UK). The samples were introduced at a flow rate of 20 µl/min and ionized by positive-ion 
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electrospray using a capillary potential of 3 kV, a cone voltage of 30 V, and a source and 
drying gas temperature of 120 ºC and 350 ºC, respectively. MS data were acquired in the 
m/z range 110 – 400 at the rate of 0.8 s/scan, with an interscan delay of 0.1 s, and MS 
spectra generated using the MassLynxTM instrument software. Structural analysis of 
selected precursor ions was subsequently performed by collision-induced dissociated 
(CID) and product-ion tandem mass spectrometry (MS/MS), using a collision gas (Ar) 
pressure of 2 x 10-3 mbar and a collision energy (ELAB) of 20 eV. MS/MS data were 
acquired in the m/z range 50 – 280, and product-ion spectra generated using MassLynxTM. 
 
2.16. Real-time quantitative polymerase chain reaction (PCR) 
  For total-RNA preparation, 3T3-L1 cells were homogenized in TRIzol® reagent 
(Invitrogen, ON, Canada) and RNA was isolated according to the manufacturer’s 
instructions. Total RNA was reverse-transcribed in triplicate using RevertAidTM H Minus 
M-MuLV reverse transcriptase (MBI, Fermentas Burlington, ON, Canada) in the 
presence of 5x RT buffer (MBI, Fermentas, MD, USA), random primer (Invitrogen, 
Burlington, ON, Canada), dNTP mixture (Amersham Pittsburgh, PA, USA) at 42°C for 
50 min, followed by 72°C for 10 min. The primers used in this study for real-time PCR 
are summarized in Table 2-1. The real-time PCR was carried out in an iCycler iQ 
apparatus (Bio-Rad, CA, USA) associated with the ICYCLER OPTICAL SYSTEM 
software (version 3.1) using SYBR Green PCR Master Mix (Bio-Rad). All PCRs were 
triplicated and performed in 96-well optical-grade PCR plates and run for 45 cycles at 
95°C for 20 s, 62°C for 1 min, and 72°C for 30s. After cycling, melting curves of the 
PCR products were acquired by stepwise increase of the temperature from 62° to 95°C.  
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Table 2-1. The primers used for real-time PCR 
Primer Sequence 
INSULIN RECEPTOR-1 5’- CGGCCCGATGCTGAGAACAAC-3' 
INSULIN RECEPTOR-2 5’- CAGCACATGCGCATCAGGTCAGT-3' 
IRS-1 5’- AGGGGCTGCTTCCATTTGTAG-3' 
IRS-2 5’- ACCACCGCTGCCCC CTCCTG-3' 
PI3K-1 5’- GCCACAGCA GCCTTCAACAAA-3' 
PI3K-2 5’- CAACATCAGCGCAAACAGGGTAAT-3' 
LEPTIN-1 5'- CGGGGCGCTGGTGTAGGGAGATT -3' 
LEPTIN-2 5'- ACACCGCATGGAGAGTCGCAGGAG -3' 
ADIPONECTIN-1 5'- ATGGGTAGTTGCAGTCAGTTGGTA -3' 
ADIPONECTIN-2 5'- GCCGCTTATGTGTATCGCTCAG -3' 
PPARγ-1 5'- AGGGCTTCCGCAGGTTTTTGA -3' 
PPARγ-2 5'- CACAGGCCGAGAAGGAGAAGC -3' 
C/EBPα 5’- CTTGCGCAGGCGGTCATTGTCACT -3' 
C/EBPα 5’- GGCCGGCCTCTTCCCCTACCAG -3' 
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2.17. Measurement of [3H]-2-Deoxyglucose uptake 
 [3H]-2-deoxyglucose ([3H]-2-DOG, PerkinElmer) was used for glucose uptake 
experiments in different insulin-sensitive cells as described previously (Brady et al., 
1999). Briefly, confluent cells in 24-well plates were washed with serum-free DMEM and 
incubated in the same medium for 3 h. The cells were then washed twice with glucose-
free and serum-free DMEM, followed by incubation in the same medium for 30 min. 
Thereafter, the cells were exposed to insulin, MG-insulin, or MG at different 
concentrations for 30 min and continuously incubated for another 20 min after the 
addition of [3H]-2-DOG (0.1 µCi/500 µl) with glucose (50 µM) to the medium. All 
incubations were performed at 37°C. The incubation was stopped by washing cells three 
times with ice-cold glucose-free phosphate buffer. The cells were lysed in 0.1% SDS and 
then transferred into scintillation vials for counting (Beckman LS 3801 scintillation 
counter). 
 
2.18. Determination of C-peptide secretion from INS-1E cells 
 C-peptide is stoichiometrically related to insulin on a one-to-one basis and is 
coreleased with insulin (Polonsky, 1995). By measuring C-peptide concentration, the 
amount of insulin secreted can be deduced. In our study, C-peptide was determined by a 
rat C-peptide ELISA kit (WAKO, Osaka, Japan) using rat C-peptide as a standard. The 
insulin secreting INS-1E cells were plated into 24-well plates at a density of 2 x 104 
cells/well. After 2-days culture, the cells were maintained at 37°C for 2 h in glucose-free 
RPMI 1640, washed, and preincubated in a glucose-free Krebs-Ringer-bicarbonate 
medium (pH 7.4) containing (in mM): 135 NaCl, 3.6 KCl, 5 NaHCO3, 0.5 NaH2PO4, 0.5 
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MgCl2, 1.5 CaCl2, 10 HEPES (KRBH buffer), and 0.1% BSA. After a 30-min 
preincubation, insulin or MG-insulin was added into the medium, respectively. Cells were 
incubated for another 90 min at 37°C in the presence of 16.7 mM of glucose. At the end 
of incubation, medium was collected and centrifuged for 10 min at 2500 g and 4°C to 
remove cell debris. The supernatant was used immediately or stored at –20°C until C-
peptide measurement. 
 
2.19. Adipogenesis assay 
3T3-L1 cells were treated with/without MG, SH-6 (10 µM) or alagebrium (50 µM) 
for 48 h and then continue cultured in fresh medium. When the cells reached 80% 
confluence, differentiation was induced by adding 2.5 µg/ml insulin, 0.25 µM 
dexamethasone (Sigma-Aldrich, MO, USA), and 0.5 mM isobutylmethylxanthine 
(Sigma-Aldrich, MO, USA) to media for 2 days according to the protocol described 
previously (Brady et al., 1999; Jia et al., 2006). The cells were then grown in post-
differentiation medium (DMEM containing 10% fetal calf serum and 2.5 µg/ml insulin). 
On the fifth day of post-differentiation, cells were fixed with 4% (v/v) formaldehyde in 
PBS, and then stained with Oil Red solution for 15 min. A stock solution of oil red O (0.5 
g in 100 ml of isopropanol) was prepared and filtered through a 0.2 µm filter. The 
working solution was prepared by diluting the stock solution by distilled water (3:2), left 
for 1 h at room temperature, and filtered through a 0.2 µm filter before use. Cells in 12-
well plate were stained with 200 µl oil red O working solution for 15 min at room 
temperature. The cells were rinsed five times with water and pictures were photographed 
under microscope. Cells were considered as being lipid-positive when droplets were 
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stained red. The dye retained by the cells was eluted by incubation with 500 µl of 
isopropanol and quantified by measuring absorbance at 500 nm by a plate reader 
(Thermo Labsystems, Finland).  
 
2.20. Determination of insulin degradation through liver cells 
            The H4-II-E cells were cultured in 12-well plates to confluence (2x105 cells/well) 
and were treated with insulin or MG-insulin at 37°C for 15 min. Thereafter, the cultured 
medium was collected and insulin concentration was measured with a rat-specific insulin 
ELISA kit (Mercodia, Uppsala, Sweden). 
 
2.21. Intraperitoneal glucose tolerance test  
The intraperitoneal glucose tolerance test (IPGTT) was carried out after 12–14 h 
fasting. After the basal glucose level was measured, conscious rats were injected 
intraperitoneally with 1.5 g/kg body weight of 50% (w/v) glucose solution in 0.9% (w/v) 
saline. A blood sample was then collected from the tail vein and blood glucose level was 
measured using OneTouch® blood glucose monitoring system (LifeScan, Canada) at 0, 
10, 15, 30, 60, and 120 min after the glucose injection.  
 
2.22. Immunohistochemistry study 
Cells were cultured on glycine coated cover glasses in DMEM medium.  
Formaldehyde solution (40%) was added directly into the culture medium to a final 
concentration of 4% and incubated at room temperature for 30 min. After rinsing the 
cover glass with PBS-T for 4 times over 30 min, cells were permeabilize with 0.5% 
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Triton X-100 in PBS-T for 5 min, and then blocked with 5% horse serum in PBS-T for 30 
min. Anti-CEL antibody(1:200) was added and incubated for 60 min. After rinsing the 
the cells with PBS-T for 4 times over 30 min, the Alexa-546 fluorescence labed anti-
mouse second antibody (1: 10000; Molecular Probes, OR, USA) was applied and 
incubated for 30 min in the dark. The cells were rinsed with PBS-T for 4 times and 
mounted with cover slips. The excess PBS-T was blotted away and the edges were sealed 
with nail polish.  A second coat was applied after the polish had dried, the slides were 
then covered with foil and stored under -80°C 
 
2.23. Biochemical examination of blood samples  
Blood samples were collected from the aorta of rats. Insulin level in serum (μg/l) 
was determined with a rat-specific insulin ELISA kit (Mercodia AB, Sweden). The levels 
of triglyceride, total cholesterol, and high-density lipoprotein (HDL)-cholesterol were 
assayed in the Laboratory of Biochemistry and Hematology, Royal University Hospital, 
University of Saskatchewan, Saskatoon, Canada. 
 
2.24. Statistical analysis 
            Data are expressed as mean SEM and analyzed using one way ANNOVA in 
conjunction with t test where applicable. Difference between groups was considered 
statistically significant when P < 0.05. 
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CHAPTER THREE 
STRUCTURAL AND FUNCTIONAL CHANGES IN HUMAN 
INSULIN INDUCED BY METHYLGLYOXAL 
 
3.1. Introduction 
Insulin resistance is a state in which increased concentrations of insulin are 
required to produce a given biological response (Rett, 1999). Because the major effect of 
insulin is to promote overall glucose utilization, insulin resistance is also defined as 
reduced insulin mediated whole-body glucose uptake (DeFronzo and Beckles, 1979; Rett, 
1999). Altered insulin action can lead to a number of important pathophysiological states, 
such as Type 2 diabetes mellitus and hypertension. All of these clinical manifestations are 
associated with an increased cardiovascular risk. Currently, the causes and mechanisms of 
insulin resistance remain poorly understood, although they could be tightly linked to both 
genetic and environmental factors (Alzaid, 1996; Permutt et al., 2005). 
MG readily interacts with certain arginine or lysine residues in selected proteins to 
form irreversible AGEs. MG is the most reactive AGEs precursor (Kalapos, 1999). The 
reaction of MG with arginine residues of proteins forms hydroimidazolone Nε-(5-hydro-
5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1), as well as argpyrimidine (Ahmed et al., 
2002). MG can also react with lysine residues of proteins to form CML and CEL. The 
physiological concentrations of plasma MG are from 0.2 to 14.2 µM in rats (Babaei-
Jadidi et al., 2003; Nagaraj et al., 2002; Wang et al., 2004) and 1.4 µM (Thornalley et al., 
1989) in healthy humans. Increased MG levels have been reported in different insulin 
resistance states. The serum concentration of MG increases 5–6 fold in patients with type 
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1 diabetes mellitus and 2–3 fold in patients with type 2 diabetes. The characteristic 
protein modification induced by MG has been found in the aorta of stroke-prone 
spontaneously hypertensive rats (Mizutani et al., 1999). Our previous results showed 
increased levels of MG and AGEs in vascular smooth muscle cells from SHR rats (Wu, 
2005; Wu and Juurlink, 2002). Plasma MG concentration was significantly elevated at 8, 
13, and 20 wk of age in parallel with increased blood pressure increase in SHR, whereas 
the MG levels remained unchanged in age-matched normotensive WKY rats (Kalapos, 
1999; Wang et al., 2005). 
 MG and related AGEs such as CEL have been recognized as indicators of 
carbonyl overload burden in vivo (Singh et al., 2001) and are correlated with age (Li et al., 
1996). It has been reported that MG decreased the activity of glutathione reductase 
(Vander Jagt et al., 1997; Wu and Juurlink, 2002), which might be due to MG-induced 
glycation of arginine residues. Whether MG induces functional and structural changes in 
the insulin molecule, which may in turn play an important role in the development of 
insulin resistance, is unknown. To investigate whether MG causes structural modification 
of insulin molecule, we have used MALDI-TOF mass spectrometry to study MG-induced 
mass changes in insulin molecules. We have also used MS/MS to identify the amino acid 
residue(s) at which the insulin molecule is modified by MG. Whether MG-modified 
insulin decreased insulin-mediated glucose uptake was examined in insulin-sensitive cells. 
To further determine the change of biological functions of insulin, the effects of insulin 
and MG-modified insulin on C-peptide secretion, an indicator for insulin release from 
pancreatic ß-cells, were examined and compared. The degradation of insulin and MG-
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insulin through hepatocytes was also compared. Finally, both the effect of MG on the 
insulin-induced glucose uptake and the expression of insulin receptor were explored. 
 
3.2. Results 
3.2.1. MG induced mass changes of insulin 
 To determine whether MG can modify on insulin molecules, we subjected human 
insulin to electrophoresis in Tricine SDS-PAGE gels after incubation with MG and/or 
phosphate buffer for 3 d. As shown in Figure 3-1, incubation of insulin (1 µg/µl) with MG 
(100 µM) resulted in additional bands with lower electrophoretic mobility than native 
insulin on SDS-PAGE. Several new bands appeared when insulin was incubated with 
higher concentration of MG (1 mM) was carried out. However, with the same MG 
concentrations and incubation conditions, no new band was observed for glucagon (data 
not shown). 
As the accuracy of molecular mass determination by SDS-PAGE is limited, we 
turned to mass spectrometry for a more accurate and sensitive determination of MG-
induced mass changes. The MALDI-TOF mass spectrum of intact human insulin (Figure 
3-2A) contained peaks at m/z 5808 and 2905, which corresponded to the singly (1+) and 
doubly (2+) protonated molecular ions of insulin. However, incubation of 1 µg/µl (170 
µM) insulin with 10 µM MG for 3 d resulted in additional peaks that provided evidence 
for the formation of MG-insulin (Figure 3-2B). The peak at m/z 5880, for example, 
corresponded to the addition of one MG molecule (72 Da), while a peak at around m/z 
5934 corresponded to the addition of two MG molecules with concomitant loss of a single 
water molecule (72+54). The same results were observed from three other independent 
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Figure 3-1. MG-induced mass changes of insulin. Human insulin was incubated with 
or without MG for 3 days. The molecular masses of different sample components were 
determined by Tricine SDS-PAGE. Line 1: molecular standard (kDa); Line 2: freshly 
prepared insulin control; Line 3: insulin incubated with phosphate buffer; Line 4: insulin 
incubated with MG (1 μM); Line 5: insulin incubated with MG (10 μM); Line 6: insulin 
incubated with MG (100 μM); Line 7: insulin incubated with MG (1 mM). The arrows 
point to new bands with lower electrophoretic mobility than insulin. 
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Figure 3-2. MALDI-TOF MS analysis of MG-induced mass changes in human 
insulin. A) In the absence of MG, human insulin gives rise to singly and doubly 
protonated molecular ions at m/z 5808 and 2905, respectively. B) Incubation of human 
insulin (1 µg/µl) with MG (10 µM) for 3 d gives rise to additional peaks, indicating the 
formation of MG-insulin adducts. Closer inspection reveals peaks that correspond to the 
addition of one or more MG molecules with (+54 Da) and without (+72 Da) concomitant 
loss of water. 
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experiments. Different incubation times were also tested. Interestingly, 24 and 48 h 
incubations gave similar MS profiles for the resulting MG-insulin adducts (data not 
shown), whereas incubation times of less than 2 h did not give rise to additional peaks, 
even when the concentration of MG was increased to 10 mM. 
 
3.2.2. Amino acid target(s) for MG modification of insulin 
To determine the position(s) of MG attachment, we treated human insulin and 
MG-insulin incubates each with dithiothreitol to reduce intramolecular disulfide bonds. 
The resulting free thiol groups were then blocked by carbamidomethylation with 
iodoacetamide to separate permanently the A- and B-chains, and the reaction products 
were analyzed by MALDI-TOF MS. The mass spectrum of reduced insulin alone 
contained major peaks at m/z 2611 and 3543 (Figure. 3-3A), corresponding to the reduced 
and alkylated A- and B-chains, respectively. However, incubation with MG produces 
additional peaks that showed progressive enlargement of the B-chain with increasing MG 
concentrations (Figure 3-3B–D). 
The most prominent B-chain adducts appearing at the final concentrations of MG 
above 15 µM corresponded to a mass increase of 54 Da (m/z 3597). MS/MS analysis of 
the corresponding 4+ ion (m/z 900.2), generated by nanoES, produced a spectrum in 
which all the observed b-ions were shifted by + 54 Da (Figure 3-4A-b) relative to the 
corresponding spectrum for the unmodified insulin B-chain (m/z 886.7) (Figure 3-4A-a). 
In contrast, all the observed y-ions remained unchanged (Figure 3-4B-b), a result 
consistent with attachment of MG (as R-Nn=CH-C (CH3)O) to the N terminus of the 
insulin B-chain. MS/MS analysis of the + 108 Da adduct (m/z 913.7) also showed a b-ion 
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Figure 3-3. MALDI-TOF MS analysis of MG-induced mass changes of the B-chain 
of human insulin.  A) In the absence of MG, the predominant peak is that of the reduced 
and alkylated B-chain, with small additional peaks corresponding to attachment of 
sodium (+22 Da) and a third carbamidomethyl (+57 Da) group. Incubation with 
increasing concentrations of MG (10, 15, and 30 µM) results in the progressive formation 
of a dehydrated (+54 Da) MG adduct at m/z 3597, along with other putative B-chain 
derivatives (B–D). 
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shift of + 54 Da (Figure 3-4A-c). However, a shift of + 54 Da was also seen in the larger 
observable y-ions (y'15 and above; Figure 3-4B-c) whereas the smaller observable y-ions 
(y'4 and below; not shown) remained unchanged. The intervening region contained 
arginine as the only basic residue, the side chain of which would increase in mass by 54 
Da on reaction with MG (vide infra). These observations indicated that MG adduction can 
occur both at the N terminus of the insulin B-chain and at an internal, arginine residue. 
Furthermore, low abundance peaks marked * (Figure 3-4A-c and 3-4B-c) provided 
evidence for a shift of + 108 Da in certain b-ions (b16+ and below) relative to the 
unmodified B-chain. This suggested that sites other than arginine might be modified, and 
that the spectrum observed for m/z 913.7 was actually a superimposition of MS/MS 
spectra for several isobaric B-chain adducts modified with two MG molecules. This also 
explained why the shifted and unshifted y- and b-ions were sometimes observed together 
in the MS/MS spectra of MG adducts. In such cases (e.g., Figure 3-4B-C) the relatively 
high abundance of the unshifted y-ions suggested that internal MG modifications were 
less stable than the N-terminal modification.  
 
3.2.3. MG-insulin impaired glucose uptake by different insulin-sensitive cells 
            [3H]-2-DOG uptake by 3T3-L1 adipocytes was determined after the cells were 
treated with insulin (1, 10, and 100 nM) or MG-insulin, which was generated by 
incubating insulin at the same concentrations as for native insulin with 1, 10, or 100 µM 
MG, respectively. As shown in Figure 3-5A, 3T3-L1 cells showed a significant increase 
of [3H]-2-DOG uptake induced by insulin in a concentration-dependent manner. However,  
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Figure 3-4. Deconvoluted MS/MS spectra of insulin B-chain. (A–a) The b-ions 
observed for the quadruply protonated ion at m/z 886.7 correspond exactly to those 
predicted for the reduced, alkylated B-chain; (A–b) a shift of + 54 Da in the b-ion series 
for m/z 900.3 is consistent with attachment of MG at the N terminus; (A-c) evidence of a 
further b-ion shift (*) for m/z 913.5 suggests that a second MG moiety can attach near the 
N terminus and/or elsewhere on the insulin B-chain. (B–a) MG-insulin adducts were 
generated by the incubation of insulin (1 µg/µl) with MG (30 µM). The y-ions observed 
for the quadruply protonated ion at m/z 886.7 correspond exactly to those predicted for 
the reduced, alkylated B-chain; (B–b) the y-ions and internal fragments observed for m/z 
900.3 are identical to those observed for m/z 886.7, confirming that MG is attached to the 
N terminus; (B–c) for m/z 913.5, a shift of + 54 Da in larger y-ions is consistent with 
further modification of insulin B-chain at the arginine residue. 
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 a significantly lower uptake of [3H]-2-DOG was observed after the cells were treated 
with MG-insulin, compared with the cells treated with the concentration-matched native 
insulin (Figure 3-5A). Similar result was also observed in L8 skeletal muscle cells (Figure 
3-5B). 
To clarify whether the lower glucose uptake in MG-insulin treated group had 
resulted from free unattached MG in the solution, the effect of MG on the expression of 
insulin receptor at mRNA concentration was also explored in 3T3-L1 cells using real-
time PCR. After treatment of 3T3-L1 cells with MG (3 or 30 µM) for 24 h, mRNA 
expression levels (computed tomography) of insulin receptor were 12.3 ± 0.2 or 12.1 ± 
0.15, which was not significantly different from that of MG-untreated group (11.9 ±0.2) 
(P >0.05 n=4 in each group, data not shown). 
 
3.2.4. Effects of MG-insulin on C-peptide secretion from INS-1E cells             
Whether MG-insulin impairs the insulin-induced feedback inhibition of insulin 
release from pancreatic ß-cells was investigated. As shown in Figure 3-6A, when INS-1E 
cells were co-exposed to native insulin (100 nM) and glucose (16.7 mM) for 2 h, the C-
peptide release dropped to 76.5% of the C-peptide release from cells treated only with 
glucose at the same concentration (P <0.05, n=4 for each group). When INS-1E cells 
were co-treated with MG-insulin and glucose, the insulin-induced inhibition of C-peptide 
secretion disappeared, in comparison with cells treated with native insulin and glucose (P 
<0.05, n=4 for each group). Without the formation of MG-insulin adducts, an acute 
application of MG and insulin did not alter the insulin-induced inhibition of C-peptide 
release (P >0.05, n=4 for each group). 
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Figure 3-5. MG-insulin induced lower glucose uptake in adipocytes 3T3-L1 (A) and 
L8 cells (B). MG-insulin adducts (MG-insulin) were prepared by incubation of human 
insulin with MG for 3 d. [3H]-2-DOG uptake was determined after the cells were treated 
with insulin or MG-insulin for 30 min. *P < 0.05 vs. insulin group, +P < 0.05 vs. insulin 
group, n = 5–6 for each group. DPM: disintegrations per minute. 
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Figure 3-6. The modification on insulin molecule decreased its biological functions. 
A) MG-insulin has lower feedback inhibition on C-peptide secretion from INS-1E cells. 
C-peptide in the medium was measured after INS-1E cells were treated 2 h with insulin 
(100 nM), MG-insulin adducts (MG-insulin), or MG + insulin (coapplication) in the 
presence of glucose (16.7 mM). MG-insulin was generated from incubating insulin (1 
µg/µl) with MG (30 µM) for 3 d as described in Materials and Methods. *P < 0.05 vs. 
control, +P < 0.05 vs. insulin group, n = 4 for each group. B) Insulin was measured after 
H4-II-E cells were treated with insulin (200 nM) or MG-insulin (200 nM) for 15 min. 
MG-insulin was generated from incubating insulin (1 µg/µl) with MG (30 µM) for 3 d as 
described in Materials and Methods. Clearance rate = (200 nM – measured insulin 
concentration in cultured medium)/200 nM. *P < 0.05 vs. insulin group, n = 6 for each 
group. 
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3.2.5. Decreased degradation of MG-insulin through hepatocytes 
Liver is the main site for insulin clearance, removing ~50% of the circulating 
insulin through a receptor-mediated endocytosis process (Gorden et al., 1978; Li Calzi et 
al., 1997). To investigate whether MG-insulin could still be removed by hepatocytes 
properly, we treated H4-II-E cells with insulin (200 nM) or same concentration of MG-
insulin for 15 min and then determined insulin clearance in culture medium. As shown in 
Figure 6B, we found a significantly higher insulin clearance rate (51.5% ± 5.6) in the 
cells treated with native insulin, compared with that from cells treated with MG-insulin 
(32.0% ± 3.6). 
 
3.3. Discussion 
 Increased plasma MG concentration and MG-induced irreversible advanced 
glycated endproducts have been observed in different insulin resistant states, including 
diabetes and hypertension (Singh et al., 2001; Thornalley et al., 1989; Wang et al., 2005). 
The abnormal MG concentration in patients paralleled the development of insulin-
resistance syndrome, which involves complex etiological factors. Previous studies have 
suggested that MG may render certain types of cells resistant to hormones and growth 
factors (Du et al., 2003; Portero-Otin et al., 2002). However, the underlying mechanisms 
for this MG effect have not been further investigated. To clarify the correlation between 
abnormal MG metabolism and insulin resistance, we explored in this study whether MG 
causes structural and functional changes the insulin molecule. 
Insulin travels from pancreatic β-cells through the circulation to its target tissues. 
Events at any one of these loci can influence the ultimate action of the hormone. If 
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arginine or lysine residue of insulin had been glycated by MG, the biological function of 
insulin in the regulation of glucose homeostasis would be significantly changed. Our 
results showed that incubation of insulin with MG for 3 d resulted in new bands with 
lower electrophoretic mobility, in addition to native insulin, on Tricine SDS-PAGE gels 
(Figure 3-1). Importantly, this was not observed when glucagon was incubated with MG 
at the same concentrations (data not shown). Both insulin and glucagon are involved in 
glucose regulation, and they have common pancreatic origin. Glucagon, a 29-amino acid 
single-chain polypeptide, contains two arginines at position 17 and 18 and one lysine at 
position 13, while insulin consists of a 21-amino acid A-chain and a 30-amino acid B-
chain with one arginine at position 22 and one lysine at 29 on its B-chain. Our results 
suggest that the generation of MG-insulin adducts may depend on a special molecular 
recognition between MG and insulin. In support of this scheme, recent studies on human 
peripheral blood lymphocytes as well as many plasma proteins from different animals (rat, 
mouse, and monkey) show that only a limited number of proteins undergo glycation (Jana 
et al., 2002; Poggioli et al., 2002). However, the selectivity of glycation of proteins, as 
assessed by measurement of extent of glycation in cells, may depend on the reactivity of 
individual proteins to glycation and the rate of degradation and/or repair of the glycated 
protein. 
 Mass spectrometry gives an accurate and sensitive measure of MG-induced mass 
changes in the insulin molecule and provides strong evidence for the formation of MG-
insulin adducts. The peak at m/z 5880 (Figure 3-2) corresponds to the addition of one 
MG molecule (72 Da) to insulin, while the peak at m/z 5934 corresponds to the addition 
of two MG molecules with concomitant loss of a single water molecule (72+54 Da). It 
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has been reported that MG derivatizes lysine or arginine residues of human serum 
albumin in vitro (Ahmed et al., 2002). These findings are consistent with our observations. 
For example, addition of MG to lysine forms the monolysyl adduct CEL, resulting in a 
mass increase of 72 Da. In contrast, MG undergoes a condensation reaction with arginine 
to form one of three hydroimidazolone isomers (MG-H1, H2, and H3), resulting in a net 
mass increase of 54 Da. However, other peaks observed during MS analysis suggest that 
multiple additions of MG occur both with and without concomitant loss of water, despite 
the fact that insulin contains a single lysine and arginine residue. For example, the peak at 
m/z 5916 corresponds to a mass increase of 108 Da (54 + 54), which implies two 
condensation reactions involving addition of MG. Glyoxal, another metabolite of glucose, 
can react with free amine groups (R-NH2) to give a reaction product (R–N =CH–CHO) 
that results in concomitant loss of water (Glomb and Monnier, 1995). Similar reactions 
between MG and side-chain or N-terminal amino groups would result in multiple mass 
increases of 54 Da, as observed for intact insulin. MG adduction at both the N terminus of 
the insulin B-chain and at internal residues (predominantly arginine) was subsequently 
confirmed by tandem MS analysis of insulin B-chain adducts (vide supra). 
 Our study shows that MG-insulin adducts induce a significant and concentration-
dependent decrease in glucose uptake in insulin-sensitive adipocytes and skeletal muscle 
cells (Figure 3-5). Normally, insulin is promptly released from pancreatic islet ß-cells in 
response to increased plasma glucose concentration and interacts with its specific 
receptors on different target cells. Fat and muscle cells express a particular GLUT protein 
isoform, GLUT-4, which is also known as the insulin-regulated GLUT (Klip et al., 1994). 
Therefore, these two types of cells exhibit an extraordinary glucose uptake response to 
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insulin stimulation. Insulin receptors locate on the membrane of insulin-sensitive cells. 
An unchanged transcriptional expression of insulin receptor was observed after the cells 
were treated with or without MG. It is, therefore, unlikely that MG has a direct effect on 
the binding affinity or expression levels of insulin receptors. Apparently, the formation of 
MG-insulin adducts reduced the capability of native insulin to stimulate glucose uptake. 
 The autocrine control of insulin release by the extracellular insulin concentration 
has attracted great attention since the discovery of insulin receptors and insulin receptor 
substrates in pancreatic ß-cells. Insulin is produced in pancreatic ß-cells as proinsulin, an 
86-amino acid single-chain polypeptide (MW 9000 kDa), and then cleaved into insulin 
(MW 5800 kDa) and C peptide (27-amino acids). C-peptide is coreleased with insulin on 
a one-to-one basis (Polonsky, 1995). By measuring the secretion of C-peptide, the amount 
of insulin released from ß-cells could be estimated, especially for the determination of 
insulin or MG-insulin on the autocrine regulation mechanism. Our result confirmed that 
insulin inhibited insulin secretion, as reflected by the decreased C-peptide release, from 
INS-1E cells. Once MG-insulin adducts are formed, the glycated insulin can no longer 
inhibit insulin (C-peptide) secretion (Figure 3-6A). It is worth noting that, in addition to 
impaired glucose uptake, hyperinsulinemia is another common phenomenon in insulin-
resistance syndrome such as T2DM or human obesity (Olefsky and Kolterman, 1981). 
Under physiological conditions, pancreatic ß-cells sense the change of blood glucose 
levels and adjust insulin output accordingly. Circulating insulin in turn further modulates 
insulin release to provide a fine-tuned control of insulin metabolism. The formation of  
MG-insulin adducts can result in an abnormal autocrine control of insulin release. 
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 In addition to the increased insulin secretion from pancreatic ß-cells, 
hyperinsulinemia might be also partially due to the disturbance of a normal receptor-
mediated insulin clearance induced by MG-insulin adducts. The circulating insulin levels 
are not only determined by its secretion from pancreatic ß-cells but also depend on insulin 
clearance from the circulation. As for other peptide hormones, endocytosis is the major 
mechanism for removal of insulin. In this process, the insulin receptor with bound 
hormone is internalized. Endocytosis of this complex in insulin-targeted cells leads to 
insulin degradation and recycling of receptors back to the plasma membrane (White and 
Kahn, 1994). Degradation of insulin occurs mainly in liver (50%) and muscles (Polonsky, 
1995). Recently, it has been noticed in obese patients that insulin resistance is associated 
with reduced clearance of insulin from plasma (Jones et al., 2000), despite no clear 
mechanism. We observed a significantly high insulin clearance rate (or lower 
concentration of insulin) in the culture medium from the cells treated with native insulin, 
compared with that from cells treated with MG-insulin (Figure 3-6B). This finding 
indicated that MG-insulin adducts cannot go through endocytosis properly, or there is an 
aggregation of MG-insulin. However, further experiments will be needed to clarify the 
mechanism behind this phenomenon. 
 The physiological concentration of plasma MG in rats is between 0.2 and 5 µM in 
vivo (Babaei-Jadidi et al., 2003; Nagaraj et al., 2002). Our previous study detected the 
plasma MG levels of 33.6 µM in 20-week-old SHR and 14.2 µM in age-matched WKY 
rats (Wang et al., 2004). It has been reported that the plasma concentration of MG is 1.4 
µM in healthy humans (Thorburn et al., 1989) and 26.6 µM in normal Chinese hamster 
ovary (Chaplen et al., 1998). Differences in these reported endogenous MG levels could 
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be explained by different species, and different MG assays used in different laboratories. 
Normal human plasma insulin concentrations are 0–0.5 nM with a 5–10 fold increase 
following ingestion of food. In the present in vitro study, MG at 1–30 µM was used to 
interact with insulin at 1–100 nM to determine the glucose uptake. Obviously, the 
concentrations used for insulin are close to those plasma concentrations observed after 
food intake, while the concentrations chosen for MG also fall into physiological and 
pathophysiological range according to different reports. Moreover, higher concentrations 
of MG may prove necessary for detection of its in vitro interaction with insulin molecule. 
In vivo conditions with physiological pH, temperature as well as intact biochemical and 
enzymatic reactions may facilitate the interaction of MG and insulin at a much lower MG 
concentration. 
 In summary, our results show that MG modifies the B-chain of human insulin in 
vitro, and that modification occurs predominantly at the N terminus and arginine residue 
via Schiff base formation. The extent of modification increases with the relative 
concentration of MG. The formation of MG-insulin adducts leads to the reduction of 
insulin-mediated glucose uptake by its target cells or tissues, impaired autocrine control 
of insulin release from pancreatic ß-cells, and decreased hepatic clearance of insulin from 
liver cells. A chronic increase in the circulating MG concentration, with enhanced 
formation of MG-insulin adducts, might play an important role in the development of 
insulin resistance. Therefore, clarification of the role of MG in the development of insulin 
resistance may lead to a discovery of new mechanisms and methods for the management  
and prevention of insulin-resistance syndromes, including diabetes and hypertension. 
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CHAPTER FOUR 
ACCUMULATION OF ENDOGENOUS METHYLGLYOXAL 
IMPAIRED INSULIN SIGNALING IN ADIPOSE TISSUE OF 
FRUCTOSE-FED RATS 
 
4.1. Introduction 
MG interacts readily with certain free amino acid residues in proteins and forms 
AGEs (Monnier and Cerami, 1981). Increased accumulation of MG was observed in 
different insulin resistance states including diabetes patients (Beisswenger et al., 2005; 
Wells-Knecht et al., 1996) and hypertensive animals (Wang et al., 2005; Wang et al., 
2004). These findings suggest that MG accumulation may play an important role in the 
development of insulin resistance. 
Insulin resistance may occur through different mechanisms including defects in 
insulin signaling (Sechi and Bartoli, 1997). When insulin binds to insulin receptor (IR), 
the intrinsic tyrosine kinase activity of IR is activated. The activated receptor then 
phosphorylates selected tyrosine residues of substrate proteins such as IRS1-4, Shc 
proteins, and SHP-2. Following insulin stimulation, tyrosine and serine phosphorylation 
of IRS-1 is increased. IRS proteins provide docking sites for PI3K. PI3K plays a critical 
role in stimulating GLUT4 translocation by catalyzing the phosphorylation of PIP2 to 
PIP3. As a consequence, PI3K activation results in an enhanced glucose uptake 
(Cheatham and Kahn, 1995; Yamauchi et al., 1996). Recent studies reported that MG 
inhibited the insulin signaling in cultured skeletal muscle cells (Riboulet-Chavey et al., 
2006). However, the effect of MG accumulation on insulin signaling in whole animal, 
particularly in adipose tissue, remains unclear.  In the present study, fructose, the MG 
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precursor, was administered to SD rats to increase the endogenous levels of MG and the 
expression of insulin signaling molecules were examined. To further explore the direct 
effect of MG on insulin signaling, cultured 3T3-L1 adipocytes were treated with MG and 
its scavenger, NAC (Wu and Juurlink, 2002). The effect of MG on the phosphorylation of 
IRS-1 and PI3K activity were then investigated. 
 
4.2. Results 
4.2.1. MG accumulation in rats correlated with the development of insulin resistance 
As shown in Figure 4-1A, 9 weeks of fructose feeding increased plasma 
triglyceride dramatically (P < 0.05 vs. untreated control rats) while NAC co-treatment 
significantly reversed this increase. Although plasma HDL-cholesterol level did not differ 
between control and fructose-fed rats, it was increased by NAC treatment (Figure 4-1A). 
An increased blood pressure was also observed in fructose-fed rats (data not shown). 
However, neither fructose (n = 10) nor NAC (n = 4) treatment changed plasma levels of 
total cholesterol and blood hemoglobin A1c (P > 0.05, data not shown). In all treatment 
groups of rats, fasting blood glucose level was 5–6 mM. At the end of 9-week of 
treatment, the intraperitoneal glucose tolerance test was performed and no difference was 
found among these four groups except a higher glucose level at the 90 min point in the 
fructose-fed rats (data not shown). As shown in Figure 4-1B, serum insulin level was 
increased significantly to 178% in fructose-fed group (n = 10) in comparison with that 
from untreated control group (P < 0.05, n = 7). NAC co-treatment lowered the fructose-
induced increase in insulin. The insulin-induced [3H]-2-DOG uptake by visceral adipose 
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Figure 4-1. Effects of fructose and/or NAC treatment on the development of insulin 
resistance in SD rats. Fructose and/or NAC feeding induced changes in serum 
triglyceride and HDL-cholesterol (A), serum insulin level (B), and insulin-stimulated 
glucose uptake in adipose tissue (C). *P < 0.05 vs. untreated control rats; + P < 0.05 vs. 
fructose-fed rats, n = 7–10 for control, fructose-fed and fructose–NAC treated group, 
n = 4 for NAC treated group. 
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tissue dropped dramatically in fructose-fed rats (P < 0.05, n = 7–10 in each group) 
(Figure 4-1C). Glucose uptake stimulated by 100 nM insulin in fructose-fed rats was only 
55% of that observed for control rats. With NAC co-treatment, however, this value was 
enhanced by 38.2% (P < 0.05 vs. fructose-fed rats, n = 4 in NAC treated group; n = 8 in 
fructose-fed group). 
As shown in Figure 4-2A, 9 weeks of fructose feeding significantly increased MG 
content by more than 2-fold in adipose tissue from 1.5 ± 0.05 μmol/g protein in untreated 
group to 4.37 ± 0.25 μmol/g protein in treated group (P < 0.05, n = 4). A significant 
increase in MG level was also observed in blood serum from 1.81 ± 0.41 μM in control 
rats to 3.29 ± 0.30 in fructose-fed rats (P < 0.05, n = 4, Figure 4-2B). The increased MG 
levels in adipose tissue and serum were both lowered by co-administration of NAC 
(Figure 4-2A, B). In serum samples, it was even returned to control level. However, NAC 
treatment alone did not show significant effect on MG accumulation. 
 
4.2.2. Alteration of PI3K expression in the adipose tissue of fructose-treated rats 
Using Western blotting analysis, we compared protein levels of key insulin 
signaling genes in adipose tissue from the rats treated with or without fructose. The 
protein level of PI3K was increased significantly by 29% in fructose-fed rats compared to 
the untreated control group (P < 0.05, n = 4 for each group; Figure 4-3A, B). The 
increased PI3K protein expression at protein level was counteracted by NAC co-
treatment. On the other hand, neither IR nor IRS-1 expression was changed significantly 
by the treatment with fructose, NAC, or fructose–NAC (Figure 4-3A, B). 
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Figure 4-2. Effects of fructose and/or NAC treatment on the MG levels in SD rats. 
MG levels were measured in adipose tissue (A) and serum (B) of untreated rats, fructose-
treated rats, fructose–NAC co-treated, and NAC-treated rats, respectively. *P < 0.05 vs. 
control rats; + P < 0.05 vs. fructose-fed rats. n = 4 for each group 
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Figure 4-3. Effects of fructose or fructose–NAC co-treatment on the expression 
of IR, IRS-1, and PI3K. Western blotting showed the expression of IR, IRS-1, and 
PI3K in adipose tissue from differently treated groups of rats (A) and the expression 
was presented as % of that from untreated rats (B). *P < 0.05 vs. control rats, 
+P < 0.05 vs. fructose-fed rats, n = 4 for each group. 
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4.2.3. Decreased association between PI3K and IRS-1 in fructose-fed rats 
Generally, the tyrosine phosphorylated IRS-1 binds to various effector molecules 
including the regulatory subunit of PI3K and recruits PI3K catalytic subunit to its 
regulatory subunit then results in its activation. We therefore, evaluated the tyrosine 
phosphorylation of IRS-1 and the recruitment of PI3K to IRS-1 in adipose tissue. In 
fructose-fed rats, the tyrosine phosphorylation of IRS-1 was not changed significantly 
compared to the control level, although a declining tendency was shown (P > 0.05, n = 4 
for each group; Figure 4-4A). However, the amount of PI3K recruited to the 
phosphorylated IRS-1 was reduced to 70.9% of the control level from untreated rats 
(P < 0.05, n = 4 for each group). The reduced IRS-1/PI3K association was restored by 
NAC co-administration (Figure 4-4B). 
 
4.2.4. Effects of MG on the insulin-signaling pathway of 3T3-L1 cells 
In order to further confirm whether the alteration of PI3K in fructose-fed rats was 
caused by the enhanced MG accumulation, we directly treated 3T3-L1 adipocytes with 
MG and examined the expression and phosphorylation of IR, IRS-1, and PI3K. As shown 
in Figure 4-5A, when the cells were treated with MG (20 μM), glucose uptake 
significantly decreased compared to the untreated cells (n = 6, P < 0.05). This MG-
reduced glucose uptake in 3T3-L1 adipocytes was counteracted by NAC co-
administration. No significant change in the protein expression of IR, IRS-1, or PI3K was 
observed in 3T3-L1 adipocytes after exposure to MG, MG-NAC, or NAC (600 μM) (data 
not shown). 
However, the insulin-induced tyrosine phosphorylation of IRS-1 (Figure 4-5B)  
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Figure 4-4. The tyrosine phosphorylation of IRS-1 (A) and PI3K associated to IRS-1 
(B) in adipose tissue of control, fructose, fructose–NAC or NAC treated rats. Tissue 
lysates were subjected to immunoprecipitation (IP) with IRS-1 antibody. The 
immunoprecipitates were then subjected to Western blotting (WB) using anti-pTyr (A) or 
PI3K p85 antibody (B). The immunoreactivity levels were compared to the control levels 
of IRS-1 phosphorylation (A) or IRS-1 associated PI3K (B), respectively. *P < 0.05 vs. 
control rats, + P < 0.05 vs. fructose-fed rats, n = 4 for each group. 
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Figure 4-5. Effects of MG and/or NAC on insulin-induced glucose uptake (A), IRS-1 
phosphorylation (B), and PI3K activity (C) in cultured 3T3-L1 adipocytes. (A) The 
insulin-stimulated glucose uptake in cultured 3T3-L1 adipocytes after different 
treatments. The differentiated 3T3-L1 adipocytes were exposed to 100 nM insulin for 
30 min and continuously incubated for another 20 min after the addition of [3H]-2-DOG 
(0.1 μCi/500 μl) with glucose (50 μM) to the medium. The cell lysate was then 
transferred into scintillation vials for scintillation counting. (B) The cells were treated 
with or without MG, NAC, or MG plus NAC at the concentrations indicated. After IRS-1 
protein was immunoprecipitated (IP), Western blotting (WB) was carried out using anti-
phosphotyrosine (pTyr) as 1st antibody. (C) PI3K activity was measured by a competitive 
ELISA kit and presented as % of that from control rats. *P < 0.05 vs. control cells, + 
P < 0.05 vs. cells treated with same concentration of MG, n = 6 in A; n = 3 in B and C 
each group. 
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and PI3K activity (Figure 4-5C) were both impaired by MG treatment. The 
phosphorylation level on tyrosine residue of IRS-1 was inhibited significantly to 
55.3 ± 4.9% or 36.9 ± 5.6% of the control levels by 10 or 20 μM MG treatments (Figure 
4-5B) (P < 0.05, n = 3). As shown in Figure 4-5C, MG markedly decreased PI3K activity 
in 10 and 20 μM MG treated groups, which were also restored by NAC co-treatment 
(P < 0.05, n = 3). 
 
4.3. Discussion 
The increased level of MG observed in different insulin resistance states including 
diabetes and hypertension (McLellan et al., 1994; Wang et al., 2004) suggests an 
important role of MG in the development of insulin resistance. The main source of MG in 
mammals is anaerobic glycolysis. MG is also formed during the metabolism of acetone or 
aminoacetone from lipolysis or protein catabolism (Kalapos, 1999; Wu, 2006). Fructose, 
a precursor of MG, is metabolized by hexokinase or ketohexokinase to glyceraldehyde-3-
phosphate and dihydroxyacetone phosphate, which can directly form MG. Recently, we 
reported that fructose significantly increased MG generation in cultured vascular smooth 
muscle cells in a concentration and time dependent manner (Wang et al., 2006). However, 
whether increased accumulation of endogenous MG induced by fructose treatment 
directly contributes to the development of insulin resistance is still unsettled. 
In the present study, we observed increased MG accumulation in serum and in 
adipose tissue, as well as the development of insulin resistance in fructose-fed rats 
(Figures 4-1 and 4-2). In addition, we found a significant reduction of IRS-1/PI3K 
association in adipose tissue (Figure 4-4). To clarify the role of MG in the development 
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of insulin resistance, we directly treated 3T3-L1 adipocytes with MG and investigated the 
effect of MG on insulin signaling in these cells. Although the expression level of IR, IRS-
1, and PI3K were not changed by MG treatment, reduced IRS-1 tyrosine phosphorylation 
and kinase activity of PI3K were observed in MG treated cells. Furthermore, MG 
treatment significantly reduced the insulin-stimulated glucose uptake by 3T3-L1 
adipocytes (Figure 5-5A). These results indicated the direct inhibition of MG on insulin 
signaling in these cultured adipocytes. The inhibition of PI3K activity by MG was 
consistent with the decreased tyrosine phosphorylation on IRS-1. Moreover, MG-induced 
alterations in IRS-1 phosphorylation and PI3K activity were reversed by NAC, which 
further supports the role of MG in the impaired insulin-mediated glucose uptake in 
fructose-fed rats. 
Since PI3K plays a pivotal role in the metabolic and mitogenic actions of insulin 
by specifically phosphorylating phosphatidylinositol substrates and producing second 
messengers to regulate glucose transport, the insulin induced tyrosine phosphorylation of 
IRS-1 and the activated PI3K are necessary for insulin signaling in different insulin 
sensitive tissues. Therefore, the impaired insulin-mediated glucose uptake in adipose 
tissue of fructose-fed rats is likely caused by the reduced IRS-1 phosphorylation and 
impaired IRS-1/PI3K association. Interestingly, enhanced PI3K expression was observed 
in fructose-fed rats (Figure 4-3), which seems inconsistent with the development of 
insulin resistance. However, this increased PI3K expression likely reflected the 
compensative response to the inhibited PI3K recruitment to IRS-1 in fructose-fed rats. 
The discrepancy between in vivo and in vitro studies on PI3K expression and IRS-1 
phosphorylation observed in the present study suggests that other metabolic factors in 
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addition to MG accumulation, for instance, the autocrine control of insulin release may 
also play a role in the development of insulin resistance in vivo. 
Given that MG and MG-derived AGEs can induce non-enzymatic modifications 
of various amino acid residues (e.g., Lys and Arg) that are generally present in the active 
sites of different insulin signaling proteins, MG-induced structural modifications of these 
proteins might also impair insulin signal transduction. Recently, a study suggested that 
MG might increase serine phosphorylation on IRS-1 in rat L6 myoblast cells (Riboulet-
Chavey et al., 2006). However, direct interaction of MG with the IRS-1 and PI3K 
proteins needs to be further explored in future. Previous studies from our as well as other 
laboratories suggest that fructose or MG induces the formation ROS and reactive nitrogen 
species (Chang et al., 2005; Fukunaga et al., 2005; Wang et al., 2006) in cultured smooth 
muscle cells or rats, which may also play a role in the MG-impaired insulin signaling 
pathway. 
In summary, our study demonstrated that elevation of endogenous MG level in 
fructose-fed rats reduced IRS-1/PI3K association and altered PI3K activity, which may 
lead to the decreased insulin-stimulated glucose uptake in adipose tissue and contribute to 
insulin resistance. Unraveling this new MG-mediated mechanism will help to better 
understand the pathogenic development of insulin resistance and related diseases. 
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CHAPTER FIVE 
 
SCAVENGING METHYLGLYOXAL BY METFORMIN IMPROVED 
INSULIN RESISTANCE IN FRUCTOSE-TREATED RATS 
 
5.1. Introduction  
The three most important tissues that are involved in the pathogenesis of insulin 
resistance are skeletal muscle, liver and adipose tissues. Skeletal muscle constitutes the 
largest insulin-sensitive tissue in the body and is the primary site for insulin-stimulated 
glucose utilization. Due to their different physiological function in metabolism, these 
tissues showed different expression profile of insulin signaling genes/proteins under 
insulin resistance condition. In the previous chapter, effect of MG on the insulin signaling 
pathway in adipose tissue from fructose-treated rats was studied. Our earlier study also 
suggested that MG causes structural modification of the insulin molecule, reducing the 
biological function of insulin in cultured adipose cells. However, the question of whether 
or not an increase in endogenous MG accumulation induces a direct change in the insulin 
signaling pathway in insulin-target skeletal muscle remains largely unresolved. In the 
present study, the consequence of MG accumulation on insulin transduction in skeletal 
muscle was investigated. 
In the present study, insulin resistance was induced in rats fed chronically with 
fructose, a precursor of MG. An increase in the formation of endogenous MG was 
observed in these fructose-treated rats, a condition associated with impairment of the 
insulin signaling pathway and the development of insulin resistance. When co-treated 
with metformin, a well known oral biguanide insulin sensitizer used for the management 
of type II diabetes, the alterations in these fructose-fed rats, including increased MG level, 
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decreased glucose uptake, and decreased or impaired IRS-1 and PI3K expression or 
activity, were markedly reversed. To further explore the mechanism for the action of MG, 
cultured skeletal muscle cells (L8 cells) were directly treated with MG in the absence or 
presence of metformin. The expression of IRS-1, PI3K and PKC at both mRNA and 
protein levels, along with IRS-1 phosphorylation status and PI3K activity, were 
investigated in the treated cells. Metformin is a well-known insulin sensitizer used for the 
management of type II diabetes.  With a guanidine structure, it has a potential inhibitive 
effect on protein glycation. Finally, whether the metformin-induced insulin-sensitizing 
effect, as observed in fructose-fed rats or MG-treated cells, is due to antagonism of MG 
or to MG sequestration was explored in vitro using mass spectrometry.   
 
5.2. Results 
5.2.1. The development of insulin resistance in fructose-fed rats 
 After 9 weeks’ treatment with fructose, the rats showed a significant increase in 
plasma triglyceride levels (Table 5-1), serum insulin (Figure 5-1A), and enhanced blood 
pressure (data not shown).  As shown in Figure 5-1A, the serum insulin level was 
enhanced significantly from 2.80±0.12 μg/L in the control group to 4.87±0.18 μg/L in 
fructose-fed group. Likewise, plasma triglyceride increased from 0.35 ± 0.04 mM to 0.84 
± 0.05 mM by fructose feeding (Table 5-1). However, total cholesterol, HDL-cholesterol 
and blood hemoglobin A1C in plasma were not changed (Table 5-1). In all groups of rats 
treated with or without MG and/or metformin, the fasting blood glucose level was 
maintained at 5-6 mM. At the end of the 9 week treatment, IPGTT was performed and a 
notable difference was observed in metformin-treated rats, compared with the control rats  
                       
          Table 5-1. Biochemical parameters of control or fructose/metformin treated rats. 
 
. 
Tests Control (n=7) 
Fructose 
(n=10) 
Fructose-
metformin 
(n=8) 
Metformin 
(n=4) 
Total cholesterol (mM) 0.85 ± 0.09 0.88 ± 0.07 0.77 ± 0.1 0.70 ±0.07 
Triglyceride (mM) 0.35 ± 0.04 0.84 ± 0.05* 0.72 ± 0.06 0.16 ±0.03*+ 
HDL-cholesterol (mM) 0.77 ± 0.07 0.66 ± 0.06 0.63 ± 0.04 0.61 ± 0.08 
Hemoglobin A1C (mM) 4.3 ± 0.21 4.4 ± 0.07 4.41 ±0.16 4.6 ±0.16 
 
                       * P<0.05 vs. control, + P<0.05 vs. fructose-treated group 
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(p<0.05, n=4 for metformin treated group, n=7 for other groups; Figure 5-1B). 
 A decreased insulin-stimulated glucose uptake in insulin targeted tissues has been 
identified as being a key indicator of insulin resistance (Matthaei et al., 2000). We 
observed that the insulin-induced glucose uptake by abdominal adipose tissue dropped 
dramatically in fructose-fed rats, in comparison with that from untreated control rats 
(P<0.05). With insulin (100 nM) stimulation, as shown in Figure 5-1C, glucose uptake by 
adipose tissue is 198% in the control group (n=6), and 117% in fructose-fed rats (n=6, 
p<0.05), of the basal glucose uptake without insulin stimulation. Similarly, insulin-
stimulated glucose uptake was reduced significantly in cultured L8 cells after a 48 h 
treatment with MG (30 μM), in comparison with control cells (P<0.05, n=6 for each 
group, Figure 5-1D). The lowered glucose uptake in adipose tissue induced by fructose 
feeding, or in MG-treated L8 cells, was restored significantly by co-treatment with 
metformin (Figures 5-1C and 1D).  
 
5.2.2. Increased endogenous accumulation of MG or related AGEs in fructose-fed 
rats or MG-treated cells 
 A 9-week fructose feeding caused a significant increase in MG concentration in 
SD rats. A dramatic increase in MG formation of more than 2-fold was observed in 
skeletal muscle, from 2.32 µmol/g protein in the untreated group to 6.98 µmol/g protein 
in the fructose-treated group (p<0.01, n=4, Figure 5-2A). In comparison with untreated 
rats, MG levels were also increased from 1.8 to 3.29 μM in serum (p<0.01, n=4, Figure 5-
2B). The increased endogenous MG accumulation was abolished by metformin co-
treatment in skeletal muscle as well as in serum (Figure 5-2A and B). 
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Figure 5-1. Effects of fructose, MG, and metformin on the development of insulin 
resistance.  A. Serum insulin levels in rats treated with fructose (n=10), fructose plus 
metformin (n=8), or metformin (n=4), respectively.  *P<0.05 vs. control rats (n=7); 
+P<0.05 vs. fructose-fed rats.  B. Glucose tolerance test. *P<0.05 vs. control rats; +P<0.05 
or ++P<0.01 vs. fructose-fed rats. C. Insulin-stimulated glucose uptake by adipose tissues 
from different treated rats. *P<0.05 vs. control rats; +P<0.05 vs. fructose-fed rats.  D. 
Insulin stimulated glucose uptake in cultured skeletal muscle cells (L8) treated with or 
without MG, metformin (100 μM) or MG plus metformin (100 μM). *P<0.05 vs. control 
cells; +P<0.05 vs. MG-treated cells.  n=6 in each group. 
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 Using immunohistochemical staining and Western blotting analysis, we further 
investigated whether or not MG-induced changes in AGEs vary in skeletal muscle cells 
from different treated groups.  Figure 5-2C indicated enhanced AGE formation in L8 
cells after 48 h treatment with MG (10 or 30 μM), as shown by a significant increase in 
the levels of CEL. Co-treatment with metformin reduced MG-induced AGE formation, 
compared with that in cells treated with MG alone (Figure 2C).  
 
5.2.3. Effects of fructose and metformin on the expression of insulin signaling 
molecules in skeletal muscle 
 To investigate the effects of fructose and metformin on the insulin signaling 
pathway, mRNA expression of IR, IRS-1, and PI3K in skeletal muscle from different 
treated groups of rats was examined using quantitative real time-PCR.  As shown in 
Figure 5-3, the mRNA levels for IRS-1 and PI3K were decreased, to 78.6±3.1% (n=7, 
P<0.05) and 61.6± 3.1% (n=7, P<0.05), respectively, in skeletal muscle from fructose-
fed rats when compared with untreated control rats (n=4).  The reduction in 
IRS-1 and PI3K expression was significantly reversed when the rats were co-treated with 
metformin (Figure 5-3). There were no significant changes in mRNA levels of IR 
observed among untreated, fructose-fed, and fructose-metformin co-treated rats. The 9 
week treatment with metformin alone increased mRNA level of PI3K but had no effect 
on IR and IRS-1 mRNA levels in skeletal muscle.  
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Figure 5-2. Formation of MG/AGEs in different treated rats or L8 cells.  MG levels 
in skeletal muscle (A) and serum (B) of control, fructose treated, metformin treated and 
fructose-metformin co-treated rats. **P<0.01 vs. control rats; *P<0.05 vs. control rats; 
++P<0.01 vs. fructose-fed rats; +P <0.05 vs. fructose-fed rats.  n=4 for each group.  C. L8 
cells seeded on cover glass slips were treated with MG (10-30 μM) for 48 h and stained 
with mouse anti-CEL antibody. More positive staining appeared in MG-treated cells and 
MG-induced CEL formation was inhibited by co-applying metformin (100 μM). 
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5.2.4. Effects of MG and metformin on IRS-1 phosphorylation and PI3K activity in 
skeletal muscle cells 
 To investigate whether the MG treatment impaired insulin resitance by changing 
the function of IRS-1, the insulin-dependent tyrosine phosphorylation of IRS-1 was 
examined after MG/metformin treatment. Tyrosine phosphorylation in IRS-1 decreased 
to 76.6% of the control level with 30 µM MG treatment (Figure 5-4A), but it was restored 
by co-administration of metformin. However, it appears that metformin alone does not 
alter IRS-1 phosphorylation in L8 cells. In addition, we found a reduction in the kinase 
activity of PI3K (Figure 5-4B). The activity of PI3K (indicated as the concentration of 
PI(3,4,5)P3 was decreased after 48 h treatment with MG at both 10 and 30 µM 
concentrations. Co-treatment with metformin improved PI3K activity in the (10 µM) 
MG-treated group.  
 
5.2.5. Identification of metformin-MG adducts 
 
We used mass spectrometry to investigate the formation of guanidine-MG adducts 
following incubation of metformin with MG for 24 h. The positive-ion ESI-MS spectrum  
of an unreacted metformin (25 μM) solution contains only one significant peak (m/z 130) 
corresponding to the [M+H]+ or protonated molecular ion of metformin (Figure 5-5A-a).  
In contrast, the ESI mass spectrum of the incubate (25 μM MG + 25 μM metformin) 
contains several peaks (Figure 5-5A-b), the most abundant of which (m/z 202) 
corresponds to the [M+H]+ ion resulting from direct addition of MG (72 Da) to 
metformin (Figure 5-6). This reaction is analogous to the formation of CEL upon reaction 
 - 124 -
 
0
20
40
60
80
100
120
140
PI3K
*
+
**
IRS-1 
m
R
NA
 e
xp
re
ss
io
n 
in
 s
ke
le
ta
l
m
us
cl
e 
tis
su
e 
(%
 o
f c
on
tr
ol
)
 Control
 Fructose
 Fructose-metformin
 Metformin
IR
+
 
 
Figure 5-3.  Expression of IR, IRS-1, and PI3K in in skeletal muscle from different 
treated rats. After 9 weeks treatment of fructose or/and metformin, skeletal muscle was 
frozen and total RNA was extracted. The mRNA expression of IR, IRS-1 and PI3K was 
determined using real-time PCR. *P<0.05 vs. control rats, +P<0.05 vs. fructose-fed rats.  
n=4 for control group, and n=7 for fructose or fructose-metformin treated group, n=3 for 
metformin treated group. 
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Figure 5-4. Effects of MG and/or metformin on IRS-1 and PI3K in L8 cells.  After 
treatment with or without MG (10 or 30 μM) in the absence or presence of metformin 
(100 μM) for 48 h, the L8 skeletal muscle cells were exposed to 100 nM insulin for 10 
min. IRS-1 phosphorylation (A) was investigated by immunoblotting (WB) experiment 
using rabbit a anti-IRS-1 antibody as the primary antibody. *P<0.05 vs. control cells, 
+P<0.05 vs. MG-treated cells. B. The PI3K activity was evaluated using a competitive 
ELISA kit. The activity of PI3K was proportional to the production of PI(3,4,5)P3. 
*P<0.05 vs. control cells, +P<0.05 vs. MG-treated cells. n=3-4 for each group. 
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 of MG with the primary amino group of a lysine side chain (Ahmed et al., 2002). The 
product ion MS/MS spectrum of this compound (Figure 5-5B-b) contains fragments 
corresponding to metformin (m/z 130) and to the neutral loss of water (m/z 184) and of 
MG bound to an amino group (m/z 113), confirming its identity as a 1:1 metformin:MG 
adduct. 
However, the heaviest ion observed in the incubate ESI-MS spectrum (Figure 5-
5A-b) corresponds to the addition of two MG molecules to a single molecule of 
metformin (m/z 274). This is consistent with the ability of metformin to form tautomeric 
structures (Figure 5-6) that contain two primary amino groups capable of forming adducts 
with MG, and which are stabilized by conjugation of the rearranged C=C bonds. The 
identity of this 1:2 metformin:MG adduct is again confirmed by the product ion MS/MS 
spectrum (Figure 5-5B-c), which contains fragments corresponding to loss of water and 
CO2 (m/z 256 and 230, respectively) from either or both of the attached MG moieties, and 
to sequential loss of MG (m/z 202) and water (m/z 184) from the molecular ion, as well as 
metformin itself (m/z 130). Other ions observed in the incubate ESI-MS spectrum (Figure 
5-5A-b) arise from the reaction of MG with certain metformin tautomers to form the 
cyclic condensation product triazepinone (m/z 184), a reaction analogous to that between 
MG and the side chain of arginine (Ahmed and Thornalley, 2002). Subsequent addition 
of a second MG molecule to the terminal primary amino group gives rise to a 
triazepinone : MG adduct (m/z 256). MS/MS spectra serve to differentiate between 
incubation products based upon metformin and triazepinone, the former (Figure 5-5B-b 
and c) containing metformin (m/z 130) as a significant product ion, whereas the latter 
(Figure 5-5B-a) contain characteristic product ions, such as those corresponding to 
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Figure 5-5. Identification of metformin-MG adducts by ESI-MS. A. Normalized 
positive ion ESI mass spectra of (a) 25 µM metformin solution, (b) incubate of 25 µM 
metformin with 25 µM methylglyoxal (MG) in 0.2 M sodium phosphate buffer, and (c) 
42-fold dilution of incubation products in 50:50 v/v water/acetonitrile containing 0.1% 
formic acid. B. Product-ion tandem mass (MS/MS) spectra obtained by collision-induced 
dissociation (CID) of the incubation products (a) triazepinone (m/z 184), (b) the 1:1 
metformin: MG adduct (m/z 202), and (c) the 1:2 metformin:MG adduct (m/z 274). The 
“daughter ions” in B refer to the fragment ions produced by collision-induced 
dissociation of MG-metformin ions in A. 
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Figure 5-6. Incubation products of metformin and MG.  
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 neutral loss of ammonia (m/z 167) and dimethylamine (m/z 139), that are consistent with 
a stabilized cyclic triazepinone structure (Figure 5-6). 
 
5.3. Discussion 
The results of our present study suggest that the endogenous accumulation of MG 
is associated with impaired insulin signaling and the development of insulin resistance in 
fructose-fed rats. The altered mRNA expression of IRS-1 and PI3K in skeletal muscle of 
fructose-fed rats, combined with a reduction in the levels, activities and phosphorylation 
of IRS-1 and PI3K proteins in MG-treated skeletal muscle cells, supports the hypothesis 
that MG plays an important role in the development of insulin resistance. Our data show 
that metformin not only reduced MG levels but also prevented the formation of MG-
induced AGEs, while protecting insulin signaling molecules against MG-induced damage 
in both fructose-fed rats and MG-treated skeletal muscle cells. Using mass spectrometry, 
we also confirmed that metformin combines readily with MG to form stable products that 
effectively sequester MG, preventing it from reacting with insulin signaling molecules 
that may be present in vivo. 
It has been shown that a diet high in fructose or sucrose can induce insulin 
resistance, although the mechanism is not yet fully understood (Hallfrisch et al., 1983; 
Reiser et al., 1989). The main source of MG in mammals is anaerobic glycolysis (Koop 
and Casazza, 1985; Lyles and Chalmers, 1992). MG is also formed during lipolysis and 
protein catabolism (Lyles and Chalmers, 1992; Yu et al., 2003). Like glucose, fructose is 
a monosaccharide and a precursor of MG. In the present study, after 9 weeks of fructose 
treatment, SD rats developed insulin resistance with decreased glucose uptake, 
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hyperinsulinemia, high blood pressure, and high triglyceride, which is consistent with 
previous reports. However, we observed a significant increase in MG accumulation in 
skeletal muscle from the rats fed with fructose as well as other tissues, including plasma 
and adipose (Figure 2A, 2B). This increased MG level coincides with the suppression of 
IRS-1 and PI3K mRNA levels in skeletal muscles from fructose-treated rats (Figure 3). 
The direct inhibitive effect of MG on the insulin signaling molecules was further 
confirmed in cultured skeletal muscle cells.  Consistent with our animal study, when the 
cells were treated with MG concentrations of 10 or 30 μM for 48 h, significant reduction 
in IRS-1 phosphorylation and in the kinase activity of PI3K were observed in these MG-
treated L8 cells (Figure 5-4).  Our results suggest that increased MG accumulation in 
fructose-fed rats might not be just a concurrent phenomenon, but likely a causative factor 
for the development of insulin resistance. It was reported recently that insulin signaling 
was induced by MG treatment in cultured skeletal muscle cells (Riboulet-Chavey et al., 
2006). In that study, 2.5 mM MG treatment reduced insulin-stimulated glucose transport 
by decreasing phosphorylation on IRS-1 and Erk proteins. Given that MG concentrations 
of 500 μM have been used to study MG-induced apoptosis in Jurkat cells (Du et al., 
2001a; Du et al., 2000), however, one should not exclude the possibility that, with 
concentrations in the milimolar range, MG-induced apoptosis may be involved in the 
decreased phosphorylation of IRS-1 and ERK proteins. Indeed, we have observed that the 
percentage of cells undergoing apoptosis is significantly higher in cells treated with 100 
μM MG, though not with 10 µM MG (unpublished data). According to our observations, 
and previous reports (Nagaraj et al., 2002), the plasma concentration of MG is less then 5 
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μM in normal adult SD rats. Hence, the concentrations of MG (10-30 μM) used to treat 
cultured cells in our present study may be considered pathophysiologically relevant.   
It has been found that MG modifies proteins by reacting with arginine or lysine 
residue. Since these reactions usually occur as a time-dependent chronic reaction, it was 
believed that MG only modifies proteins with long half lives, such as albumin or certain 
structural proteins. However, our previous study indicated that MG can also modify the 
insulin molecule and impair its biological function (Jia et al., 2006). The recent discovery 
that MG modifies transcriptional co-repressor protein mSin3A also suggests a potential 
role for MG in modifying key transcription-related proteins and hence, regulating gene 
expression (Yao et al., 2006). It is not clear, however, which particular molecule(s) in the 
insulin signaling pathway have been modified by MG. Theoretically, MG could interact 
with insulin signaling molecules at many potential steps, modifying IR, IRS-1, PI3K 
and/or other downstream molecules. Although arginine and lysine residues are 
considered the main targets for MG, and are widely distributed in many proteins, 
modification by MG appears to be quite specific (Jana et al., 2002; Poggioli et al., 2002; 
Yao et al., 2006), depending, at least in part, on the conformation of the protein.  
In this study, we used metformin to treat fructose-fed rats or MG-treated L8 cells, 
since decreased plasma levels of MG have been reported in type 2 diabetes patients 
following treatment with metformin (Beisswenger et al., 1999; Ruggiero-Lopez et al., 
1999; Tanaka et al., 1999). A similar inhibitive effect of metformin on the MG levels in 
serum and skeletal muscle was observed in our fructose-fed rats. In addition, we observed 
that the administration of metformin inhibited the formation of MG-induced AGEs, 
including MG-glycated lysine and MG-glycated arginine residues (Figure 5-2C), while 
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greatly improving insulin-stimulated glucose uptake (Figure 5-1). Moreover, the altered 
expression of IRS-1 and PI3K, and decreased IRS-1 phosphorylation and PI3K activity 
induced by MG were markedly reversed by metformin treatment in fructose-treated rats 
or MG-treated cells (Figure 5-3 and 5-4). Although the mechanism of metformin action 
remains somewhat controversial, different studies have shown it to be an insulin 
sensitizer (Bailey and Turner, 1996; Cleasby et al., 2004; Lord et al., 2003; Santos et al., 
1997; Stith et al., 1996), whether or not this activity depends upon its MG-reducing 
capabilities is unclear. One in vitro study suggests that metformin acts as a scavenger of 
MG, due to its reaction with MG to form guanidine-dicarbonyl adducts (Brownlee et al., 
1986). A 1:1 metformin-MG adduct (202 Da) was also observed in our MS experiments, 
confirming the existence of the guanidine-dicarbonyl adduct reported previously 
(Brownlee et al., 1986). In addition, our ESI-MS and MS/MS experiments (Figure 5-5) 
identified a stable 1:2 metformin:MG adduct (274 Da), with additional peaks (256 and 
230 Da) corresponding to loss of water and CO2 respectively, from either or both of the 
attached MG moieties. These results clearly demonstrate the MG-scavenging capabilities 
of metformin, under experimental conditions. Indeed, the almost complete disappearance 
of metformin from the full scan MS spectrum upon addition of MG (Figure 5-5A) 
suggests that most of the metformin is converted to various incubation products. 
Furthermore, all of the ions observed in the undiluted incubate are present in the ESI-MS 
spectrum of a (42-fold) diluted incubate (Figure 5-5A-c), showing that these reaction 
products can be formed at physiologically relevant concentrations. Taken together, our 
results show that metformin combines readily with 1 or 2 mole equivalents of MG to 
form stable products that effectively sequester MG, preventing it from reacting with 
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proteins and other molecules that may be present in vivo. The propensity of metformin to 
form stable adducts with MG is consistent with this drug’s effectiveness in treating 
insulin resistance and type 2 diabetes.  
In conclusion, the MG-induced impairment of insulin signaling observed in this 
study may help us to better understand the pathogenic development of insulin resistance 
and diabetes. Furthermore, the simultaneous attenuation of insulin resistance and MG 
levels by metformin indicates that the MG-sequestrating capability of metformin could 
directly contribute to its insulin sensitizing effect.  
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CHAPTER SIX 
 
METHYLGLYOXAL MEDIATES ADIPOCYTE PROLIFERATION 
AND CONTRIBUTES TO THE DEVELOPMENT OF OBESITY 
 
6.1. Introduction 
MG, a reactive dicarbonyl compound, is mainly created by glycolysis and 
lipolysis (Kalapos, 1999; Kalapos, 2007a; Kalapos, 2007b). It interacts readily with 
certain free amino acid residues in proteins and forms AGEs (Monnier and Cerami, 1981).  
MG-induced ROS (Chang et al., 2005; Chang and Wu, 2006; Pi et al., 2007) and MG-
derived protein modifications (Riboulet-Chavey et al., 2006; Shamsi et al., 1998) have 
been addressed as possible cause factors for insulin resistance in vitro or in vivo.  
Moreover,  increased accumulation of MG and AGEs were observed in diabetic 
(Beisswenger et al., 2005; Wang et al., 2007a; Wang et al., 2004) and hypertensive 
(Vasdev et al., 1998; Wang et al., 2004; Wu and Juurlink, 2002) animals and patients. For 
this reason,  alagebrium, an AGE breaker, has been clinically tested to treat hypertension 
and cardiovascular diseases by reversing this mechanism of aging (Coughlan et al., 2007). 
As the most common cause of hypertension and diabetes, obesity is well 
recognized as a result of excessive consumption of dietary fat and carbohydrates, which 
are both precursors of MG and AGEs. The association between obesity and diabetes and 
hypertension led us to postulate a possible role of MG in the development of obesity. The 
development of obesity involves both adipocyte hypertrophy (increased size of adipocyte) 
and hyperplasia (increased adipocyte number)  (Gregoire, 2001; Hausman et al., 2001). 
While imbalanced energy intake-induced adipocyte hypertrophy contributes to the 
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typically adult-onset obesity, the development of hyperplastic adipose tissue is thought to 
be mainly associated with the obesity in children (Ebbeling et al., 2002; Hager et al., 
1977). However, proliferation of adipocytes is also observed in adult obesity. Recently, 
the role of PI3K/Akt pathway and its downstream effectors in adipogenesis especially the 
proliferation of pre-adipocytes (Chuang et al., 2007; Fajas et al., 1998; Graff et al., 2000; 
Menghini et al., 2005; Rosen et al., 2000; Zhou et al., 2001), has been recognized. It has 
been found that Akt phosphorylates p27 and p21(Cdk inhibitors), prevents the 
localization of these proteins to nucleus, and thus attenuates their inhibitory effect on 
Cdk2 and the cell cycle progression from G1 to S phase (Bhattacharya and Ullrich, 2006; 
Naaz et al., 2004; Peng et al., 2003). Loss of Cdk inhibitors produces adipocyte 
hyperplasia and obesity (Naaz et al., 2004). In addition, the degradation of Akt is also 
required for the cellular transition from quiescence to the proliferative state. 
Inhibitory effect of MG on cell growth has been extensively reported (Cantero et 
al., 2007; Kani et al., 2007; Ota et al., 2007). In the present study, we hypothesized that 
MG stimulates adipocyte proliferation through the PI3K/Akt pathway. To investigate this 
hypothesis, we first compared the MG levels in obese and normal patients and rats. The 
effects of MG on Akt signaling and cell proliferation were further examined in cultured 
adipocytes (3T3-L1 cells). Our results suggest that increased MG accumulation may 
induce adipocyte proliferation and differentiation by stimulating Akt activity, and thus 
contributes to the development of obesity. 
 
6.2. Results 
6.2.1. Increased MG accumulation in obese patients 
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There was no difference between the age and sex distribution in the obese and 
non-obese patient groups. The body weight of non-obese and obese group was 
73.78±2.70 kg and 98.31±7.38 kg, respectively. The mean BMI value for non-obese 
group and obese group was 25.23±1.05 and 33.5±3.0, respectively. The mean plasma MG 
level in obese patients was 3.5 ±0.4 µM, which was significantly higher than that of the 
non-obese group (2.1 ±0.1 µM). Correlation analysis indicated a strong correlation 
between plasma MG level and BMI value (r=0.606, P=0.0046, Figure 6-1). 
 
6.2.2. MG stimulated proliferation of cultured adipose cells 
To investigate whether MG induces the proliferation of adipose cells, we carried 
out cell proliferation assay with or without MG treatment. The result showed that 5, 10 
and 20 μM MG significantly increased the proliferation rate of 3T3-L1 cells to 115±2.1%, 
126±3.6% and 119±3.3% of the untreated cells (P<0.05 vs. Control; n=48 in each group, 
Figure 6-2A). The co-treatment with Akt inhibitor SH-6 (10 µM) or the AGE breaker 
alagebrium (50 μM) alleviated the cell proliferation induced by MG (10 μM) to the 
control level (Figure 6-2B). 
The effect of MG on cell proliferation was further confirmed by the cell cycle 
phase distribution after MG treatment (Figure 6-3). Comparing the cell number in G1, S 
and G2 cell phase at different time points, we found that the MG-treatment lead to a faster 
cell cycle progression (Figure 6-3A), which represented as increased cell number in S 
phase after 16 or 20 h of MG (10 µM) treatment (Figure 6-3A-b) and increased cell 
number in G2 phase after exposure of cells to MG (10 µM) for 20 h (Figure 6-3A-c).  The  
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Figure 6-1.  Plasma MG concentration is closely correlated to BMI value of patients 
Blood samples were obtained from 20 untreated patients with mild to moderate 
hypertension from the clinical research units at Sacré-Coeur Hospital and at Hôtel-Dieu 
Hospital in Montreal.  The body mass index (BMI) =body weight in kg/ square of the 
height in meter, r=0.606, P=0.0046.
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Figure 6-2. The effect of MG, SH-6 or alagebrium on 3T3-L1 cell proliferation. The 
proliferation of 3T3-L1 cells was determined by using a Celltiter 96® non-radioactive cell 
proliferation assay kit. The relative cell proliferation of each group was presented as the 
ratio between arbitrary absorbance on 570 nm of each group and that from the control 
group without treatment. The effect of different MG concentrations on cell proliferation 
was shown in (A) and the effect of 10 μM MG with/without SH-6 and alagebrium was 
shown in (B). *P<0.05 vs control cells; +P<0.05 vs MG treated cells; n=48 in each group. 
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co-administration of SH-6 (10 µM) significantly reversed the effect of MG on cell cycle 
progression in S and G2 phases (Figure 6-3B-b, c).  
 
6.2.3. Effect of MG on the expression and activity of Akt and its downstream 
effectors 
As Akt plays an important role in regulating cell growth by phosphorylating p21 
and p27 (Zhou et al., 2001), we further examined the effect of MG on phosphorylation 
and expression of Akt and its targeted effectors p21 and p27 (Figure 6-4). After treating 
3T3-L1 cells with MG (10 µM) and/or SH-6 (10 µM)/alagebrium (50 µM)  for 24 h,  
increased levels of phospho-Akt (p-Akt) as well as phospho-p21 (p-p21) and phospho-
p27 (p-p27) were observed (Figure 6-4-A, B). The co-administration of SH-6 or 
alagebrium significantly prevented the phosphorylation of Akt, p21 and p27 induced by 
MG. Furthermore, the expression of p21 protein was attenuated in cells co-treated with 
SH-6 or alagebrium (P<0.05 vs MG-treated cells, n=3). However, the expression of p27 
protein was not affected by MG treatment. 
In another group of experiments, we examined the effect of MG on Cdk2 activity 
in 3T3-L1 cells. As shown in Figure 6-6C, after the cells were treated with MG (10 µM) 
for 24 h, the activity of Cdk2 was increased to 4 fold of the control level. The increased 
Cdk2 activity was reversed by co-administration of either SH-6 or alagebrium. However, 
there was no significant change in the protein levels of Cdk2 in the cells treated with or 
without MG (10 µM) for 24 h (data not shown).
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Figure 6-3. Effect of MG on cell cycle progression of 3T3-L1 cells. After 12, 16, 20 
and 24 h of MG (10 µM) treatment, cellular DNA content was determined by a flow 
cytometer (A). The effect of MG with/without SH6 (10 µM) or alagebrium (50 µM) on 
cellular DNA content is shown in (B). *P<0.05 vs control group; +P<0.05 vs MG treated 
group; n=6 in each group. The indicated percentage of the cell number is average of three 
experiments. 
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6.2.4.  MG-stimulated proliferation resulted in more lipid accumulation in 3T3-L1 
cells  
We have observed that incubation of 3T3-L1 cells with MG (10 μM) caused 
increased cell proliferation. To investigate whether the increased pre-adipocyte number 
could cause more differentiated adipocytes, we treated the 3T3-L1 cells with MG, SH-6 
or ALT711, respectively, for 48 h. On the fifth day of post-differentiation, the 
triglyceride deposition in 3T3-L1 cells was measured using the Oil Red O staining. 
Results showed that MG treatment for 48 h increased the lipid content in differentiated 
3T3-L1 cells to 115.7±1.6% of the control level (Figure 6-5A, B). The increased lipid 
content in MG-treated cells was attenuated by SH-6 or alagebrium co-administration. 
More importantly, the enhanced mRNA expression of adiponectin and leptin, two 
important adipogenic markers, further confirmed the increased adipogenesis in MG (10-
30 μM)-treated 3T3-L1 cells (Figure 6-5C).   
 
6.3. Discussion 
Increased MG levels and MG-related advanced glycation endproducts have been 
reported in different insulin resistance states, which is associated with various clinical 
manifestations such as hypertension and diabetes (Chang et al., 2002; McLellan et al., 
1994; Riboulet-Chavey et al., 2006; Wang et al., 2004). As one of the major factors of 
insulin resistance, the correlation between endogenous MG accumulation and the 
development of obesity remains unidentified.  
In the present study, we for the first time indicated an association between an 
increased MG level with the development of obesity. Our data showed an increased MG 
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Figure 6-4. Effect of MG on Akt and its target effectors in 3T3-L1 cells. After 24 h 
treatment with or without MG (10 μM) in the presence or absence of SH-6 (10 
μM)/alagebrium (50 µM), the protein levels of Akt, p21 and p27 (A), the levels of 
phospho-Akt (p-Akt), phosphor-p21 (p-p21) and phosphor-p27 (p-p27) (B), and the 
activity of Cdk2 (C) were determined and compared. The results of Western blotting 
were quantified by Chemigenus2 Bio imaging system and presented as the percentage of 
that from control cells.  The activity of Cdk2 in 3T3-L1 adipocytes treated with 10 μM 
MG was determined by measuring ATP consumption with a PKLight Assay Kit. *P<0.05 
vs control (CT) cells; +P<0.05 vs MG treated cells. The results were based on data from 
three experiments. 
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Figure 6-5. MG induced adipogenesis in 3T3-L1 adipocytes. After treating the cells 
with MG, SH-6 or alagebrium for 48 h, the cells were cultured till confluence and 
differentiation was then induced by adding 2.5 µg/ml insulin, 0.25 µM dexamethasone 
and 0.5 mM isobutylmethylxanthine for 48 h. When 70% of the cells became 
differentiated (after about 5 days culture) in post-differentiation medium, the Oil Red O 
staining or the RNA extraction was carried out. The lipid staining in adipocytes was 
shown in (A). The lipid content in adipocytes from different groups was quantified and 
presented as the percentage of that from control cells (B). The mRNA expression of 
adiponectin, PPARγ, C/EBPα and leptin in differentiated cells treated with MG alone or 
with MG and alagebrium were determined by real-time PCR (C). *P<0.05; **P<0.01; 
n=3 in each group. 
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level in obese patients (Figure 6-1). With cultured 3T3-L1 cells, we futher confirmed that 
MG induced an increase in p-Akt, p-p21 and p-p27, enhanced the activity of Cdk2, 
accelerates the cell cycle progression and proliferation of pre-adipocytes, thus 
contributing to the development of obesity.  
Obesity is an enlargement of adipose tissue. Obesity in children involves both 
adipocyte hyperplasia and hypertrophy while adult-onset obesity was generally 
considered due to adipocyte hypertrophy.  However, various lines of evidence indicate 
that adipocyte hyperplasia is also an important factor in the development of adult-onset 
obesity, especially morbid obese patients whose BMI value are greater than 39 (Drolet et 
al., 2008; Hirsch and Batchelor, 1976; Jo et al., 2009; Naaz et al., 2004).  In the present 
study, we demonstrated that MG increased the fat cell number by promoting growth and 
proliferation of pre-adipocytes (3T3-L1 cells). After 16 to 20 h of treatment, MG (10 µM) 
increased the cell numbers in S and G2 cell cycle phase (Figure 6-5A) which indicated a 
stimulated progression of cell cycle. As a result, treatment with 10-20 μM MG for 48 h 
increased the number of 3T3 –L1 cells as measured by a cell proliferation assay (Figure 
6-4). To our knowledge, this is the first report about the stimulating effect of MG on cell 
proliferation.  The increased proliferation was also observed when vascular smooth 
muscle cells were treated with MG (unpublished data). On the contrary, the effect of MG 
on apoptosis has been extensively studied (Cantero et al., 2007; Kani et al., 2007; Ota et 
al., 2007). A previous study reported an increased apoptotic cell number when mouse 
Schwann cells were treated with 500-1000 μM MG (Ota et al., 2007). The major 
difference in our study is that the 3T3-L1 cells were treated with 5-20 μM MG instead of 
500-1000 µM. The dose we used is much more relevant to the physiological 
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concentration of MG, which is around 0.2-5 µM in human/rats based on previous studies 
(Babaei-Jadidi et al., 2003; Nagaraj et al., 2002; Wang et al., 2008) and the present study. 
We did observe a decreased proliferative effect when the MG concentration increased to 
100 µM. This might indicate a biphasic effect of MG on cell proliferation. Most probably, 
the inhibitory effect of MG might be due to the acute effect of high MG concentration, 
but not the effect of MG at the physiological level. 
Our observation on MG-treated 3T3-L1 cells not only showed the effects of MG 
on cell proliferation and cell cycle regulation, but also implied a possible underlying 
mechanism. The PI3K/Akt signal cascade plays an important role in regulating cell 
proliferation. Based on our results, the effect of MG on cell proliferation was at least to 
some extent due to the MG-increased activity of Akt and its related signaling pathway. In 
our study, 10µM of MG in cultured 3T3-L1 cells increased the phosphorylation of Akt. 
Furthermore, MG treatment increased the phosphorylation of p21 and p27 (Figure 6-6A, 
B), major regulators that arrest the cells at the G1/S checkpoint. The increased 
phosphorylation of p21 and p27 activates their degradation and leads to the entry of cells 
into S phase from G1 phase. This explains the MG-activated cell proliferation detected in 
our experiment. Further observation of the increased activity of CDK2 in MG-treated 
cells supported this hypothesis (Figure 6-4C). Increased Akt activity was observed in 
MG-treated 3T3-L1 cells suggesting that change in Akt, especially its activity, is critical 
in adipocyte proliferation in these obese rats. 
Alagebrium, also known as ALT-711, is the first drug to be clinically tested for 
the purpose of breaking the crosslinks caused by AGEs (Coughlan et al., 2007). It is 
designed to reverse the stiffening of blood vessel walls that contributes to hypertension 
 151
and cardiovascular disease, as well as many other forms of degradation associated with 
protein cross linking. In our study, alagebrium was used as a specific inhibitor to block 
the effects of MG (Wang et al., 2009). A similar role of alagebrium in reversing the MG-
induced cell proliferation and attenuating the activity of Akt and its downstream effectors 
(Figures 6-3, 4) confirmed our observation that MG mediates adipocyte proliferation by 
stimulating Akt activity. In the cell cycle assay, however, alagebrium showed a less 
potent effect in reversing MG’s effect compared with SH-6. This seems reasonable 
because SH-6 directly targets Akt whereas alagebrium does not. 
In summary, our study revealed the effect of MG in stimulating adipogenesis by 
up-regulating the signaling of Akt and its downstream pathway.  This stimulates cell 
cycle progression and proliferation of the pre-adipocyte, which eventually leads to 
increased number of adipocytes and contributes to the development of obesity. The study 
of MG might offer a new approach to explain the development of obesity especially the 
adult-onset mobid obesity. 
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CHAPTER SEVEN 
DISCUSSION AND CONCLUSIONS  
 
7.1. General discussion 
 MG and related AGEs have been recognized as indicator of carbonyl overload 
burden. Increased MG accumulation have been reported in diabetes and hypertensive 
patients and animals (Kalapos, 1999; Mizutani et al., 1999; Wu and Juurlink, 2002). In 
the present study, increased MG levels in different tissues were observed in SD rats with 
insulin resistance (Figure 4-2 and Figure 5-2).  In adipose tissue, the MG content 
increased from 1.5 μmol/g protein in normal rats to 4.37 μmol/g protein in rats with 
insulin resistance. Similarly, a dramatic increase in MG formation of more than 2-fold 
was observed in skeletal muscle, from 2.32 to 6.98 μmol/g protein. In addition, the MG 
level also elevated in blood serum from 1.81 μM to 3.29 μM after 9 weeks treatment of 
fructose. MG inhibitor, NAC and metformin efficiently reversed the MG accumulation 
and the progress of insulin resistance. Increased accumation of MG was detected in both 
obese patients and Zucker fatty rats (Figure 6-1). With the BMI value changed from 25 to 
33, the plasma MG in obese patients increased from 2.1 μM to 3.5 μM. Correlation 
analysis indicated a strong correlation between plasma MG and BMI value/body weight 
in the tested human/animal samples.   
 At the cellular level, the mechanism responsible for the development of insulin 
resistance can be categorized as three levels: 1) pre-receptor defect (defective insulin 
production and function); 2) receptor defect (decreased number of receptors, reduced 
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binding of insulin, mutations of IR); or 3) post-receptor defect (defective insulin signal 
transduction and abnormal GLUT4 molecules). 
In chapter three, the MG-induced structural modification on insulin molecule was 
investigated. The mass spectrometry study provided strong evidence for the formation of 
MG-insulin adducts. MG additions at both the N-terminus of the insulin B chain and at 
internal arginine residue were subsequently confirmed by tandem MS analysis of insulin 
B-chain adducts. The MG-insulin adducts induced a significant and concentration-
dependent decrease in glucose uptake in insulin-sensitive adipocytes and skeletal muscle 
cells as compared to intact insulin.  The autocrine control of insulin release by the 
extracellular insulin level was also altered by the glycation of insulin. Our results 
suggested that the formation of MG-insulin could no longer inhibit insulin (C-peptide) 
secretion.  In addition, a significant lower MG-insulin clearance rate was observed 
through hepotocytes, which indicated that MG-insulin adducts could not go through 
endocytosis properly, or there was an aggregation of MG-insulin. The reduced glucose 
uptake by insulin sensitive cells leads to an increased glucose level in the circulation 
system. Together with the over accumulation of insulin/MG-insulin, the MG-induced 
glyation on insulin molecules resulted in the development of insulin resistance.  
Skeletal muscle and adipose tissue, which, account for two-third of all cells in a 
typical human body, are most strongly influenced by insulin. The former plays a central 
role in movement, breathing, circulation, etc, and the latter accumulates excess food 
energy against future needs. In Chapter four and five, the effects of MG on insulin 
signaling transduction in these tissues/cells were investigated, respectively. In adipose 
tissue of fructose-treated rats, the elevation of endogenous MG level reduced IRS-1/PI3K 
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association and PI3K activity (Figure 4-3, 4). Fructose treatment also decreased the 
expression of IRS-1 and PI3K in skeletal muscle tissue (Figure 5-3). In cultured fat cells 
and skeletal muscle cells, MG treatment mimicked the impaired insulin signaling under 
in vivo condition, with reduction on IRS-1 phosphorylation and PI3K activity. The 
impaired insulin signaling observed in cultured cells, to some extend, explains the 
development of insulin resistance in fructose-fed SD rats.  
One major factor in the development of insulin resistance syndrome is obesity, 
especially abdominal obesity or belly fat. In Chapter six, we examined the link between 
MG accumulation to the increased number of white adipose cells. Treatment of MG 
during the pre-adipocyte stage induced a increased proliferation of 3T3-L1 cells, which 
were shown by cell proliferation assay and cell cycle assay (Figure 6-3, 4). When the 
function of Akt and its downstream effectors were examined, a more active Cdk2 and 
lower activity of Cdk inhibitive protein (p21, p27) were detected (Figure 6-4) in MG 
treated cells. Furthermore, it was found that MG treatment during the pre-adipocyte stage 
caused more lipid accumulation later on in the differentiation stage. These results 
indicated that by stimulating Akt signaling pathway, MG might mediate adipocyte 
proliferation and increase the cell number in adipose tissue, thus, contribute to the 
occurrence of obesity, especially obesity in children and serious adult-onset obesity. 
 
7.2. Conclusions 
 Based on this study, we clarified the effect of MG in the pathogenesis of insulin 
resistance syndrome. MG, as the most potent precursor of AGEs, impairs the activity of 
insulin signaling pathway by glycating insulin molecule and possibly other proteins in the 
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insulin signaling pathway Moreover, this study revealed a previously unrecognized effect 
of MG in adipogenesis by up-regulating Akt activity. In summary, this study elucidates 1) 
the correlation of increased MG accumulation and insulin resistance syndrome; 2) the 
causative effects of MG on the development of insulin resistance syndrome through 
modifying the structure and biological function of insulin, impairing insulin signaling and 
inducing obesity as summarized in Figure 7-1. 
 
7.3. Significance of the study  
 Insulin resistance or metabolic syndrome is a group of phenotyles including 
hypertension, obesity, dyslipidemia and hyperinsulinemia. It promotes the development 
of coronary artery disease, stroke and type 2 diabetes, which contribute significantly to 
the spiraling cost of health care in the world, especially in western countries. Our study 
found that MG may contribute to the pathogenesis of insulin resistance syndrome through 
its effects on insulin signaling and adipogenesis. The results from this study might offer 
new mechanisms to explain the development of insulin resistance and to prevent the 
related diseases. 
 
7.4. Future direction 
A number of future considerations were brought up in each study of this thesis. 
The future directions of immediate interest are discussed below:  
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Figure  7-1. The role of methylglyoxal in the pathogenesis of insulin resistance. 
Increased MG accumulation induces insulin resistant state through three mechanisms. 
First, MG can modify the structure of insulin and alter its biological function. Second, 
MG accumulation in animals result impaired insulin signaling in adipose tissue and 
skeletal muscle tissue. Furthermore, increased MG accumulation induces proliferation 
and differentiation of adipocytes and causes obesity which is the major cause of insulin 
resistance.  
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7.4.1. To study whether MG alters the structure of insulin signaling proteins 
 
A previous study reported the modification of MG on IRS protein (Riboulet-
Chavey et al., 2006). In Chapter three, we also observed that MG glycates the insulin 
molecule in vitro on the Arg residue and N-terminus. In chapter four and five, while we 
found MG treatment impaired the insulin signaling in adipose cells and skeletal muscle 
cells, the further mechanism that causing this effect was not elucidated. Although we 
detected that MG could modify insulin on Arg residue, this specific MG-insulin adduct 
has not been detected in vivo. To this purpose, we have collected plasma samples from 
patients with obesity, hypertension or/and diabetes, for further examination. Preliminary 
MS study will be carried out to detect the existence of MG-inulin adduct in these samples. 
In future studies, how MG change the structure and function of insulin signaling proteins, 
such as IR, IRS and PI3K, should be explored both in vitro and in vivo.  
 
7.4.2. The biological and pathological effects of MG in different tissues 
MG research has become a “hotspot” in the field of metabolism study from 
recently. In previous research, very high concentration of MG, compared to physiological 
levels, were applied to treat animals and cells.  In Chapter four and five, we found 
different expression level of IR and IRS-1 in adipose cells and skeletal muscle cells. In 
addition, different expression profile was also observed in adipose cells during different 
adipogenetic stages.  When the cells were treated with MG in the pre-adipocyte stage, the 
PI3K expression and kinase activity were not altered. However, a decreased PI3K activity 
was detected when differentiated adipose cells were treated with MG. Other than the MG 
concentration and time duration of treatment, the different physiological condition of 
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cells might due to the different results. In the future, we will investigate the effects of MG 
in other tissues, such as liver and neruo cells. 
 
7.4.3. To find the most potent MG/AGE inhibitor with minimum side effects 
As introduced in Chapter one, a variety of MG inhibitors/breakers have been 
reported to interfere with the formation of AGE or AGE precursors. Although anti-AGE 
drugs are also being intensively studied, pharmacological approaches are still in early 
stages of development. In the present study, NAC, metformin and alagebrium were tested. 
Each of them to some extend inhibited the effect of MG when administered together. 
However, their side effects, which limit their clinical use, were not fully evaluated. In the 
future study, we will try both in vitro and in vivo system and compare the different effect 
of these agents. This study will prepare theoretical basis for the preventive and 
therapeutic use of anti-AGE drugs in clinic. 
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